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Zusammenfassung
Das Protein GMAP-210 (Golgi Mikrotubuli Assoziiertes Protein von 210 kDa) ist ein
großes, Golgi lokalisiertes Protein mit ausgeprägten Doppelwendel Proteindomänen. Es
ist Teil der lose definierten Proteinfamilie der Golgins, die an der Etablierung der Golgi-
morphologie und am vesikulären Transport im Bereich des Golgis beteiligt sind.
Unter Benutzung biochemischer, zellbiologischer und molekularbiologischer Methoden
wurde GMAP-210 auf seine Golgilokalisierung, seine Interaktionspartner und seine Funk-
tion im Aufbau und der Positionierung des Golgis untersucht.
In vitro und in vivo Experimente zeigten, dass GMAP-210 mittels seiner C-terminalen
GRAB-Domäne an den Golgi bindet. Die vermutete Interaktion mit der kleinen GTP-
ase Arf1 konnte, trotz überzeugender Hinweise, nicht abschließend geklärt werden. Die
Bindung zwischen Arf1 und der GRAB-Domäne ist, bei Untersuchung des volllängen
Proteins, nicht nachweisbar. Kurze C-terminale Fragmente, die die GRAB-Domäne ent-
halten, zeigen allerdings Interaktion mit Arf1. Dies deutet darauf hin, dass zur Bindung
von GMAP-210 an den Golgi noch andere, regulierende Faktoren benötigt werden.
Ein Hefe 2-Hybrid Experiment, dass die gesamte Familie der kleinen Rab GTPasen auf
Interaktion testete, konnte Rab1, dass am Golgi und im ER zu finden ist, als weiteren
Interaktionspartner von GMAP-210 identifizieren. GMAP-210 wurde in Zellen auch an
kleinen, vesikulären Strukturen gefunden, die zum Teil mit COPII und ERGIC53, Kom-
ponenten des frühen, sekretorischen Transportweges, überlappen. Dies ist ein weiterer
wichtiger Hinweis darauf, dass GMAP-210 am Transport vom ER zum Golgi beteiligt ist,
obwohl der Transport eines Modellsubstrats, des G-Proteins des vesikulären Stomatitis
Virus (VSV-G), bei Abwesenheit von GMAP-210 nicht beeinträchtigt war. GMAP-210
funktioniert offenbar nur in spezialisierten, intrazellularen Transportwegen.
Reduzierung der GMAP-210 Proteinmenge in HeLa L Zellen mittels siRNA Technik
veränderte die Golgimorphologie und führte dazu, dass der Golgi zu räumlich konzentrier-
ten Ansammlungen von Vesikeln fragmentierte. Überexpression verursachte das Wachs-
tum von langen, tubulären Strukturen aus dem Golgi. Beide morphologischen Effekte
konnten allerdings nur in HeLa L Zellen beobachtet werden, nicht jedoch in hTERT-
RPE1 Zellen. Da eine direkte Interaktion mit Mikrotubuli oder γ-Tubulin nicht gezeigt
werden konnte, muss GMAP-210 die Golgimorphologie auf anderem Wege beeinflussen.
Reduktion der GMAP-210 Menge durch siRNA zeigte ebenfalls, dass GMAP-210 mit dem
intraflagellaren Transportprotein IFT20 interagiert. Das Protein befand sich nicht mehr
am Golgiapparat, wenn die GMAP-210-Konzentration in der Zelle vermindert wurde.
Die Interaktion beider Proteine ist direkt, GMAP-210 ist aber nicht an der Bildung des
primären Ciliums in hTERT-RPE1 Zellen beteiligt, und der Verlust des Proteins IFT20
am Golgi verhinderte die Bildung des Ciliums ebenfalls nicht.
Diese Ergebnisse distinguieren GMAP-210 von den archetypischen Golgins, GM130 und
p115, und lassen vermuten, dass GMAP-210 an einem hochspezialisierten Transportweg
beteiligt ist, dabei aber trotzdem die Golgimorphologie in bestimmten Zelltypen beein-
flussen kann.
Abstract
The protein GMAP-210 (Golgi Microtubule Associated Protein of 210 kDa) is a long
coiled-coil protein, which localises to the Golgi apparatus. It is part of the loosely defined
protein group of the golgins, which are involved in establishing the Golgi morphology and
in vesicular trafficking around the Golgi.
By using biochemical, cell biological and molecular biological methods GMAP-210 was
examined in regards to its Golgi targeting capability, its interaction partners and its func-
tion in establishing Golgi morphology and positioning.
In vitro and in vivo experiments showed that GMAP-210 targets to the Golgi via its
C-terminal GRAB domain. Its proposed interaction with Arf1, however, could not be
definitely determined, although there is strong evidence for it. Arf1 binding to the GRAB
domain was hindered in the full-length protein, but not with short C-terminal fragments
containing the minimal GRAB domain. This implies that additional factors are needed
for GMAP-210 Golgi binding.
A yeast 2-hybrid screen of the entire family of small Rab GTPases identified the Golgi and
ER localised Rab1 as a novel interaction partner of GMAP-210. GMAP-210 also labels
vesicular tubular structures in the cell, which partially overlap with COPII and ERGIC53,
components of the early secretory pathway. This gives additional evidence that GMAP-
210 is involved in ER to Golgi transport. Trafficking of a model substrate, the vesicular
stomatitis virus G-protein (VSV-G), however, was not impaired in the absence of GMAP-
210. This indicates that GMAP-210 functions only in specialised transport pathways.
Knockdown of GMAP-210 in HeLa L cells by siRNA changed the Golgi morphology and
the Golgi fragmented into a cluster of vesicles. Its overexpression caused the Golgi to grow
long tubular structures. Both effects on morphology could only be observed in HeLa L
cells, not in hTERT-RPE1 cells. As direct interaction with microtubules or γ-tubulin
could not be detected, and GMAP-210 is therefore unlikely to affect Golgi morphology
by directly perturbing microtubule function.
GMAP-210 knockdown by siRNA also showed its interaction with the intraflagellar trans-
port protein IFT20. This protein lost its Golgi localisation when GMAP-210 was depleted.
Both proteins interacted directly. GMAP-210, however, was not involved in primary cil-
ium formation in hTERT-RPE1 cells and loss of IFT20 from the Golgi did not impair
formation of the cilium, proposing that the Golgi pool of IFT20 had a function apart from
intraflagellar transport and formation of the primary cilium.
These results set GMAP-210 apart from the archetypal golgins GM130 and p115 and in-
dicate that GMAP-210 is involved in a highly specialised transport pathway, which could
nevertheless influence the morphology of the Golgi apparatus in certain cell types.
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1 Introduction
Eukaryotic cells are highly compartmentalised, which is one of the main features setting
them apart from prokaryotes. These compartments are formed by membrane boundaries
and are defined by unique lipid and protein composition They thus provide unique en-
vironments within the cell. Compartmentalisation gives the cell the ability to conduct a
great variety of different processes necessary for cell survival and function. It allows for
basic functions like protein and lipid synthesis, modification, degradation and transport
to take place in a coordinated fashion.
Proteins and lipids have to be specifically distributed to the respective compartment,
where they are further processed or fulfil their biological function. The distribution of
proteins within the cell is orchestrated in a tightly controlled series of steps in transport
pathways, which bridge specific donor and acceptor compartments. The transport path-
ways make use of vesicles, themselves small membrane compartments usually less than
100 nm in size (Palade, 1975; Dunphy and Rothman, 1985). The formation, loading,
locomotion and incorporation of cargo into these compartments is regulated by proteins
and lipids.
Although this complex web of interacting molecular mechanisms and pathways was stu-
died intensively in the last years, a great amount of questions and problems still remain
to be solved.
1.1 The Mammalian Golgi Apparatus
The Golgi apparatus in mammalian cells is a membrane structure composed of stacked
cisternae, which are linked into ribbons. It is situated in the perinuclear region of the cell
(Palade, 1975). The Golgi apparatus is the central organelle of intracellular transport.
Proteins are post-translationally modified, while transported through the Golgi, before
they are sorted and transported to the plasma membrane or their destination in the
endosomal and lysosomal system (Farquhar and Palade, 1998).
As the central hub for transport, the Golgi receives a constant influx and efflux of proteins
and it is clear, that the Golgi is not a static organelle, but highly dynamic (Barr and
Warren, 1996). That it nevertheless keeps its size, position and composition is a hint at the
immense amount of control that is exerted on intracellular trafficking, which unavoidably
passes through the Golgi (Rothman et al., 1982).
1 Introduction 2
1.1.1 Golgi Morphology
The Golgi was discovered by Camillo Golgi in the year 1898 (Golgi, 1898) as a reticulate
structure in silver stained Purkinje cells. Since then, and especially in the recent years,
much has been discovered about Golgi morphology, structure and function.
The stacked Golgi is polarised along the vector of intracellular traffic. Its stacked cisternae
can be subdivided into three regions (Schweizer et al., 1988; Griffiths and Simons, 1986).
The side, which receives synthesised material from the endoplasmic reticulum is called cis-
Golgi, followed by the medial and the trans-Golgi. Beyond the trans-Golgi is a system of
tubular Golgi membranes, called the trans-Golgi network (TGN) where secreted material
is sorted and transported to the respective target compartment. A similar structure
is observed at the cis-face, which is accordingly called cis-Golgi network (CGN). The
CGN is also called the Vesicular Tubular Compartment (VTC) or ER-Golgi-Intermediate
Compartment (ERGIC) (Appenzeller-Herzog and Hauri, 2006).
1.1.2 Golgi Matrix And Golgins
The Golgi is composed of membranous flattened cisternae, which are stacked onto each
other. These stacks stay attached when Golgi membranes are purified (Morre and Mollen-
hauer, 1964; Morre et al., 1970), indicating anchors, which tether the cisternae together.
Additionally, detergent extraction of these isolated membranes leaves a proteinaceous exo-
skeleton with the characteristic organisation of Golgi cisternae (Slusarewicz et al., 1994).
Members of this putative Golgi matrix behave in a special way upon disassembly of the
Golgi. After inhibition of ER-to-Golgi transport by the fungal compound Brefeldin A
or overexpression of the dominant negative form of the small GTPase Sar1, most Golgi
resident enzymes redistribute back to the ER. Golgi matrix proteins, however, were found
attached to small Golgi remnants, which are distributed near the ER-exit-sites (Seemann
et al., 2000; Ward et al., 2001) throughout the cell.
Two classes of proteins are implied in Golgi matrix formation, the Golgi Reassembly and
Stacking Proteins (GRASP) and the golgins.
Golgins Golgins have initially been identified as cause for a variety of autoimmune
diseases. Their tertiary structure contains long coiled-coil stretches, giving them a rod-
like structure (Barr and Short, 2003; Gillingham and Munro, 2003). Furthermore, most
of them interact with small Ras-like GTPases (Short et al., 2005) of the Rab or ADP-
ribosylation factor families (see 1.3, p.10ff). Golgins are not only responsible for main-
tenance of the Golgi matrix but also for several other functions (Barr and Short, 2003;
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Gillingham and Munro, 2003).
GM130, p115 and giantin are believed to be central players in establishing Golgi structure
by tethering arriving vesicles to cisternae (Cao et al., 1998; Seemann et al., 2000; Sonnich-
sen et al., 1998). GM130 is linked to the Golgi cis-face by GRASP65 and is the acceptor
for vesicle-bound p115 or a complex made up of p115 and the type II transmembrane
golgin giantin.
p115 is a myosin shaped homodimer with an N-terminal globular head domain, a coiled-
coil tail and a short acidic domain in the C-terminus (Sapperstein et al., 1995). It acts
in tethering in the early secretory pathway and it is necessary for proper SNAREpin for-
mation during vesicle fusion (Shorter et al., 2002). It binds the GTPase Rab1 with its
globular head domain. Its acidic C-terminus interacts with the basic N-terminal motif of
GM130 (Sonnichsen et al., 1998). GM130 forms a homodimer (Nakamura et al., 1997) and
interacts with the Golgi localised GRASP65 by a C-terminal motif (Barr et al., 1998). It
also binds to the small GTPases Rab1, Rab2 and Rab33b (Barr and Short, 2003). Giantin
is a 400 kDa transmembrane protein with a large N-terminal, cytosolic coiled-coil domain
(Linstedt and Hauri, 1993). Giantin localises mainly at the edges of the Golgi stack and
binds p115 by its N-terminus just like GM130 (Sonnichsen et al., 1998). The cis-Golgi
localised type II transmembrane protein Golgin-84 has also been proposed to be involved
in Golgi structure maintenance, although it does not behave like Golgi matrix proteins
in respect to Brefeldin A treatment, as Golgin-84 redistributes to the endoplasmic reticu-
lum (Diao et al., 2003). While the Golgi matrix proteins described above influence Golgi
cisternae stacking, Golgin-84 is involved in lateral Golgi organisation (Diao et al., 2003;
Satoh et al., 2003). Overexpression and depletion of the protein cause fragmentation of
the Golgi ribbon (Diao et al., 2003). Depletion also reduces ER-to-Golgi transport and
increases the ER volume (Diao et al., 2003). Interaction of Golgin-84 with the small
GTPase Rab1 gives further evidence that Golgin-84 is involved in ER-to-Golgi trafficking
(Satoh et al., 2003).
GRASPs In mammalian cells, two GRASP proteins exist, GRASP65 and GRASP55
(Barr et al., 1997; Shorter et al., 1999). GRASP65 is located on the cis-Golgi where it re-
cruits GM130 to the membrane surface (Barr et al., 1998), GRASP55 at the medial-Golgi
recruits Golgin-45 (Short et al., 2001). GRASPs are peripheral membrane proteins tar-
geted to the membrane by N-terminal myristoylation (Short et al., 2005). Both proteins
are required for Golgi stacking and their phosphorylation is involved in Golgi fragmenta-
tion during mitosis (Sutterlin et al., 2002; Preisinger et al., 2005).
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1.2 The Secretory Pathway
1.2.1 ER To Golgi Transport
The Golgi is the central organelle in intracellular transport and secretion (Palade, 1975)
(Fig.1). Membrane and lumenal proteins are synthesised by ribosomes, which are located
on the nuclear envelope and the rough ER (Shibata et al., 2006). The newly synthe-
sised polypeptide is, most of the time co-translationally, translocated into the ER lumen.
They fold into their native conformation most often by the help of chaperons like cal-
nexin and calreticulin (Nehls et al., 2000). Properly folded proteins are labelled by the
quality control machinery in the ER for export. Golgi-bound vesicles are formed in the
transitional part of the smooth ER at so-called ER exit sites (ERES) (Bannykh et al.,
1996). Cargo is recruited into vesicles, which are formed by the COPII coat machin-
ery (Fig.2, p.6). COPII coated vesicles undergo homotypic fusion and form the ERGIC
(Appenzeller-Herzog and Hauri, 2006). These ER-Golgi-intermediate compartments are
transported by microtubule based motors to the cis-face of the Golgi apparatus and fuse
(Allan et al., 2002). Cargo escaped from the ER or cargo receptors ready to be recycled
for another round of ER export are transported back to the ER in COPI-coated vesicles
(Wieland and Harter, 1999).
The mechanism by which transport from the ERGIC to the TGN happens is still contro-
versial. One model is the cisternal maturation model (Allan and Balch, 1999). ERGICs
travel to the cis-face of the Golgi and undergo homotypic fusion in order to form new
cis-Golgi cisternae. At the same time COPI coated vesicles travel in retrograde direction,
not only to recycle proteins to the ER, but also to retrieve proteins from the medial and
trans-Golgi cisternae. Thus, cis-Golgi cisternae mature gradually to medial and trans
cisternae.
In the stable cisternae model (Rothman, 1994), cisternae remain unchanged. ERGIC fuses
with the cis-Golgi or sends forth anterograde transport vesicles. At cis-Golgi proteins are
modified and transferred to medial- and trans-Golgi cisternae by anterograde, COPII
coated vesicles. COPI coated retrograde transport vesicles would then be responsible for
retrieval of escaped early Golgi and ER-resident proteins.
Whichever is the mode of Golgi transition, proteins are then packaged into clathrin coated
vesicles at the trans-Golgi network (TGN) and exported to endosomes and lysosomes or
into exocytic transporters, which are destined directly to the plasma membrane for exo-
cytosis (Maxfield and McGraw, 2004).
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Figure 1: Schematic View Of Intracellular Traffic. Schematic view of compartments and cargo
carriers of the secretory and endocytic pathway; dark blue: COPI vesicles; light green: COPII vesicles;
grey: clathrin coated vesicles; orange: endocytic carriers; white: internal vesicles of multivesicular
bodies; arrows specify routes of transport; not drawn to scale.
1.2.2 Vesicular Traffic
Intracellular traffic is performed in vesicular cargo carriers (Palade, 1975; Novick et al.,
1980; Balch et al., 1984). These carriers form from donor membranes, travel to the
acceptor membrane and fuse with it (Fig.2). These events follow the same principle
irrespective of the donor and acceptor membranes. However, the proteins and protein
complexes involved in these processes are mostly different.
Coating Biogenesis of vesicles occurs by a process called coating (Kirchhausen, 2000;
Bonifacino and Lippincott-Schwartz, 2003). In the region of the donor membrane where
vesicles bud off, the coat complexes are recruited by activated, small GTPases and as-
semble into a cage-like structure (Fig.2A and B) which deforms the membrane into a
vesicle bud and eventually pinches off the membrane (Fig.2B). However, the structural
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Figure 2: Schematic Summary Of Vesicular Transport From Budding To Fusion. The Schematic
shows the principle of vesicle biogenesis at the donor membrane and fusion with the acceptor membrane
as described in the text; A: Bud Initiation; B: Pinch-off; C: Uncoating; D: Tethering; E: Docking;
F: Fusion; v-SNAREs are mostly R-SNAREs, t-SNAREs mostly Q-SNAREs; not drawn to scale;
inspired by Bonifacino and Glick (2004)
deformation of membranes is not the only function of coat proteins. They also interact
with recognition motives in cargo proteins and concentrate them in the budding vesicle.
These cargo proteins are often transmembrane proteins that interact with coat proteins
by their cytoplasmic domain (Fig.2A and B). They themselves may be cargo receptor
proteins, which bind soluble proteins in the lumen of the compartment and thus recruit
them specifically to the carrier vesicle (e.g. the lectin ERGIC53, (Hauri et al., 2000)).
Another functional class of proteins, the SNAREs (SNAP receptors), are also recruited to
the membrane of the budding vesicle and are necessary for vesicle fusion with the target
membrane (Sollner et al., 1993; Short and Barr, 2004). Furthermore, molecular motors
and their cargo adaptors are often needed on the vesicle to give them directed motility.
They are recruited from the cytosol after coat disassembly (Allan et al., 2002).
At some point in the budding process, the GTP hydrolysing activity of the coat initiating
small GTPase is triggered by a GTPase activating protein (GAP) and the coat disassem-
bles (Kirchhausen, 2000). Subsequently, the vesicle is prepared for fusion with the target
membrane by recruiting additional factors for tethering and priming the SNAREs (see
Fig.2 A, B and C).
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Tethering When reaching the acceptor membrane, vesicles undergo a process called
tethering (Fig.2D), in which long coiled-coil proteins, so-called golgins, and protein com-
plexes (e.g. TRAPP, Exocyst, VFT, HOPS) establish long-range contact between the
membranes (Shorter and Warren, 1999; Sonnichsen et al., 1998). These tethers are often
recruited to donor and acceptor domains by small, Ras-like GTPases. In the case of the
Golgin p115 (Uso1p in S.cerevisiae) this is Rab1 (Ypt1 in S.cerevisiae) (Allan et al., 2000;
Cao et al., 1998). Other golgins have also been reported to bind to Golgi-Reassembly-
and-Stacking-Proteins (GRASPs), like GM130, which binds to GRASP65 (Barr et al.,
1998). After establishing a first contact between vesicle and acceptor membrane, vesicle
diffusion is limited. The tether collapses the vesicle onto the target membrane to reduce
the distance between the surface of the two bilayers and the actual fusion is initiated by
the SNARE proteins (Fig.2 E and F).
SNAREs SNAREs are proteins with a C-terminal α-helical transmembrane anchor, or,
as in the example of Ykt6 or SNAP-25, with a C-terminal lipid moiety for membrane
insertion (Nichols and Pelham, 1997). The N-terminus is variable and the middle part
consists of heptad repeats of hydrophobic amino acids. This allows the protein to form
coiled-coils of α-helices, which are able to form a bundle of four parallel helices with other
SNARE proteins (Weber et al., 1998). This finally drives merging of the membranes
and the fusion of the vesicle with the target membrane (Weber et al., 1998). SNAREs
are divided into four classes: R-SNAREs with an arginine residue in the centre of the
SNARE domain and Qa-, Qb-, Qc-SNAREs with a glutamine instead of arginine. Each
SNARE bundle, also called SNAREpin, consists of one of each R-, Qa-, Qb- and Qc-
SNARE (Weimbs et al., 1997; Fasshauer et al., 1998; Bock et al., 2001).
SNAREs localised to the same membrane compartment are found assembled into cis-
SNARE complexes and would thus be unable to drive membrane fusion. They have to be
primed, which is done by the cytosolic NSF (N-ethylmaleimide sensitive fusion protein)
(Hanson et al., 1995, 1997). This is an ATPase associated with diverse cellular activities
(AAA), which is recruited to SNARE bundles by a second soluble factor: SNAP (α-,
β- or γ-soluble NSF attachment proteins)(Clary et al., 1990). NSF is inactivated by
N-ethylmaleimide’s cysteine alkylating activity, thus its name. NSF hydrolyses ATP,
delivering the needed energy to unravel the SNARE bundle leaving the single SNAREs
in an energy rich state (Wilson et al., 1992; Whiteheart et al., 1992). This is believed to
overcome the energy barrier of membrane fusion. How specificity of SNARE bundling is
achieved is still unknown, but it is suspected, that the factor Sec1/Munc18 (SM proteins)
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could interact with SNAREs (Nichols and Pelham, 1997), probably on their N-terminus
and act as fusion inhibitor until the vesicle reaches the proper target membrane. Vesicle
tethers, like p115, are also supposed to prevent premature SNAREpin formation (Shorter
et al., 2002).
COPII-Coated Vesicles COPII-coated vesicles are carriers of the anterograde trans-
port from the ER to the ER-Golgi-Intermediate Compartment (ERGIC) (Barlowe et al.,
1994). They might also be involved in the anterograde transport of cargo from cis-Golgi to
later Golgi cisternae. The 60-100 nm sized COPII vesicles form at ER exit sites (ERES),
stable membrane domains on the smooth ER (Murshid and Presley, 2004).
COPII-coat formation is initiated by the GTP-bound Ras-like GTPase Sar1. This GTP-
ase recruits the coat complex Sec23/24 from the cytosol to the endoplasmic reticulum
membrane to form the “pre-budding complex” (Bonifacino and Glick, 2004). Prior to
this, Sar1 is activated by the guanine nucleotide exchange factor (GEF) Sec12 by indu-
cing the exchange of GDP to GTP in the centre of Sar1 (Barlowe and Schekman, 1993).
The pre-budding complex recruits a heterotetramer, containing two Sec13 and two Sec31
subunits, which form a mesh-like scaffold on top of the Sar1-Sec23/24 coat (Lederkremer
et al., 2001). The polymerising coat deforms the membrane to form a bud, which eventu-
ally pinches off the membrane. Whether the neck of the nascent vesicle is closed by coat
protein or if there is a factor, which helps this process is presently unknown (Bonifacino
and Glick, 2004).
The hydrolysis of Sar1 is activated by the Sec23 subunit of the coat complex. Addition-
ally, Sec13/31 improve the GAP-activity of Sec23 (Bi et al., 2002). Inactivation of Sar1
leads to uncoating of the vesicles. How this is coordinated on a temporal scale, so that
the nascent vesicle is not uncoated too early, is still subject of speculation.
While the vesicle is formed it is loaded with cargo at the same time. Transmembrane
cargo proteins bind directly to the COPII coat, whereas soluble cargo binds indirectly by
the means of cargo receptors (Appenzeller et al., 1999; Muniz et al., 2000; Powers and
Barlowe, 2002). The receptors unload their cargo at the target compartment. Cargo and
cargo receptors show specific recruitment signals in their cytoplasmic tail. Most common
motifs are di-acidic ([DE]X[DE]) (Nishimura and Balch, 1997) or short hydrophobic se-
quences (FF, YYM, FY, LL, IL) (Kappeler et al., 1997; Nakamura et al., 1998). For ER
export signal recognition the Sec24 component is the major player (Barlowe, 2003). In
humans there are four Sec24 isoforms, each of, which show three different cargo binding
sites. As there are also two isoforms of Sar1 and two Sec23 isoforms, it is likely that
specificity of cargo recruitment can be regulated and that specialised COPII vesicles exist
for different species of cargo (Fromme and Schekman, 2005). Important cargo receptors
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like p24 and ERGIC-53 are discussed below. After uncoating, the COPII vesicles are
tethered to each other and undergo homotypic fusion to form the ERGIC. The tethering
agents are p115/Uso1p and Rab1 (Cao et al., 1998; Allan et al., 2000). Rab1 is activated
by its GEF (Allan et al., 2000; Cao et al., 1998), which is in fact a component of the seven
subunit comprising complex called “transport protein particle I” (TRAPPI)(Wang et al.,
2000), and recruited to the COPII vesicle by the Sec23 COPII subunit (Cai et al., 2007).
Vesicle fusion is driven by the SNAREs, which form SNAREpins of three Q-SNAREs and
one R-SNARE (see 1.2.2, p.7)(Fasshauer et al., 1998). In the early secretory pathway five
SNAREs have been identified, which are Syntaxin5 (Sed5p), Ykt6 (Ykt6p) as Q-SNAREs
and Sec22 (Sec22p), Bet1 (Bet1p) and Membrin (Bos1p) as R-SNAREs (Nichols and
Pelham, 1997).
COPI-Coated Vesicles COPI coatomer vesicles are also part of the early secretory
pathway. They are important for retrograde traffic from Golgi-to-VTC-to-ER, but also
for retrograde traffic within the Golgi, where it recycles early Golgi proteins back to fur-
ther cis-localised cisternae (Kirchhausen, 2000; Murshid and Presley, 2004). Transport
from Golgi to ER or VTC to ER is especially needed to recycle cargo receptors of the
anterograde pathway, like p24 or ERGIC-53 (Letourneur et al., 1994; Fiedler et al., 1996).
Cargo is recruited by the γCOP subunit, which recognizes a di-lysine (KKXX, KXKXX)
signal (Harter et al., 1996). The multi-spanning membrane protein KDEL receptor re-
trieves proteins by their lumenal KDEL signal and recruits them to the COPI vesicles
(Pellham, 1990).
COPI is a seven subunit complex (α, β, β′, γ, δ, ε, ζ) (Kirchhausen, 2000). COPI for-
mation is initiated by the GTP-bound, active Arf1 GTPase. This GTPase is activated
by its early Golgi localised guanine nucleotide exchange factor (GEF) GBF1 (Kawamoto
et al., 2002; Zhao et al., 2002; Garcia-Mata et al., 2003). Arf1 binds directly to the β-
and γ-subunit (Majoul et al., 2001; Zhao et al., 1999). The remaining components are
then recruited to the complex, together with cargo, cargo receptors and the Arf1 GTPase
activating protein ARFGAP (Goldberg, 1999). COPI and ARFGAP stimulate hydrolysis
of Arf1 bound GTP and thus inactivation, which leads to subsequent uncoating of vesicles
(Kirchhausen, 2000).
Tethering of retrograde intra-Golgi transport vesicles happens most probably by the in-
teraction of giantin and p115 with GM130 (Sonnichsen et al., 1998). Another tethering
complex implied in COPI retrograde trafficking is the COG complex, which is composed
of eight subunits (Ungar et al., 2006). Whether it is a tether for specific COPI vesicles or
co-acts with the p115-GM130-Giantin tether is yet unknown.
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Cargo Receptor ERGIC-53 One important cargo receptor incorporated into COPII
vesicles is the lectin ERGIC-53 (ER-Golgi-Intermediate Compartment Protein of 53kDa;
p58 in rat) (Hauri et al., 2000). This type I transmembrane protein is most concentrated in
the vesicular-tubular clusters, but could also be found in the ER and cis-Golgi. ERGIC-53
contains a CRD (carbo-hydrate recognition domain) in its N-terminal, lumenal domain.
It binds soluble D-Mannose glycoproteins from the ER lumen and recruits them into the
nascent vesicle. ERGIC-53 forms homodimers and homohexamers (Schweizer et al., 1988;
Lahtinen et al., 1992) by disulfide bridging.
In its cytosolic C-terminus, ERGIC-53 also shows a di-lysine KKXX signal, which allows
it to be sorted back to the ER by the COPI vesicle coat (Schindler et al., 1993). Thus
ERGIC-53 cycles from the ER to the ERGIC and cis-Golgi by the anterograde transport
machinery and is retrieved to the ER by retrograde transport.
Cargo Receptor p24 Family Members of the p24 cargo receptor family are trans-
membrane proteins with a short C-terminal stretch, which contains recognition signals
for COPI- and COPII-coat recruiting (Dominguez et al., 1998; Stamnes et al., 1995; Rojo
et al., 1997). p24 family members cycle between ER and Golgi, transporting lumenal
cargo (Muniz et al., 2000; Dominguez et al., 1998). It has been found that oligomers of
some p24 family members interact with GRASPs (see 1.1.2, p.2) by their cytoplasmic
domain and that this interactions prevents p24 export to the cell surface (Barr et al.,
2001).
1.3 Small GTPases
Rab- and Arf-Proteins are small monomeric GTPases or guanine nucleotide binding pro-
teins (GNBPs). They are part of the Ras superfamily (Pereira-Leal and Seabra, 2000;
Burd et al., 2004), which also includes Ras, Rho/Rac and Ran. They are 20 to 25 kDa in
size and regulate growth, motility and trafficking by acting as molecular switches. They
change from an inactive, GDP-bound to an active, GTP-bound state in a regulated and
timed manner.
All small G-proteins (which also include the α subunit of the heterotrimeric G-Protein
and factors of protein synthesis) have a common structural feature, the G-domain (Vetter
and Wittinghofer, 2001). The G-domain is a α-β-structure made from a mixed 6-stranded
beta sheet and five helices located on both sides. The catalytic centre contains a Mg2+
ion and the guanosine nucleotide, which is bound between the P-loop and the two switch
regions, switch I and II. In the active form, the switch regions build hydrogen bonds to
the γ-phosphate of GTP by conserved threonine and glycine residues. The conformation
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is often compared to a loaded spring mechanism, as hydrolysis of the GTP releases the
two switch regions and leads to profound conformational changes.
As both, the GDP to GTP exchange and the GTP hydrolysis are rather slow, accessory
proteins are needed to accelerate the processes. For activation GNBPs interact with gua-
nine nucleotide exchange factors (GEFs) (Klebe et al., 1995), for inactivation they depend
on the GTPase activating proteins (GAPs) (Scheffzek et al., 1998). The conformational
change during activation of the GTPase allows effectors to bind with the GTPase and
form an active complex.
Mutations in two conserved residues of Ras have been found to lock the protein in one of
the two conformations, active or inactive. Mutation of threonine 35 to asparagine keeps
Figure 3: Phylogenetic Tree Of The Rab-, Arf- And Arl-Family. Phylogenetic tree of the human
and S.cerevisiae Arf- and Arl-family, compared to selected members of Rab-GTPases involved in
membrane trafficking; black: human Arl; violet: human Arf; red: human Rab, blue: S.cerevisiae Arf;
light blue: S.cerevisiae Arl; generated with VectorNTI 10 (Invitrogen).
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the GTPase in its inactive, GDP-locked conformation, mutation of a catalytic glutamine
to leucine or alanine (Haas et al., 2005) prevents the GTPase from hydrolysing the GTP
to GDP and thus remains constitutively active.
For intracellular transport three families of the Ras superfamily are of special importance
(Fig.3): the Rabs, the ADP-ribosylation factor (Arf) and ADP-ribosylation factor like
(Arl) proteins.
1.3.1 Rab GTPases
The Rab family is one of the biggest of the Ras-superfamily. It consists of more than
60 members (Short et al., 2005). Rabs contain the G-domain as a basic unit, but some
features are specific for Rab GTPases and set them apart from other members of the su-
perfamily (Vetter and Wittinghofer, 2001). They have a highly flexible C-terminus with
a double cysteine prenylation signal. This lipid tail is inserted into the target membrane
(Rak et al., 2003; Sivars et al., 2003). In their inactive form, Rabs are found soluble in
the cytosol, which makes it necessary for the hydrophobic prenylated tail to be protected
by GDIs (guanine nucleotide dissociation inhibitors), which shield the hydrophobic lipid
moiety against the hydrophilic environment.
Thus, Rab GTPases cycle between the cytosol and the target membrane. GDP-bound,
inactive Rab is associated with GDI in the cytosol, gets delivered to the target membrane,
binds its GEF and gets activated. After interacting with its effectors, Rabs subsequently
are deactivated by their specific GAP and leave the membrane, again bound to the GDI
(Pfeffer and Aivazian, 2004; Short et al., 2005).
Rab GTPases are involved in many different processes. They give identity to the mem-
branes of organelles of the endocytic and secretory pathway (Pfeffer, 2001; Short et al.,
2005; Zerial and McBride, 2001), like Rab5 (early endosomes) and Rab7 (late endosomes)
(Miaczynska and Zerial, 2002; Maxfield and McGraw, 2004). Rabs are involved in vesicle
tethering, like Rab1 (Allan et al., 2000; Moyer et al., 2001) and Rab2 (Short et al., 2001),
and vesicle motility, like Rab6 (Short et al., 2002; Matanis et al., 2002). A recent find-
ing by Yoshimura et al. (2007); Nachury et al. (2007) showed that Rab8a is involved in
primary cilium formation and that loss of Rab8a prevents cilium growth, whereas Rab8a
overexpression provokes formation of an exaggerated primary cilium.
When Rabs are targeted to the membrane they recruit their effectors either from the cy-
tosol or from the pool of membrane bound proteins. In this process, many Rabs bind to
golgins and other proteins with coiled-coil structures and may change their conformation
(Short et al., 2005; Pfeffer, 2001). The Rab GTPase family is one of the most impor-
tant regulators of intracellular traffic and a number of Rab proteins still has no function
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assigned to them.
1.3.2 ADP-Ribosylation Factors
Another class of small G-proteins involved in membrane trafficking are the ADP-ribosyla-
tion factor proteins (Chavrier and Goud, 1999). They were initially discovered as co-
factors in the cholera toxin induced ADP-ribosylation of the Gs-subunit of the het-
erotrimeric G-proteins (Kahn and Gilman, 1986). In human cells five members of the
Arf family are expressed. They are divided into three groups: class I containing Arf1 and
Arf3 (some mammals like mouse and rat also have Arf2), class II containing Arf4 and
Arf5 and class III containing Arf6. Arf1 and Arf3 might be redundant, although most
experimental results were achieved with Arf1. Arf4 and Arf5 have partially overlapping
functions with class I Arfs. The most divergent member is Arf6, which is not Golgi lo-
calised but is found at the plasma membrane (Gillingham and Munro, 2007).
By sequence homology another subgroup of Arfs, termed Arf-like (Arl) proteins, has been
found (human Arl1 shares 56% identity and 76% similarity with human Arf1) (Burd et al.,
2004). The main difference in comparison to Arf is that Arf-like proteins cannot function
as cofactors for cholera toxin (Tamkun et al., 1991). The Arl protein family consists of
about 20 members (Fig.3, p.11). Most Arl proteins have unknown functions. The small
GTPase Sar1 (see 1.2.2, p.8) is also a distant Arf-family member (Munro, 2005).
Arf proteins feature a G-domain (Vetter and Wittinghofer, 2001), but instead of a flex-
ible C-terminal tail with a prenyl anchor, like in Rab proteins, they have an N-terminal
amphipathic helix by which they bind to membranes (Amor et al., 1994). This amphi-
pathic helix is myristoylated in most Arfs. Exceptions are Sar1, the acetylated Arls, like
AFRP1/Arl3p (Behnia et al., 2004; Setty et al., 2004), Arl8A/B (Hofmann and Munro,
2006) and Arls with a myristoylation signal, which is probably not myristoylated (Arl2
and Arl3) (Sharer et al., 2002).
Additionally, Arf proteins have a unique structural feature in comparison to all other
small G-proteins (Pasqualato et al., 2002), the interswitch toggle. The loop connecting
switch I and switch II of the nucleotide binding domain forms a hydrophobic pocket in the
GDP-bound conformation. This hydrophobic pocket can accommodate the amphipathic
helix with its hydrophobic myristoyl moiety. Upon nucleotide exchange, the interswitch
toggle undergoes a two-residue register shift, which causes the hydrophobic pocket to
vanish. The amphipathic helix is released and ready for membrane binding. This has two
consequences: first, in the Arf family, activation and membrane binding are tightly linked
and, second, Arf family members do not need GDP-dissociation inhibitors (GDI) to travel
through the cytosol (Gillingham and Munro, 2007), as the hydrophobic membrane anchor
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is secured within the interswitch pocket. Additionally, the amphipathic helix is short in
comparison to the Rab C-terminus, which brings the Arf GTPase and its effectors closer
to the membrane (Neu et al., 1997).
Two of the best studied Arf GTPases are the Golgi localised Arf1 and Arl1.
ADP-Ribosylation Factor 1 Arf1 is crucial in intracellular transport and in organelle
organisation (Bonifacino and Lippincott-Schwartz, 2003). The key function of Arf1 is
twofold. First, it initiates Golgi-to-ER retrograde trafficking by assembling the COPI
coat (see 1.2.2, p.9). Second, it is required for TGN-to-endosome trafficking as it regulates
assembly of the clathrin coat at both compartments, TGN and endosomes. Thus, Arf1
can be found on all Golgi cisternae, its spacial specificity regulated by different factors.
The most important regulator is the guanine nucleotide exchange factor, which activates
the GTPase by replacing GDP for GTP. There are a total of 7 Arf GEF families. They
are peripheral membrane proteins with a central, conserved 200 residue domain, the Sec7
domain (Chardin et al., 1996). The seven families are GBF (Golgi specific Brefeldin A
resistance factor), BIG (BFA Inhibited GEF), PSD (PH and Sec7 domain), IQSEC (IQ
and Sec7), cytohesin and FBXO8. For most of them substrate specificity is not entirely
clear, but it is proposed that GBF1 acts on cis-Golgi localised Arf1 and is involved in
COPI vesicle formation (Gillingham and Munro, 2007). BIG is trans-Golgi localised and
acts in clathrin coated vesicle formation (Shinotsuka et al., 2002).
Arf1 activation can be blocked by the fungal compound Brefeldin A. Brefeldin A binds
at the interface between Arf1 and its GEF and forms a stable Arf1-GDP-GEF complex.
All available GEF protein is sequestered and Arf1 cannot be activated, Arf1-dependent
transport is inhibited and Golgi proteins redistribute to the ER (Sciaky et al., 1997).
The GTPase activating proteins (GAPs) of Arf1 have a 140 residue domain in common.
It was discovered in ArfGAP1 and DDEF1 (Goldberg, 1999; Mandiyan et al., 1999). The
24 known ArfGAPs can be divided into 10 families: ArfGAP1, ArfGAP3, SMAP, Hrb,
Git, Centaurin α, β, γ and δ and DDEF1 (Gillingham and Munro, 2007). Furthermore,
it is proposed that in COPI-assembly the coatomer Sec23 subunit greatly stimulates the
ArfGAP activity and may, in fact, even be more important for Arf inactivation (Goldberg,
1999).
Two more functions of Arf1 will be discussed briefly. First, Arf1 influences the lipid
composition of membranes by recruiting and/or activating phospholipase D (PLD) (Brown
et al., 1993) and Phosphatidylinositol 4-kinase (PI4K) Type IIIβ (Haynes et al., 2005).
Second, in S.cerevisiae, Arf1p recruits the golgin Rud3p to the cis-Golgi (Gillingham
et al., 2004).
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ADP-Ribosylation Factor Like 1 And The GRIP Domain Arl1 is a trans-Golgi
localised small GTPase (Munro, 2005). Although its GEF is still elusive, it is known
to be recruited to the Golgi apparatus by a cascade of signals, which involves the small
Arl GTPase AFRP1 (Arf related protein 1)/Arl3p (Behnia et al., 2004; Setty et al.,
2004). AFRP1 is rather divergent from the Arl family (Fig.3, p.11). This becomes most
obvious by the fact that it is not myristoylated on its N-terminal amphipathic helix, but
acetylated (Behnia et al., 2004; Setty et al., 2004). Upon activation AFRP1 binds to
the four transmembrane protein Sys1 (Fig.4). The following steps in the cascade are
unknown, but in this process Arl1 is recruited to the trans-Golgi membrane and activated
(Behnia et al., 2004; Setty et al., 2004).
Arl1 itself is necessary to bind a special class of golgins to the trans-Golgi membrane
(Munro and Nichols, 1999; Gangi-Setty et al., 2003; Panic et al., 2003a; Wu et al., 2004).
These golgins have a conserved 50 amino acid motif at their C-terminus, the GRIP domain
(Golgin-97, RabBP2α, Imh1p, p230). The first two helices of the GRIP domain interact
mainly with the switch II region, but also partially switch I and the interswitch region of
Arl1 (Wu et al., 2004).
The GRIP domain protein binds as a homodimer and needs two active Arl1 molecules.
A conserved tyrosine residue is absolutely necessary for Golgi binding (Y697 in Golgin-97
(Barr, 1999), Y2185 in Golgi-245 (Panic et al., 2003b)). It is proposed that residues at
the C-terminus of the GRIP domain protein are inserted into the membrane.
In mammals there are four proteins, which comprise a GRIP domain: Golgin-97, p230/gol-
gin-245, GCC185 and GCC88 (Barr and Short, 2003; Gillingham and Munro, 2003). In
yeast there is only one, Imh1p. They are all involved in endosome to TGN trafficking
Figure 4: Binding Of GRIP Domain Proteins To ADP-Ribosylation Factor Like 1.
Left: Structure of the Arl1/GRIP complex; N-terminal myristoyl group and GRIP domain trypto-
phanes are inserted into the membrane; adapted from Panic et al. (2003b). Right: Schematic steps
of Arl GTPase cascade necessary for GRIP protein recruitment to the Golgi; AFRP1 is activated and
binds to the transmembrane protein Sys1; this activates and recruits Arl1 from the cytosol to the
membrane, where two molecules Arl1 bind to a GRIP domain protein dimer; not drawn to scale.
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(Lu et al., 2004; Yoshino et al., 2003). Deletion of Arl1 or competing for Arl1 binding by
overexpressing a GRIP domain-only construct, removes Golgin-97 and Golgi-245 from the
Golgi and inhibits Shiga-toxin transport to Golgi and TGN46 recycling (Lu et al., 2004;
Yoshino et al., 2003). Recent evidence shows that the golgin GCC185 may participate
in the docking of late endosome-derived, Rab9-bearing transport vesicles at the TGN
(Reddy et al., 2006).
1.4 Golgi And The Cytoskeleton
1.4.1 Microtubules, Dyneins And Kinesins
Microtubules form a major part of the cytoskeleton. In fibroblasts microtubules originate
from the microtubule organising centre (MTOC) or centrosome and radiate out to the cell
periphery (Hirokawa and Takemura, 2004). They are the main component of the mitotic
spindle and are necessary for separating the homolog chromosomes in mitosis, but are
also necessary for organelle movement in interphase cells (Raynaud-Messina and Merdes,
2007).
Microtubules are built of α- and β-tubulin, which polymerise to form thirteen paral-
lel protofilaments of linearly arranged heterodimers (Hirokawa, 1998). For nucleation,
microtubules need a third tubulin, γ-tubulin, which forms, together with accessory pro-
teins, γ-tubulin small complexes (γ-TuSC) or bigger γ-tubulin ring complexes (γ-TuRCs)
(Raynaud-Messina and Merdes, 2007). The Microtubules are 25 nm in diameter and have
a fast growing end, the microtubule plus-end, and a slow growing end, the microtubule
minus end. Building blocks are constantly dissociating from microtubules and it depends
on the rate of assembly versus disassembly whether microtubules grow on the plus-end or
shrink. This mechanism is called “tread-milling” and allows the microtubule network to
scan the cell’s interior for binding partners (Vaughan, 2005).
The microtubules form “rails” for microtubule motors (Hirokawa, 1998), but can also
anchor structures to their ends, like the kinetochore of chromosomes. This allows the cell
to organise its interior by active transport and anchoring.
In most cell lines, the Golgi apparatus is situated near the microtubule organising cen-
tre (MTOC) (Allan et al., 2002). Microtubule depolymerising drugs, like nocodazole,
cause the Golgi apparatus to fragment into mini-stacks near the ER-exit sites (Thyberg
and Moskalewski, 1999) and to reform into a normal Golgi ribbon near the MTOC upon
washout of the drug (Ho et al., 1989). This clearly shows that the microtubule network
and its molecular motors are essential for Golgi morphology and positioning.
An effect similar to the one caused by microtubule depolymerisation could be achieved
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by inactivation or depletion of cytoplasmic dynein (Burkhardt et al., 1997). Dynein is
a microtubule minus-end directed, molecular motor, which is attached to Golgi or vesi-
cle membranes by the protein complex dynactin. Dynactin localisation at membranes
is dependent on the small GTPase Rab6, which recruits the dynactin subunit p150glued
(Matanis et al., 2002; Short et al., 2002) and the golgin Bicaudal-D (Hoogenraad et al.,
2001). As dynactin binds to microtubule plus-ends, a search and capture mechanism
for microtubule-membrane interaction is proposed (Vaughan, 2005): microtubules grow
from the MTOC and “search” the cytoplasm for membrane bound dynactin. After es-
tablishing contact, dynein is recruited and the captured membranes start travelling to
the microtubule minus-ends. By this mechanism, dynein brings ER-Golgi-intermediate
compartments (see 1.2.2, p.8) to the Golgi cis-face or aid in recycling protein from the
trans-Golgi to the ER, independent of COPI (Young et al., 2005). Distribution of en-
docytic cargo carriers is also influenced by dynein/dynactin and interaction of the late
endosomal Rab, Rab7, with dynein/dynactin has been proposed (Murshid and Presley,
2004). This would enable directed transport of vesicles from late endosomes to the TGN.
In contrast to dynein-bound vesicles, vesicles leaving the Golgi apparatus travel in the
opposite direction. Kinesins are molecular motors directed to the microtubule plus-ends
(Hirokawa, 1998). In humans, like in mouse, there are 45 kinesins (Miki et al., 2001) and
many of them are thought to be involved in intracellular trafficking. The isoform Kif5B
has been found at the Golgi apparatus (Gyoeva et al., 2000) and knockdown by siRNA
caused the Golgi to acquire a compact structure (Feiguin et al., 1994). Several other
kinesins are supposed to be involved in transport away from the Golgi to the microtubule
plus-ends and thus may bring exocytic vesicles from the Golgi to the plasma membrane
(Hirokawa, 1998). This is especially true in neurons, where the localisation of cargo is
more specialised and it is likely that more and different kinesins are involved (Hirokawa
and Takemura, 2004). Notably, in polarised epithelial cells the Golgi is positioned at
the microtubule plus-ends and thus directions of transport are reversed (Hirokawa and
Takemura, 2004).
Apart from centrosomally anchored microtubules, microtubules could origin from the cis-
Golgi (Chabin-Brion et al., 2001; Marsh et al., 2001). Here the golgin GMAP-210 is
implied (Infante et al., 1999) as anchoring agent. CLASP (Clip-associating protein) is an-
other protein, which binds to microtubule plus-ends and stabilises them at the cell cortex
(Mimori-Kiyosue et al., 2005). It also localises to the Golgi apparatus, but its function
there is not yet clear. The microtubule binding protein Hook3 is also localised on cis-Golgi
membranes and is supposed to anchor the Golgi apparatus near the centrosome (Walenta
et al., 2001).
Considering all this, the importance of the microtubule cytoskeleton for Golgi positioning,
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maintenance and morphology becomes obvious.
1.4.2 Actin, Spectrin And Intermediate Filaments
The second big cytoskeletal system is the actin network. Actin fibres are nucleated at
different places in the cell. The most prominent place is the plasma membrane (Wang,
1985; Svitkina et al., 1986), where actin is involved in endocytosis and cell motility. Actin
filaments are built of actin monomers (G-actin) and have, like microtubules, a plus-end
(barbed end) and a minus-end (pointed end). The cortical actin network is most often
of mixed polarity (Lewis and Bridgeman, 1992). Actin filaments also form stress fibres,
lamellipodia and filopodia (DePina and Langford, 1999) and are found in the cytosol in-
teracting with organelles and microtubules.
The Golgi apparatus is linked to the actin meshwork and it is implied in different func-
tions of transport and Golgi morphology. The actin associated motor protein Myosin Va
is in complex with the small GTPase Rab27a and melanophilin on melanosomes and is
involved in their trafficking to the plasma membrane (Fukuda et al., 2002; Wu et al.,
2002). Other Myosin motors, like Myosin VI, or the propelling force of assembling actin
comets could transport vesicles away from Golgi membranes nearer to microtubule based
motors where vesicles are captured for long range transport (Egea et al., 2006).
Additionally, actin is not only involved in vesicle budding and transport, but also in main-
tenance of Golgi morphology. Disruption of the actin network by drugs like latrunculin,
causes the Golgi cisternae to fragment, swell (Lazaro-Dieguez et al., 2006) and increase
their intra cisternal pH. Microtubules had no influence in this morphological change.
It is also interesting to note that the small GTPase Arf1 (1.3.2, p.14), which is involved
in initiation of clathrin and COPI coat formation (see 1.2.2, p.9), also recruits the Rho-
GTPase Cdc42 to the Golgi and thus induces actin polymerisation (Stamnes, 2002). Cdc42
binds to γCOP, but competes with the p23 cargo receptor. Furthermore the Golgi bound
Cdc42-GAP, ARHGAP10, is dependent on Arf1 (Dubois et al., 2005). Actin nucleation
and polymerisation need the effectors WASP (Wiskott-Aldrich syndrome protein) and
Arp2/3 (Matas et al., 2004). Cdc42 bound to coatomer recruits these actin nucleators
and prevents dynein binding to the nascent vesicle (Chen et al., 2005). Hehnly and
Stamnes (2007) propose that Cdc42 prevents premature dynein driven transport of the
forming vesicle.
The actin network interacts also with the spectrin network. Spectrin was identified in
erythrocytes on the cytosolic face of the plasma membrane. It gives structure to these
cells (Luna and Hitt, 1992). On the Golgi apparatus special isoforms of spectrin and its
adaptors the ankyrins have been identified, which have links to every cytoskeletal net-
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work, especially to the actin meshwork (DeMatteis and Morrow, 2000). Spectrin anchors
the dynactin complex to the membrane and thus is necessary for microtubule minus-end
directed transport (Holleran et al., 1996). Its localisation to the Golgi is dependent on
Arf1 function and it is removed immediately by BFA treatment (DeMatteis and Morrow,
2000). Its function in Golgi morphology and transport, however, is still not clear.
The third network of cytoskeletal structures in eukaryotic cells are the intermediate fila-
ments. IFs are different, depending on cell type, and consist of keratins, neurofilament-like
proteins, lamins or the vimentin-related proteins (desmins, glial fibrillary acid proteins,
peripherins)(Gao and Sztul, 2001). Vimentin IFs have also been shown to interact with
Golgi localised proteins, although the function is not known yet.
1.5 The Intraflagellar Transport System
Cilia and flagella are organelles found in many cells and organisms. They function in
cell mobility or for sensory reception (Scholey, 2003) and are formed of a microtubular
axoneme (Fig.5), protruding from the basal body and sheathed by plasma membrane
(Rosenbaum and Witman, 2002). This complex structure is built by a unique machinery,
which transports axonemal building blocks from the cytoplasm to the distal tip of the
cilium or flagellum. The transport within the cilium is independent of vesicular membrane
carriers, but relies on a unique proteinaceous particle complex, the intraflagellar transport
(IFT) machinery (Koeminski et al., 1993; Qin et al., 2004).
Many studies about the intraflagellar transport system were performed in Chlamydomonas
reinhardtii and Caenorhabditis elegans, but most findings also apply to mammals.
1.5.1 Cilia And Flagella: Morphology And Function
Cilia and flagella are cylindrous protrusions from the plasma membrane, which contain an
axoneme (Johnson, 1995; Porter and Sale, 2000). In motile cilia and flagella, this structure
is built in a 9+2 conformation (Fig.5), which means 9 microtubule doublets surround a
central microtubule doublet. The outer doublets are linked by inner and outer dynein
arms and are connected to the central doublet by radial spokes. The dyneins cause
sliding of microtubules against each other, while radial spokes, nexins and the central
microtubule pair transform the movement into coordinated cilium beating (Scholey, 2003).
Non-motile cilia, so-called primary cilia, have a simpler composition, as the axoneme is
missing dynein, nexin arms, radial spokes and the central doublet (9+0) (Perkins et al.,
1986). In both types, the axoneme grows directly from the basal body, which moved into
the vicinity of the plasma membrane upon cilium formation. The basal body is built
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from a ring of triplet microtubules and is attached to the plasma membrane by transition
fibres (Rosenbaum and Witman, 2002), which separate the space within the cilium from
the cytoplasm (Witman, 1990) (Fig.5). Although primary cilia were considered immotile,
it has become clear that at least cilia on embryonic nodal cells are motile (Nonaka et al.,
1998). Their beating is necessary for establishing left-right asymmetry in the embryo
(Nonaka et al., 2002).
Flagella are necessary for cell motility, but also for signalling as has been shown in mating
Chlamydomonas (Wang et al., 2006). One example for specialised, immotile, primary
cilia is the vertebrate photoreceptor. These polarised sensory neurons consist of the
cell body (called inner segment IS) and the outer segment (OS), which contains discs
of membranes where opsin, a photosensitive protein, can be found. The OS is formed
from a primary cilium (DeRobertis, 1958; Tokuyasu and Yamada, 1959) and a small
9+0 connection still exists in adult vertebrates. By this bridge protein is shuttled from
the IS, where it is synthesised, to the OS. Failure by the cell to do so causes rapid
degeneration of the photosensitive stacks and destruction of the outer segment, which
leads to blindness (Sung and Tai, 2000). Primary cilia also function as chemical sensors in
Figure 5: Intraflagellar Transport And Cilium with 9+2 Morphology. Left: Schematic overview
of the intraflagellar transport of cargo from the cytoplasm to the cilium tip and retrograde transport
to the base; arrows indicate movement direction; cilium is simplified and not to scale; Right: section
of cilium; 9+2 structure with outer and inner microtubule doublets; A: A-fibre of outer microtubules;
B: B-fibre of outer microtubules; CD: central microtubule doublet with sheath; FM: flagellar membrane;
IA: inner dynein arms; OA: outer dynein arms; N: nexins; RS: radial spokes; not to scale.
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olfactory and auditory sensory cells, mechanosensors in bone and kidney and are vital for
signal transduction, providing a platform where membrane receptors can be concentrated
(Scholey, 2003; Rosenbaum and Witman, 2002; Scholey and Anderson, 2006).
1.5.2 Intraflagellar Transport
Cilia and flagella are assembled by the intraflagellar transport machinery (Qin et al.,
2004). This machinery consists of several proteins organised in two complexes or lobes.
Lobe A consists of about 4-6 polypeptides and is supposed to bind to a version of flagellar
transport specific, cytoplasmic dynein (Dhc1b/Dhc2) (Cole et al., 1998; Pazour et al.,
1998, 1999). It is involved in retrograde transport from the cilium tip to the basal body.
Lobe B consists of about 11-13 proteins (Cole et al., 1998; Piperno et al., 1998) and
binds to heterotrimeric kinesin-II (Cole et al., 1998). The IFT-machinery was observed
by electron microscopy and formed readily visible rafts, which travel on the B fibre of the
outer microtubule doublets of the axoneme, directly underneath the plasma membrane
sheath of the cilium (Ringo, 1967)(Fig.5). After reaching the distal tip with the help of
MT-plus-end directed kinesin-II, cargo is unloaded, kinesin deactivated and minus-end
directed dynein activated. The IFT particle travels back to the basal body (Koeminski
et al., 1993). Apart from transporting building blocks for the axonemes, it is proposed
that the IFT machinery also helps to bring cilium-localised receptors to the cilium mem-
brane compartment. Thus, it not only builds the cilium but is also necessary for its
function (Scholey and Anderson, 2006; Qin et al., 2005; Pan and Snell, 2003).
Defects of the IFT machinery cause severe diseases like blindness, deafness, polycystic
kidney disease and situs inversus amongst others (Bisgrove and Yost, 2006).
1.5.3 Heterotrimeric Kinesin-II
Heterotrimeric kinesin-II consists of two motor proteins, Kif3A and Kif3B, and a non-
motor accessory protein KAP3 (kinesin accessory protein 3) (Marszalek and Goldstein,
2000). The two motor monomers dimerise by a 35 nm long coiled-coil rod (DeMarco
et al., 2001). KAP3 is associated with the tail domain of the Kif-subunits (Wedaman
et al., 1996). As an N-kinesin it performs ATP-dependent microtubule plus-end directed
transport and was shown to be involved in intraflagellar trafficking (Walther et al., 1994;
Kozminski et al., 1995). Kif3 is also proposed in ER-to-Golgi transport (LeBot et al.,
1998), although this has only been seen in X.laevis with the Kif3 homologue Xklp3.
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1.5.4 Intraflagellar Transport Protein of 20 kDa (IFT20)
Human IFT20 is the homologue of the Chlamydomonas IFT20. The protein is 158 amino
acids long, has a molecular mass of 18.1 kDa and an isoelectric point of 4.95 (Yin et al.,
2003). It is expressed in a wide array of tissues.
IFT20 is part of Lobe B of the IFT particle (Rosenbaum and Witman, 2002) and interacts
with IFT57 (Baker et al., 2003). Furthermore, it directly binds to the Kif3B component
of the heterotrimeric kinesin-II. Depletion of IFT20 from cells prevents primary cilium
formation (Follit et al., 2006). The most surprising feature of IFT20, however, is its
localisation. As expected, it can be found at the basal body and faintly at the primary
cilium, but also shows a clear presence in the perinuclear region, co-localising with different
Golgi markers (Follit et al., 2006). A faint stream of IFT20 signals has been reported in
cells where cilium and Golgi apparatus are separated. IFT20’s function on the Golgi is
still unknown, but it is suspected that it is involved in transport of newly synthesised
material from the Golgi to the cilium, which is needed for cilium assembly and function
(Follit et al., 2006). At the cilium IFT20 and its cargo would then be incorporated into
the IFT particle and transported into the cilium.
1.6 Golgi-Microtubule Associated Protein 210kDa (GMAP-210)
1.6.1 General Aspects
GMAP-210 was found independently by two groups with different experimental approaches.
Durfee et al. (1993) found GMAP-210 cDNA in a Yeast 2-Hybrid screen as an interactor
of the retinoblastoma protein and named it Trip-230, whereas Rios et al. (1994) found
GMAP-210 in a screen with the serum of patients with the Sjoegren’s autoimmune dis-
order and named it p210. The same group renamed it some years later to GMAP-210
(Golgi Microtubule Associated Protein of 210 kD) as they found it to not only localise to
the Golgi apparatus (Rios et al., 1994; Chen et al., 1999), but also to interact with short,
stable microtubules (Infante et al., 1999).
GMAP-210 is a 1979 amino acids long protein with an apparent molecular weight of
210 kDa (Rios et al., 1994), a calculated molecular weight of 224 kDa and a pI of 5.1
(Infante et al., 1999). It has long stretches of coiled-coil and localises peripherally to the
cis-Golgi as shown by staining with antisera from Sjoegren’s disease patients, electron
microscopy studies (Rios et al., 1994) and transfection of tagged recombinant protein (In-
fante et al., 1999; Gillingham et al., 2004). Its coiled-coil structural elements, its Golgi
localisation and its behaviour in cells treated with Brefeldin A qualify GMAP-210 as po-
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tential Golgi matrix protein (Barr and Short, 2003; Gillingham and Munro, 2003). Upon
Brefeldin A treatment GMAP-210 does not recycle to the ER, but localises to the same
Golgi remnants as does the Golgi matrix protein GM130 (Rios et al., 1994).
1.6.2 Golgi Targeting
Without doubt GMAP-210 localises to the Golgi apparatus (Rios et al., 1994; Infante
et al., 1999; Chen et al., 1999; Gillingham et al., 2004). The targeting motif is, however,
not clear. Infante et al. (1999) map the Golgi interacting domain to the N-terminal 375
amino acids (Fig. 6). The theory of N-terminal membrane binding is supported by a
finding, which identifies an amphipathic α-helical ALPS motif (ArfGAP1 lipid packing
sensor) in the first 38 amino acids of GMAP-210. This domain binds membranes with a
high degree of positive membrane curvature, similar to that found in 50 nm vesicles (Drin
et al., 2007). Infante et al. (1999) also show that the GMAP-210 C-terminal GFP-fusion
protein targets to the centrosome and displaces CTR453, a marker for the pericentriolar
material. This is however in contrast to publications by Chen et al. (1999) and Gillingham
et al. (2004) which showed that binding of GMAP-210 is mediated by the C-terminus.
Figure 6: GMAP-210 And Rud3p Domain Structure. Domains of GMAP-210 and their proposed
function as described by either Infante et al. (1999) or Gillingham et al. (2004); Chen et al. (1999).
Modified from Barr and Egerer (2005).
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1.6.3 Function Of GMAP-210 As Microtubule Binding Protein
Infante et al. (1999) also claimed that the C-terminus of GMAP-210 is responsible for
binding GMAP-210 to short stable microtubules and co-sediments with them from cold
calcium washed cells. Overexpression of GMAP-210 showed that the microtubules, nor-
mally radiating from the centrosome, became less focused, attributing this to recruitment
of microtubule minus-ends to Golgi localised GMAP-210 (Infante et al., 1999). This find-
ing was further supported in Rios et al. (2004), where GMAP-210 was found to bind
γ-TCCs (γ-Tubulin Containing Complexes) and to recruit them to the Golgi apparatus
upon overexpression of GMAP-210. This is consistent with the need of γ-TuRCs for mi-
crotubule nucleation and their attachment to the centrosome (Rios et al., 2004; Barr and
Egerer, 2005). It has also been found that microtubules could nucleate from the Golgi
apparatus (Marsh et al., 2001; Efimov et al., 2007) and GMAP-210 would be predestined
to function as nucleator of these non-centrosomal microtubules (Efimov et al., 2007).
1.6.4 GMAP-210: GRIP Related Arf-Binding Domain
This would all be very compelling except that microtubule interaction of the GMAP-210
C-terminus contradicts with observations by Gillingham et al. (2004); Chen et al. (1999),
which localise the Golgi binding domain to the same region. Additionally, Gillingham
et al. (2004) could specify a distinct Golgi binding motif and interaction protein for the
S.cerevisiae homologue of GMAP-210, Rud3p or Grp1p (golgin-160-related protein).
Rud3p was discovered by a high copy suppressor screen with sec34-2, a temperature-
sensitive mutant defective in the late stages of ER to Golgi transport (Kim, 2003). Rud3p
is a 484 amino acids long, peripheral, cis-Golgi localised protein with coiled-coil struc-
tures (Fig.6), which does not redistribute back to the ER upon block of ER export by
Brefeldin A or by transfection of the Sar1p dominant negative mutant (Kim, 2003).
Gillingham et al. (2004) also found an analogy between the GRIP domain of trans-Golgi
localised golgins (see 1.3.2, p.14) and a 80 residues long domain in the C-terminus of
Rud3p. GRIP interacts with Arl1p in a GTP-dependent manner (Panic et al., 2003b;
Wu et al., 2004). Rud3p GRAB domain likewise binds to Arf1p and is thus targeted to
the Golgi apparatus (Gillingham et al., 2004). Like the essential tyrosine residue in the
GRIP domain (Barr, 1999), GRAB domain-Arf1p interaction is disturbed by mutation
of conserved residues. In Rud3p GRAB domain these residues are leucine 410 and, to a
lesser degree, aspartate 407 (Gillingham et al., 2004).
It was further shown that a ER-to-Golgi cargo receptor Erv14p, which is found on COPII
vesicles, is necessary for Golgi targeting of Rud3p, but not for in vitro binding of Arf1p
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with Rud3p (Gillingham et al., 2004). Erv14 is involved in transport of the Axl2p plasma
membrane protein (Powers and Barlowe, 2002). Rud3p, however, does not bind directly
to Erv14p (Gillingham et al., 2004) and after deletion of Rud3p, Axl2p is still transported
to the plasma membrane, although it shows defects in post-translational glycan modifi-
cation (Powers and Barlowe, 1998; Gillingham et al., 2004).
A simple bioinformatical search for GRAB domain relatives revealed that this is a motif
found in proteins of all eukaryotes. Normally one protein with this feature is found per
organism, in A.thaliana there are two (Gillingham et al., 2004). The homologue of Rud3p
in humans is, although essentially bigger in size, GMAP-210. The minimum domain ne-
cessary to target GMAP-210 to the Golgi apparatus proved to be amino acids 1757 to
1838. The mutation of the residues aspartate 1780 and leucine 1783 abolished Golgi lo-
calisation (Gillingham et al., 2004). Nevertheless, human Arf1 shows no interaction with
the GMAP-210 GRAB.
The C-terminus of GRAB-domain golgins has a second feature, which Gillingham et al.
(2004) termed GA1. It has no influence on Rud3p targeting, but seems to be necessary
for Rud3p function.
1.6.5 Overexpression And Knockdown: Effects On Transport
GMAP-210 has been shown to bind to microtubule minus-ends, the Golgi apparatus
and centrosome (Rios et al., 1994; Chen et al., 1999; Infante et al., 1999; Pernet-Gallay
et al., 2002) and to interact with γ-tubulin, proposing it to be responsible for microtubule
nucleation. Although some of these points are still debatable (Gillingham et al., 2004;
Barr and Egerer, 2005), further studies have been performed to elucidate GMAP-210
function, especially in regards to its role at the Golgi apparatus of mammalian cells
(Infante et al., 1999; Pernet-Gallay et al., 2002). Depletion of GMAP-210 fragments the
Golgi ribbons dramatically (Rios et al., 2004). Overexpression of GMAP-210 not only
disturbs the microtubule network, but enlarges and fragments the Golgi apparatus (Rios
et al., 2004; Pernet-Gallay et al., 2002). GMAP-210 also seems to have a function in
intracellular protein transport, as overexpression disrupts anterograde transport from ER
to cis-/medial-Golgi (Pernet-Gallay et al., 2002) and blocks retrograde transport of the
shiga toxin B-subunit from Golgi-to-ER.
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1.7 Aim Of This Work
The golgin GMAP-210 has been identified as a homologue of S.cerevisiae Rud3p, which
localises to the Golgi apparatus by its conserved GRAB domain. This domain is present
in proteins throughout the realm of eukaryotes (Gillingham et al., 2004). Rud3p GRAB
domain has been shown to interact with the small GTPase Arf1p, which is necessary
for Rud3p to localise to the Golgi apparatus. Human GMAP-210 also localises to the
Golgi membranes in a GRAB domain dependent fashion, although involvement of Arf1
could not be shown yet (Gillingham et al., 2004). Nevertheless, involvement of a small,
Golgi-localised GTPase is very likely. Finding a GTPase, which recruits GMAP-210 to
Golgi apparatus by its GRAB domain will enable us to deduce the function of GMAP-210
in the secretory pathway. This information will also settle the dispute about the Golgi
localising region of GMAP-210, may it be the N-terminus (Infante et al., 1999) or the
C-terminus (Chen et al., 1999; Gillingham et al., 2004).
Furthermore, various functions have already been proposed for GMAP-210. GMAP-210
was shown to bind to microtubules and might even be involved in their nucleation by
recruiting γ-TCCs (Infante et al., 1999; Rios et al., 2004). Other publications show
GMAP-210’s involvement in anterograde and retrograde trafficking (Pernet-Gallay et al.,
2002), whereas it is also discussed that GMAP-210 might be similar to Rud3p and is rather
necessary for proper Golgi function, influencing glycosylation (Kim, 2003; Gillingham
et al., 2004; Barr and Egerer, 2005). GMAP-210 is also proposed to be involved in
maintenance of Golgi morphology, either by interaction with the cytoskeleton (Infante
et al., 1999) or by acting as a Golgi matrix protein (Barr and Egerer, 2005).
This work will deal with the ambiguous findings about GMAP-210, its localisation and
function. Furthermore, it will study the interaction partners and mechanisms in which
this elusive, but interesting, protein may be involved.
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2 Results
2.1 GMAP-210 Is A Golgi Binding Protein
The protein GMAP-210 was found at the Golgi apparatus (Rios et al., 1994; Chen et al.,
1999). It has long stretches of coiled-coil and behaves like a Golgi matrix protein (Rios
et al., 1994; Barr and Short, 2003; Gillingham and Munro, 2003). Nevertheless, the exact
Golgi binding domain of GMAP-210 is disputed (Infante et al., 1999; Chen et al., 1999;
Gillingham et al., 2004). To settle this dispute the full length coding sequence of GMAP-
210 and various N- and C-terminal truncation constructs were cloned and antibodies
against an N-terminal, recombinant fragment prepared. With these tools, localisation of
GMAP-210 in cells stained with the antibody or transfected with GFP-tagged constructs
was studied by immunofluorescence microscopy.
2.1.1 Tools For GMAP-210 Characterisation
First, various tools for studying the golgin GMAP-210 were produced.
Cloning Of GMAP-210 Full-Length, Fragments And Mutants The full-length
coding sequence of GMAP-210 was cloned from a human liver cDNA library (Becton-
Dickinson, Heidelberg) by standard polymerase chain reaction. Following the shortway
system cloning strategy a BamHI and a XhoI restriction sites were added to the 5’- and
3’-end, respectively. Thus, the cloned DNA construct could be subcloned in any shortway
compatible vector. The tags provided by the vector were in frame at the 5’- or the 3’-end.
For easier subcloning a silent adenosine to thymidine mutation was inserted at position
2924 of the GMAP-210 coding sequence in order to disrupt a BamHI restriction site, which
would interfere with the chosen cloning strategy. N- and C-terminal truncation constructs
and GRAB domain mutations were derived by using the full-length clone as template in
a standard PCR (see Table 13, p.148ff.). For the D1780A L1783A mutation of the GRAB
domain a special, 42 base pairs long quickchange primer was designed, which changed
both codons at the same time (GAC to GCCbp:5338−5340 and CTA to GCAbp:5347−5349).
Before subcloning, all DNA constructs were sequenced and checked for compliance with
the data base sequence.
Polyclonal Antibodies Against GMAP-210 In order to detect endogenous GMAP-
210 in immunofluorescence and Western blot experiments and for use in co-immunopre-
cipitations, an antibody to the N-terminus of GMAP-210 (amino acids 1 to 375 with
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6xHis-tag) was raised by Biogenes in two rabbits (#6129 and #6130) with a total of
2 mg recombinant protein (see 4.5.6, p.135). Testbleeds were evaluated approximately
1 month after initial immunisation and boost injections. Bleedout of rabbits was per-
formed 1 month after the 2nd testbleed.
Antibodies were affinity purified from rabbit #6130 bleedout with the GST-6xHis-tagged
version of the initial antigen.
Antibody specificity was tested in immunofluorescence and Western blot and for both
methods a concentration of 1:500 proved to be optimum. In immunofluorescence, that
antibody stained a structure in the perinuclear region and co-localised with the Golgi
marker GM130 (Fig.7). The antibody also showed staining on small vesicular tubular
structures in the cell periphery, which did not co-stain for GM130. After knockdown of
GMAP-210 with a specific siRNA oligo, the signal in the perinuclear region and on the
vesicular tubular structures vanished (Fig.24, p.49). In Western blot experiments, the an-
tibody revealed a single band at 210 kDa, which also disappeared after siRNA knockdown
(Fig.23, p.49). The antibody against the N-terminal 375 amino acids of GMAP-210 speci-
fically and exclusively recognised endogenous protein in immunofluorescence and Western
blotting.
Figure 7: GMAP-210 Localisation In HeLa L Cells. HeLa L cells were fixed with paraformaldehyde
and stained with mouse anti GM130 (red, 1:500) and rabbit anti GMAP-210 (green, 1:500) primary
antibodies; lower pictures show a contrast and brightness enhanced close-up of the region indicated in
the upper pictures, box=10 μm; pictures were acquired by delta vision microscopy and image stacks
were subsequently deconvolved and merged into one picture; blue channel: DAPI staining; Bar=15 μm.
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2.1.2 The C-Terminal GRAB Domain Of GMAP-210 Targets The Protein
To The Golgi Apparatus
Although GMAP-210 localises undoubtedly to the Golgi apparatus, it is still debatable
whether GMAP-210 targets to the Golgi via its N- or C-terminus (Infante et al., 1999;
Chen et al., 1999). In order to solve this contradiction, the behaviour of several N- and
C-terminal, GFP-tagged constructs was tested in HeLa cells.
First the localisation of endogenous GMAP-210 was elucidated in greater detail by stain-
ing untreated cells with the polyclonal antibody and examining them by delta vision
microscopy.
For this end, HeLa L cells were fixed with paraformaldehyde and stained for GMAP-210
and the cis-Golgi marker GM130 (Fig.7). GMAP-210, stained by polyclonal antibody,
was localised mainly in a juxtanuclear region and co-localised partially with the signal of
GM130 staining, although not completely. Thus, GMAP-210 is at the cis-Golgi compart-
ment as described before (Rios et al., 1994). Additionally, vesicular tubular structures
could be observed in the periphery of the cell, stained for GMAP-210, but not GM130. As
Gillingham et al. (2004) described, a domain in the C-terminus is responsible for target-
Figure 8: Localisation Of GMAP-210 C-Terminus In HeLa L Cells. Heal L cells were transfected
with the indicated full-length or C-terminal GMAP-210 constructs (green) for 24 h and fixed with
paraformaldehyde; cells were stained with mouse anti GM130 (red, 1:500); pictures were acquired by
delta vision microscopy and image stacks subsequently deconvolved and merged into one picture. For
better visibility of fine structures, contrast and brightness were enhanced by the same values in each
picture and channel; blue channel: DAPI staining; Bar=5 μm.
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ing GMAP-210 to the Golgi. In order to test this, GFP-tagged constructs of GMAP-210
full-length and the C-terminal 382, 223 and 201 amino acids were transfected into HeLa
L cells. After fixation with paraformaldehyde and co-staining for the golgin GM130,
cells were analysed by delta vision microscopy (Fig.8). Expressed GFP-tagged full-length
GMAP-210 localised to the Golgi just like antibody staining had shown for the endogenous
protein (Fig.7, p.28). The C-terminal 382 amino acids (pEGFPC2-GMAP-210 1598-1979)
also decorated the Golgi apparatus and even as few as the C-terminal 201 amino acids
(pEGFPC2-GMAP210 1779-1979) were enough for Golgi targeting. The two shorter frag-
ments, however, showed a diffuse cytosolic pool in addition to Golgi targeting instead of
staining vesicular tubular structures. This showed, that the C-terminus of GMAP-210 can
target to the Golgi. Closer examination of Fig.8 showed, that overexpression of full-length
GMAP-210 caused the Golgi to grow out into long “spider-leg”-like tubules, which can
also be observed with GM130 staining. A similar effect was not seen by overexpressing
Figure 9: GRAB Domain And GRAB Domain Mutants In HeLa L Cells. HeLa L cells were
transfected for 24 h with constructs for expression of GMAP-210 GRAB domain (amino acids 1757-
1875) or GRAB domain plus the C-terminally adjacent coiled-coil region (amino acids 1683-1875)
in wild-type or GRAB mutant form (D1780A L1783A) as indicated (green); cells were fixed with
paraformaldehyde and stained with mouse anti GM130 (red, 1:500); pictures were acquired by delta
vision microscopy and the attained image stacks deconvolved and merged into a single picture; blue
channel: DAPI staining; Bar=5 μm.
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any of the other
C-terminal constructs.
To further narrow down the domain, which recruits GMAP-210 C-terminus to the Golgi,
the GRAB (GRIP Related Arf Binding) domain described by Gillingham et al. (2004)
was transfected into HeLa L cells (Fig.9), fixed with paraformaldehyde and co-stained
with an antibody against GM130. Two different constructs were used. One expressed the
minimal GRAB domain (pEGFPC2-GMAP-210 1757-1875), the second the GRAB do-
main with the N-terminally adjacent coiled-coil region (1683-1875), which should enable
dimerisation (Panic et al., 2003b). Both constructs localised to the Golgi. The shorter
construct, however, also showed a diffuse cytosolic signal, whereas the construct com-
prising the coiled-coil region, showed distinct vesicular structures in the cell periphery.
Neither construct had an effect on Golgi morphology. As Gillingham et al. (2004) dis-
covered the GRAB domain by an analogy to the GRIP domain (Barr, 1999), they could
identify conserved residues, aspartate at position 1780 and leucine at position 1783, which
were necessary for Golgi targeting. Mutation of the two amino acids to alanine should
abolish Golgi localisation.
First GRAB domain mutants were made by quickchange mutagenesis and then transfected
into HeLa as GFP-tagged constructs (Fig.9; pEGFPC2-GMAP-210 1757-1875 D1780A
L1783A and pEGFPC2-GMAP-210 1683-1875 D1780A L1783A). Both constructs showed
strongly reduced Golgi localisation in HeLa L cells. This was especially visible from the
diffuse cytosolic distribution of mutant GRAB domain (GMAP-210 1683-1875 D1780A
L1783A), when compared to wild-type (GMAP-210 1683-1875). Some protein was still
present at the Golgi.
As a next step, the targeting of longer GMAP-210 constructs with disturbed GRAB do-
main targeting was tested. Three different constructs were transfected into HeLa L cells,
fixed, co-stained with an antibody against GM130 and analysed by delta vision microscopy
(Fig.10). Two of these constructs, full-length GMAP-210 and a C-terminal construct of
GMAP-210 (pEGFPC2-GMAP-210 1598-1997 D1780A L1783A) were double mutants, re-
placing the essential aspartate 1780 and leucine 1783 with alanine, whereas the third con-
struct was completely missing the GRAB domain (pEGFPN3-GMAP-210 1-1712). Mu-
tant GMAP-210 C-terminus (pEGFPC2-GMAP-210 1598-1997 D1780A L1783A) showed
reduced binding affinity to the Golgi apparatus. A diffuse cytosolic pool of GFP ap-
peared in cells expressing this construct. Full-length GMAP-210 with the D1780A L1783A
mutation was still localised on the Golgi (upper row in Fig.10), although the vesicular-
tubular structures became much more prominent in comparison to transfection of wild-
type GFP-tagged GMAP-210. When the GRAB domain was removed entirely from the
protein (pEGFPN3-GMAP-210 1-1712), the construct no longer localised at the Golgi,
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Figure 10: Localisation Of GRAB Domain Mutants In HeLa L Cells. HeLa L cells were trans-
fected for 24 h with constructs for expression of GMAP-210, which either lacked GRAB domain (amino
acids 1-1712) or were mutated in the GRAB domain (D1780A L1783A) as indicated (green); cells were
fixed with paraformaldehyde and stained with mouse anti GM130 (red, 1:500); pictures were acquired
by delta vision microscopy and the attained image stacks deconvolved and merged into one picture;
blue channel: DAPI staining; Bar=5 μm.
but showed very pronounced vesicular tubular structures. Some of those clustered in a
juxtanuclear region, overlapping with the Golgi localised GM130. With all three con-
structs, Golgi morphology was not changed in comparison to untransfected cells.
Transfection of various C-terminal constructs into HeLa L cells showed, that the C-ter-
minus of GMAP-210 localises to the Golgi apparatus. The GRAB domain described by
Gillingham et al. (2004) could be identified as minimal Golgi targeting motif and mu-
tation of its two essential residues, aspartate 1780 and leucine 1783, reduced the Golgi
targeting capability strongly. Full-length constructs with the GRAB mutation or without
a GRAB domain localised more and more prominently to the vesicular tubular structures,
on which endogenous, full-length GMAP-210 could also be seen.
2.1.3 GMAP-210 N-terminus Does Not Target To The Golgi
The GMAP-210 N-terminus was described as sole Golgi targeting domain by Infante et al.
(1999). Although, the C-terminal GRAB domain has already been shown to target to the
Golgi apparatus, Golgi binding of the N-terminus had to be ruled out.
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Several GFP-tagged N-terminal constructs of GMAP-210 were transfected into HeLa L
cells. Cells were fixed, co-stained for GM130 and analysed by epifluorescence (Fig.11).
The transfected constructs did not have an effect on Golgi morphology. The construct
comprising amino acids 1 to 375 (pEGFPC2-GMAP-210 1-375) weakly overlapped with
the GM130 signal, but most of it showed a diffuse cytosolic localisation. A longer N-
terminal construct, GMAP-210 amino acids 1 to 1332 (pEGFPC2-GMAP-210 1-1332),
had stronger localisation to Golgi, but still high cytosolic background. When GMAP-
210 is broken down further, a construct comprising amino acids 618 to 803 (pEGFPC2-
GMAP-210 618-803) had some juxtanuclear concentration around the signal for GM130,
but was very diffuse and most GFP signal could be found in the cytosol. Amino acids 855
to 1332 (pEGFPC2-GMAP-210 855-1332), however, showed a weak, but specific Golgi
localisation. Amino acids 1332 to 1712 (pEGFPC2-GMAP-210 1333-1712) showed no
Golgi localisation at all and a construct combining the latter two (pEGFPC2-GMAP-
210 855-1712) had only a very weak Golgi localisation, with most protein going to the
nucleus. Amino acids 1598 to 1778 (pEGFPC2-GMAP-210 1598-1778) were only found
in the cytosol.
The N-terminus of GMAP-210 and constructs from the middle part, between amino acids
855 and 1333, showed some Golgi localisation, although much weaker than the GRAB
domain targeted C-terminus (see 2.1.2, p.29ff).
2.1.4 Summary
Examining the localisation of GMAP-210, it became clear, that GMAP-210 is a cis-
localised protein, which targets to the Golgi by its C-terminal GRAB domain, as described
by Chen et al. (1999) and Gillingham et al. (2004). Mutation of the essential amino acids
aspartate 1780 and leucine 1783 diminished Golgi binding of the GRAB domain greatly.
However full-length constructs of GMAP-210 with GRAB mutation or with truncated
C-terminus accumulated on small vesicular tubular structures. These also stained for
endogenous GMAP-210 in untransfected cells but not for GM130. Overexpression of
full-length GMAP-210 led to “spider-leg”-like outgrowth from the Golgi apparatus. The
N-terminus showed little to no Golgi localisation. Fragments containing amino acid 855
to 1332 also targeted weakly to the Golgi.
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Figure 11: Localisation Of Different GMAP-210 Fragments In HeLa L Cells. HeLa L cells
were transfected with various truncation constructs of GMAP-210 for 24 h; cells were fixed with
paraformaldehyde and stained with mouse anti GM130 antibody (red, 1:500); blue channel: DAPI
staining; Bar=5 μm.
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2.2 The GMAP-210 GRIP Related ARF Binding Domain
As described by Gillingham et al. (2004), the S.cerevisiae homologue of mammalian
GMAP-210, Rud3p, targets to the Golgi apparatus by its C-terminal GRAB domain.
The binding is mediated by the ADP-ribosylation factor 1 (Arf1p), which binds Rud3p
in a similarly to the way Golgin-97 and p230 GRIP domain targets to the trans-Golgi by
Arl1p. It is likely, that GMAP-210 also interacts with a small GTPase, probably human
Arf1.
2.2.1 GMAP-210 GRAB Domain Interacts With ADP-Ribosylation Factor
Like 4A, C And D In A GTP Dependent Manner In Yeast 2-Hybrid
Experiments
In analogy to Rud3p (Gillingham et al., 2004) GRAB domain interaction with the small
GTPase Arf1p, GMAP-210 should also bind a small GTPase by its GRAB domain.
This was first examined with yeast 2-hybrid interaction studies, testing GMAP-210
against human Arf1 and human ADP-ribosylation factor-like protein, Arl1 (Fig.12). Arf1
and Arl1 were used as bait in the pFBT9 vector with GMAP-210 and Golgin-97 as prey
(in pAct2). The G-proteins were used in their wild-type and GTP-locked, active form.
For Arl1 an N-terminally truncated construct was created, which was missing the N-
terminal amphipathic helix, which often causes problems in interaction studies, due to its
hydrophobic character (Gillingham and Munro, 2007). In yeast 2-hybrid, Golgin-97 inter-
acted with Arl1 in its active, GTP-locked form, not with the wild-type. GMAP-210 did
Figure 12: Yeast 2-Hybrid Of GMAP-210 And ADP-ribosylation Factor. Yeast 2-Hybrid in-
teraction study of full-length GMAP-210 or Golgin-97 (fused to GAL4 transactivating domain; prey)
and ADP-ribosylation factor 1 or ADP-ribosylation factor-like 1 as bait (fused to GAL4 binding do-
main) either in wild-type, GTP-bound, active (Q-L or Q-A) or N-terminally truncated form (ΔN14;
without amphipathic helix); -LW: leucine and tryptophane deficient medium (growth control); QDO:
quadruple drop out medium; leucine, tryptophane, alanine and histidine deficient medium.
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not interact with any protein tested, neither Arf1 nor Arl1, independently of nucleotide
state or truncations.
In human cells nearly 30 members of the Arf/Arl family are know, but only 6 in S.cerevisiae.
This makes it possible, that mammalian GMAP-210 interacts with another member of
the ADP-ribosylation factor family apart from Arf1. Thus, all members from this family
were cloned from human cDNA libraries and subcloned into the pFBT9 vector for testing
against full-length GMAP-210 in yeast 2-hybrid interaction studies (Fig.13). In yeast
2-hybrid experiments full-length GMAP-210 interacted with three out of four members of
the Arl4 group (isoforms A, C, D) and with Arl16. Arl11 showed unspecific self-activation.
The Arl8A result was ambiguous and further experiments showed, that Arl8A is unlikely
to interact with GMAP-210. No member of the Arf family showed a positive signal, nor
did the Arl-related protein Sar1 or any of the Arf-domain proteins (ARD1-3).
As the Golgi binding capability of GMAP-210 is mediated by the GRAB domain, the
Arl-family members, positive in the yeast 2-hybrid screen, also had to interact with only
the GRAB domain of GMAP-210 rather than the full-length protein.
Thus, the GMAP-210 GRAB domain in wild-type and GRAB mutant form (GMAP-210
1683-1875 D1780A L1783A) was tested against Arl4A and Arl4C in GDP- and GTP-
locked conformation, Arl16 wild-type and Arf1/Arl1 in wild-type and GTP-locked form
(Fig. 14, p.38). Wild-type and active-mutant Arl4A and Arl4C interacted with wild-type
GRAB domain, but not with the GRAB domain mutant. Inactive Arl4 showed no reaction
with any GRAB construct. Arl16 did not show any interaction with GMAP-210 GRAB
domain. Interestingly, GTP-locked, active Arf1 (Arf1Q71L) and Arl1 (Arl1Q71L) reacted
with the GRAB domain construct, while showing dependency on the GRAB mutation.
This result was in contrast to experiments with full-length GMAP-210 and Arf1/Arl1
(Fig.12).
GMAP-210 GRAB domain interacts with members from the Arl4 group of Arl-GTPases
in a nucleotide-state-dependant manner.
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Figure 13: Yeast 2-Hybrid Screen For GMAP-210 Interaction Partners In The Arf- And Arl-
Family. Yeast 2-Hybrid interaction study of full-length GMAP-210 (fused to GAL4 transactivating
domain; prey) and ADP-ribosylation factor family, ADP-ribosylation factor-like family or Sar1 (GTP-
locked, active form) as bait (fused to GAL4 binding domain); “+” and “-” indicate positive and negative
interaction results; “?” indicates ambiguous result; -LW: leucine and tryptophane deficient medium
(growth control); QDO: quadruple drop out medium; leucine, tryptophane, alanine and histidine
deficient medium.
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Figure 14: GRAB Domain Interaction With Arf1 And Arl4A/C. Yeast 2-Hybrid interaction study
of wild-type and GRAB mutant (D1780A L1783A) GMAP-210 GRAB domain (amino acids 1683-1875)
(fused to GAL4 transactivating domain as prey) and ADP-ribosylation factor 1 or ADP-ribosylation
factor-like 4 family as bait (fused to GAL4 binding domain), either in wild-type, GTP-bound active
(Q-L) or GDP-bound inactive (T-N) form as indicated; -LW: leucine and tryptophane deficient medium
(growth control); QDO: quadruple drop out medium; leucine, tryptophane, alanine and histidine
deficient medium.
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2.2.2 Transfected Arl4A, Arl4C And Arl4D Localise To The Plasma
Membrane Of HeLa L Cells
To show that the Arl-GTPases, which were found to interact with GMAP-210 in yeast
2-hybrid, also co-localise on the Golgi apparatus, their localisation had to be shown in
living cells. To this end, all members of the ADP-ribosylation factor and ADP-ribosylation
factor like family were transfected into HeLa L cells and in vivo localisation was studied
by epifluorescence microscopy (Fig.15 and Fig.16). The cells were co-stained with an
antibody against GMAP-210. Arf1-GFP showed localisation in a juxtanuclear position
and overlapped with the signal of the GMAP-210 antibody at the Golgi complex (Steams
et al., 1990). Some nuclear localisation could be seen, depending on expression levels.
Arf3-, Arf4- and Arf5-GFP had weak Golgi staining, but most of the protein was present
in the cytosol. Arf6 was localised in the cytosol, although it also was concentrated at
the mid-body of dividing cells. The Arl-family of small GTPases localised to a greater
variety of compartments when transfected into HeLa L cells. Interesting in the context
Figure 15: Localisation Of The Arf Family Members In HeLa L Cells. HeLa L cells transfected
for 24 hours with a construct for expression of the the indicated member of the ADP-ribosylation factor
family with an enhanced GFP-Tag on the C-terminal end (green) were fixed with paraformaldehyde
and stained with the rabbit anti GMAP-210 antibody (red, 1:500); blue channel: DAPI staining;
Bar=10 μm.
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Figure 16: Localisation Of The Arl Family Members In HeLa L Cells. HeLa L cells transfected for
24 hours with a construct for expression of the indicated member of the ADP-ribosylation factor-like
family with an enhanced GFP-Tag on the C-terminal end (green) were fixed with paraformaldehyde
and stained with the rabbit anti GMAP-210 antibody (red, 1:500); blue channel: DAPI staining;
Bar=10 μm.
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of this study were only Arl-proteins localising to the Golgi complex. These were Arl1-
GFP, Arl5-GFP (isoforms A and B) and Arl15-GFP. Arl16-GFP could be found mainly
in the nucleus and cytosol; plasma membrane ruffles were also stained by Arl16-GFP.
The Arl4 group, which interacted with the GMAP-210 GRAB domain in yeast 2-hybrid
experiments (see 2.1.2, p.29ff), localised to the plasma membrane of HeLa L cells.
The Ratio of GTPases in active, GTP-bound form in comparison to inactive GDP-bound
form is rather low in cells. Localisation of transfected wild-type protein, hence, could be
difficult to distinguish from a high background signal. Better targeting of small GTPases
could be achieved by transfection of GTP-locked mutants. Thus, selected members of
the Arf and Arl family, in their constitutively active mutant form, were transfected into
HeLa L cells and their localisation examined (Fig.17). GTP-locked Arl2-, Arl3- and Arl6-
Figure 17: Localisation Of The Arf and Arl Family Members As GTP-Locked Mutants.
HeLa L cells transfected for 24 hours with a construct for expression of the indicated member of the
ADP-ribosylation factor or ADP-ribosylation factor-like family with an enhanced GFP-Tag on the
C-terminal end (green); the catalytic glutamine was mutated to leucine thus the GTPase was locked
in a GTP-binding, active conformation; the cells were fixed with paraformaldehyde and stained with
the rabbit anti GMAP-210 antibody (red, 1:500); blue channel: DAPI staining; Bar=10 μm.
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GFP could be observed only in the cytosol of HeLa L cells, Arl1Q71L (GTP-locked)
and Arf1Q71L (GTP-locked) localised to the Golgi complex, as did Arl5A and Arl5B.
The putative GRAB domain interactors Arl4A and Arl4C still localised at the plasma
membrane. Only some weak Golgi targeting was observable.
So neither wild-type nor GTP-locked, active Arl4 shows a distinct targeting to the Golgi
apparatus and no co-localisation with GMAP-210.
2.2.3 Recombinant Arl4 Does Not Interact With Endogenous GMAP-210 In
Pulldown Experiments
The Arl4 group of the ADP-ribosylation factor family showed GRAB-domain dependent
binding to GMAP-210, but did not co-localise with GMAP-210 on the Golgi apparatus.
As transfection of tagged proteins could sometimes lead to mis-localisation, a biochemical
approach was used to prove the results found in yeast 2-hybrid.
The interaction of GMAP-210 and ADP-ribosylation factor-like 4 was tested in pulldown
experiments. Recombinant GST-tagged Arl-proteins (Arl1ΔN14, Arl3, Arl4AΔN14,
Arl4CΔN14 and Arf1ΔN14) were incubated with HeLa L cytosol from cells transfected
with pEGFPN3-GMAP210 or pEGFPC2-GMAP-210 1683-1875, both as wild-type or
D1780A L1783A GRAB mutants. Bound proteins were analysed by Western blotting
and identified with antibodies against GFP, GMAP-210 or p230 (Fig.18). Staining for
p230 would show binding of endogenous p230 GRIP domain to Arl1ΔN14 under the
experimental conditions, and served as positive control. Staining for GFP showed binding
of exogenously expressed GMAP-210 full-length or GRAB domain, GMAP-210 staining
compared endogenous against exogenous GMAP-210 binding to the GTPases.
Arl1 pulled down Golgin-245/p230 and no other GTPase tested showed any signal. Under
no conditions binding of GMAP-210 was visible (weak signal of wild-type GMAP-210-GFP
with Arl4AΔN14 is not mirrored by GMAP-210 antibody staining; signal is due to spill-
over during gel loading process).
Also in pulldown experiments, Arl4 interaction with GMAP-210 could not be proven.
2.2.4 Arl4-GFP Does Not Co-Immunoprecipitate With Endogenous
GMAP-210 From HeLa L Cells
Co-immunoprecipitation experiments were also performed to examine GMAP-210 interac-
tion with Arl-GTPases. HeLa L cells were transfected with pEGFPN3-Arl4A, pEGFPN3-
Arl4C or pEGFPN3-Arl1 and a lysate produced. The lysates were incubated with anti
GFP or rabbit anti GMAP-210 antibody and Protein G sepharose. Antibody free beads
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Figure 18: Pulldown of GMAP-210 From HeLa Cell Extract With Recombinant Arl GTPases.
HeLa L cells were transfected with constructs for expression of wild-type GMAP-210 or GRAB mutant
GMAP-210 D1780A L1783A (top); wild-type GRAB domain (amino acids 1683-1875) or mutant GRAB
domain (1683-1875; D1780A L1783A) (middle); HeLa L cytosol was prepared in TMK buffer and
incubated with GST-proteins produced on the same day and coupled to glutathione-sepharose; 0.05%
Triton-X100 and 100 μM GTP were added for incubation; beads were boiled in SDS sample buffer and
analysed by Western blotting from 6% or 12.5% SDS-PAGE gels; proteins were detected with either
rabbit anti GMAP-210 (1:500, top), goat anti GFP (1:1000, top and middle) or mouse anti Golgin-245
(1:250, bottom) antibodies.
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were used as control. Precipitated proteins were analysed by SDS-PAGE and Western
blotting (Fig.19). Detection of proteins was done with sheep anti GFP and rabbit anti
GMAP-210 antibodies. Exogenously expressed, GFP-tagged Arl1, Arl4A and Arl4C were
precipitated efficiently by the sheep anti GFP antibody but no endogenous GMAP-210
was co-immunoprecipitated from the extract. GMAP-210 was efficiently precipitated from
the extract, without co-purifying transfected GFP-tagged GTPases. Therefore, GMAP-
210 and Arl4 do not interact in vivo.
Figure 19: Immunoprecipitation Of GMAP-210 And GFP-Tagged Arl Family Members.
HeLa L cells were transfected for 24 hours with the indicated constructs; a cell lysate was produced in
NL100 buffer and incubated with rabbit anti GMAP-210, goat anti GFP or no antibody and protein-G
sepharose; bound protein was extracted from beads by boiling in SDS sample buffer and analysed on
6% (GMAP-210) or 10% (GFP) SDS-PAGE gels and subjected to Western blotting; membranes from
6% gels were analysed with rabbit anti GMAP-210 (1:500), membranes from 10% with goat anti GFP
(1:1000) antibodies.
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2.2.5 S.cerevisiae Rud3p Also Interacts With H.sapiens Arl4 Family Members
As there is no evidence for GMAP-210 interaction with ADP-ribosylation factor family
proteins so far, the original results, which describes S.cerevisiae Rud3p and Arf1p interac-
tion were analysed with a different approach than presented in Gillingham et al. (2004).
First, yeast 2-hybrid interaction studies were done with S.cerevisiae Arf1p (ScArf1) as
bait in the pFBT9 vector and Rud3p and human GMAP-210 in the prey pAct2 vector
(Fig.20). Neither Rud3p full-length nor GMAP-210 full-length interacted with ScArf1 in
yeast 2-hybrid experiments. The nucleotide state of the GTPase was of no consequence
as shown by use of the GTP-locked, active mutant ScArf1Q71L. Tested against human
Arl-family members, however, Rud3p interacted with Arl4A and Arl4C in yeast 2-hybrid
interaction screening just like GMAP-210 (2.2.1, p.35). Gillingham et al. (2004) showed
yeast 2-hybrid interaction of Rud3p and Arf1p, however.
Next, ScArf1 was transfected into human HeLa L cells to see if it would localise to the
Golgi as in S.cerevisiae. Fig.21 (upper panel) showed, that GFP-tagged Arf1p from
S.cerevisiae co-localised with GM130 in perinuclear region, thus targeted to the mam-
malian Golgi. The lower row, however, makes clear, that Rud3p did not localise to the
Figure 20: Interaction Studies For GMAP-210 or Rud3p Against Arf1p, homo sapiens Arl1
and Arl4. Yeast 2-Hybrid interaction study of full-length GMAP-210 or full-length S.cerevisiae
Rud3p (fused to GAL4 transactivating domain; prey) against S. cerevisiae ADP-ribosylation factor
1 (fused to GAL4 binding domain) either in wild-type or GTP-bound, active form (Q71) (left) and
ADP-ribosylation factor like 1, 4 and AFRP1 (right); -LW: leucine and tryptophane deficient medium
(growth control); QDO: quadruple drop out medium; leucine, tryptophane, alanine and histidine
deficient medium.
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Golgi of HeLa L cells, even if they were co-transfected with Arf1p-GFP, which should have
provided the proper interaction partner. In yeast 2-hybrid, Rud3p showed interaction with
the same Arf/Arl-GTPases as GMAP-210. Furthermore, Rud3p could not target to the
Golgi apparatus if transfected into mammalian cells, even not when S.cerevisiae Arf1p
was present.
2.2.6 The Small GTPase Arf1 Interacts With The GMAP-210 GRAB
Domain
As the most likely candidate for GRAB domain interaction, Arf1 did not interact with
full-length GMAP-210 (Fig.12, p.35), the whole Arl and Arf family was tested for binding
partners of GMAP-210. The Arl-GTPases, which interacted with GMAP-210 in yeast
2-hybrid, Arl4A, B and C (Fig.13, p.37) did not co-localise with GMAP-210 in vivo
(Fig.16, p.40) and showed no interaction in biochemical experiments (Fig.18,19, p.43,44).
Arf1, however, interacted in yeast 2-hybrid with a fragment containing only the GRAB
domain (aa 1683-1875) (Fig.14, p.38). Thus, several fragments of GMAP-210 were tested
for their interaction capability with Arf1 in yeast 2-hybrid (Fig.22). Full-length GMAP-
210 did not interact with Arf1, neither did fragments, which did not contain the GRAB
domain. The minimal GRAB domain (aa 1779-1835) did also not interact with Arf1,
probably due to missing dimerisation elements. The GRAB domain with a short stretch
Figure 21: Localisation of Arf1p and Rud3p In HeLa L Cells. HeLa L cells were transfected with
S.cerevisiae pEGFPN3-Arf1p (top, green) or S.cerevisiae pMyc-Rud3p (bottom) and pEGFPN3-Arf1p
(bottom green) for 24 hours and fixed with paraformaldehyde; cells were stained sheep anti GM130
(red, 1:500, top) or mouse anti c-myc (9E10, 1:1000, red, bottom); blue channel: DAPI staining;
Bar=10 μm.
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Figure 22: Mapping Of GMAP-210 GRAB Domain Interaction With Arf1. Yeast 2-Hybrid
experiment testing Arf1 bait with GMAP-210 fragments as prey; cartoon shows tested fragments,
transparent fragments are non-interacting; -LW: leucine and tryptophane deficient medium (growth
control); QDO: quadruple drop out medium; leucine, tryptophane, alanine and histidine deficient
medium.
of coiled-coil structure (aa 1683-1875) and C-terminal constructs comprising the GRAB
domain on their N-terminus (aa 1757-1979 and aa 1779-1979) showed binding with Arf1.
A C-terminal fragment (aa 1598-1979), which contained a longer stretch of coiled-coil,
N-terminally to the GRAB domain, however, did not interact with Arf1. Some element
within amino acids 1598 to 1682 is likely responsible for inhibiting Arf1 interaction with
the GRAB domain of full-length GMAP-210.
2.2.7 Summary
The GMAP-210 homologue Rud3p interacts with the small GTPase Arf1p by its GRAB
domain and is thus recruited to the Golgi apparatus. As the Arf/Arl-family in mammals is
much bigger than in S.cerevisiae, GTPases apart from Arf1 could be possible interaction
partners and recruiting factors for human GMAP-210. The whole family of Arf- and
Arl-proteins was tested in yeast 2-hybrid and members of the Arl4 group showed positive
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interaction with full-length GMAP-210, which was abolished by GRAB domain mutation
and usage of the inactive mutant of Arl4. GFP-tagged Arl4 showed no co-localisation with
GMAP-210 in HeLa L cells. Arl4-GFP targeted to the plasma membrane. Additionally,
pulldown experiments with GST-tagged Arl4 and co-immunoprecipitation of Arl4-GFP
with GMAP-210 gave no evidence for interaction. This makes it unlikely, that GMAP-210
and Arl4 are interaction partners in vivo. Arf1 did not interact with full-length GMAP-
210, but interacted with GRAB domain containing fragments. Mapping of GMAP-210
showed, that inclusion of amino acids 1598 to 1682 in yeast 2-hybrid constructs abolished
Arf1 interaction with the GMAP-210 GRAB domain.
2.3 GMAP-210 siRNA Oligo Depletes Endogenous Protein And
Causes Golgi Apparatus To Compact In HeLa L Cells
Rios et al. (1994) showed, that depletion of GMAP-210 by siRNA fragments the Golgi
apparatus. Knocking down GMAP-210 would prove a useful tool, not only to monitor
morphology of the Golgi apparatus in absence of GMAP-210, but also to examine effects
on the microtubule network, intracellular transport events and effects on localisation of
various Golgi markers. For depletion of GMAP-210 from cultured human cells, an siRNA
oligo was designed, which targets a sequence in the 3’-untranslated region of the GMAP-
210 gene (see Table 5, p.122).
2.3.1 Efficiency Of GMAP-210 3’-UTR siRNA Oligo Examined By
Western Blot
Depletion efficiency of the GMAP-210 siRNA oligo had to be tested by Western blotting.
Extracts of HeLa L and hTERT-RPE1 cells treated for 72 h with the siRNA oligo against
the GMAP-210 3’-UTR or the control oligos GL2 or Lamin A were subjected to Western
blotting. Protein was detected with the affinity purified rabbit anti GMAP-210 antibody
(Fig.23). The Western blot showed a single, specific band well above the 175 kDa marker
in extracts from control HeLa L and hTERT-RPE1 cells. After 72 h of treatment with
GMAP-210 siRNA oligo, the band disappeared completely. GMAP-210 was depleted by
the chosen siRNA oligo.
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Figure 23: GMAP-210-3’UTR siRNA Efficiency In hTERT-RPE1 and HeLa L. HeLa L or
hTERT-RPE1 cells were transfected with siRNA oligos against GL2 or Lamin A (control) or GMAP-
210 3’-UTR for 72 h; cells were extracted in mammalian lysis buffer and 20 μg protein loaded onto
6% and 10% SDS-PAGE gels and subjected to Western blotting; proteins were detected with either
rabbit anti GMAP-210 or mouse anti α-tubulin DM1A antibodies.
2.3.2 The Golgi Apparatus Compacts After GMAP-210 Knockdown
GL2, Lamin A or GMAP-210 siRNA oligos were transfected for 72 h into HeLa L and
hTERT-RPE1 cells. After fixation and staining for GM130 and GMAP-210, cells were
analysed by immunofluorescence microscopy (Fig.24). The signal for GMAP-210 was
strongly reduced in both cell types after 72 h of treatment with the siRNA oligo against
Figure 24: GMAP-210 siRNA Effect On HeLa L And hTERT-RPE1 Cells. HeLa L and hTERT-
RPE1 cells were transfected for 72 h with siRNA oligos against GL2 (control) and GMAP-210 3’-UTR,
fixed with paraformaldehyde and stained with mouse anti GM130 (red, 1:500) and rabbit anti GMAP-
210 (green, 1:500) antibodies; blue channel: DAPI staining; Bar=10 μm.
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GMAP-210 3’-UTR. While in hTERT-RPE1 cells no morphological change of the Golgi
could be observed, the Golgi in HeLa L cells became small and rounded up upon deple-
tion of GMAP-210 by siRNA. Furthermore, the signal intensity of GM130 became much
brighter and remained on the Golgi, indicating a higher concentration of protein within
a smaller area.
In order to quantify the observed Golgi shrinking in HeLa L and hTERT-RPE1 cells,
cells from two independent experiments, performed as described above, were analysed
and nuclear diameter compared to Golgi diameter. Long Golgi ribbons were measured
from compartment tip to tip (Fig.25) using the Photoshop CS2 measuring tool. 15 to
25 cells were measured per experiment and condition. In HeLa L cells, nuclear diameter
changed from 6.05(+/-0.17) to 5.41(+/-0.52), Golgi diameter changed from 4.78(+/-0.4)
to 2.27(+/-0.52). Thus, Golgi diameter in HeLa L cells decreased to half the value of
Figure 25: Graphical Representation Of GMAP-210 siRNA Effect. HeLa L or hTERT-RPE1
cells were transfected for 72 h with siRNA oligos against GL2 (control) and GMAP-210 3’-UTR,
fixed with paraformaldehyde and stained with mouse anti GM130 (1:500) and rabbit anti GMAP-
210 (1:500) antibodies (see Fig.24); measurement of nuclear and Golgi diameter was done with Adobe
Photoshop measuring tool, measuring 15-25 individual cells per experiment (n=2); nuclear diameters in
HeLa L cells are: GL2 6.05+/- 0.17; GMAP-210 5.41+/-0.52; Golgi length (maximum distance between
endpoints): GL2 4.78+/-0.4; GMAP-210 2.27+/-0.62. In hTERT-RPE1 cells nuclear diameters were:
GL2 7.19+/-0.85; GMAP-210 6.36+/-1.44; Golgi length: GL2 4.55+/-0.95; GMAP-210 4.51+/-1.26;
all given in arbitrary units.
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wild-type cells upon depletion of GMAP-210 by siRNA. In hTERT-RPE1 cells, nuclear
diameter was 7.19(+/-0.85) and 6.36(+/-1.44), Golgi size changed from 4.55(+/-0.95) to
4.51(+/-1.26) for control and GMAP-210 siRNA, respectively. Golgi size did not change
in hTERT-RPE1 cells after GMAP-210 depletion. In both cell types, however, overall cell
size stayed approximately the same as monitored by nucleus diameter.
GMAP-210 depletion caused shrinking of the Golgi apparatus in HeLa L cells by approxi-
mately 50% whereas hTERT-RPE1 cells’ Golgi did not change.
2.3.3 Electron Microscopy Of HeLa L Golgi Apparatus After GMAP-210
Depletion
For a closer examination of the changes in Golgi morphology caused by depletion of
GMAP-210 in HeLa L cells, electron microscopy was performed (4.6.5, p.139). HeLa L
cells were treated for 72 h with siRNA oligos against GL2 as control or GMAP-210
3’-UTR (Fig.26) and then processed for electron microscopy as described in 4.6.5 (p.139).
In HeLa L control cells, the Golgi consisted of stacked cisternae, which formed ribbons
in the perinuclear region (Fig.26; white arrowheads; pictures only show section of Golgi
ribbon). In GMAP-210 depleted cells the Golgi ribbon structure broke down, stacks
vanished and only oddly shaped, bloated vesicles of varying sizes remained (Fig.26; black
arrowheads). In some cells, these vesicular structures clustered in a small area near the
nucleus. This was reminiscent of the collapse effect observed in immunofluorescence of
HeLa L cells (Fig.24, p.49).
GMAP-210 depletion in HeLa L by siRNA causes fragmentation of the Golgi apparatus
and fragments cluster near the nucleus.
2.3.4 After GMAP-210 Depletion, Expressed Protein Is Recruited To The
Golgi Apparatus Independently Of GRAB Domain
In order to examine whether the GMAP-210 siRNA phenotype (see 2.3, p.48) is reversible
by transfection of GFP-tagged GMAP-210 constructs, HeLa L cells were transfected with
GL2 control siRNA oligos or GMAP-210 3’-UTR siRNA oligos for 72 h. 48 hours after
siRNA treatment, constructs for GMAP-210 expression with enhanced GFP-tags were
transfected (Fig.27, p.53). The cells were fixed and stained for GM130. As can be seen in
Fig.27, transfection of full-length GMAP-210 (pEGFPN3-GMAP-210) had little effect on
the compacted Golgi, also transfection of GMAP-210 GRAB domain (pEGFPC2-GMAP-
210 1683-1875) had no effect. Surprisingly enough, the GRAB mutant of full-length
GMAP-210 (pEGFPC2-GMAP-210 D1780A L1783A), which showed only weak target-
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Figure 26: Electron Microscopy Of HeLa L Golgi Apparatus. HeLa L cells were transfected
with siRNA oligo against GL2 control (left) or GMAP-210 3’-UTR (right) for 72 h and fixed in 2.5%
glutaraldehyde in 0.1 M cacodylate buffer containing 5% sucrose, pH 7.1-7.2, at room temperature
for 30-40 min, then in the same fixative containing 1% tannic acid at 4◦C for 30-60 min, postfixed
in 1% OsO4 for 1-2 hrs, stained en bloc in 1% aqueous uranyl acetate at 60◦C overnight, dehydrated
in ethanol and embedded in Spurr’s medium. Thin sections were taken on a Leica Ultracut with a
Diatome diamond knife and investigated in a Philips (FEI) CM 12 electron microscope operated at
120 kV; white arrowheads: stacked Golgi cisternae in control cells; black arrowheads: Golgi fragments
after GMAP-210 depletion; pictures by Dr. Thomas Keil.
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Figure 27: GMAP-210 Fragments In GMAP-210 siRNA Background. HeLa L cells were trans-
fected for 72 h with an siRNA oligo against GMAP-210 3’-UTR or GL2 (control); after 48 h the cells
were also transfected with the indicated GMAP-210 fragments for 24 h (green); cells were fixed with
paraformaldehyde and stained with the mouse anti GM130 antibody (red, 1:500); blue channel: DAPI
staining; Bar=10 μm.
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ing to the Golgi in control cells, showed clear and distinct localisation to the Golgi after
depletion of endogenous GMAP-210. In order to analyse this effect, more fragments of
GMAP-210 were transfected. Transfection of the GRAB domain mutant (pEGFPC2-
GMAP-210 1683-1875 D1780A L1783A) was mostly localised diffusely in the cytosol.
The weak Golgi localisation was not changed after siRNA of GMAP-210. N-terminal
constructs missing the GRAB domain like pEGFPC2-GMAP-210 1-1712 or pEGFPC2-
GMAP-210 1-1332, however, showed a clear signal at the Golgi apparatus in absence of
endogenous GMAP-210. This was in contrast to control cells. Further mapping for this
putative Golgi targeting signal in GMAP-210 showed, that the region between amino
acids 855 and 1332 got recruited to the Golgi apparatus after GMAP-210 siRNA treat-
ment (pEGFPC2-GMAP-210 855-1332). Constructs comprising amino acids 618 to 803 or
1333 to 1712 remained diffusely localised in the cytosol (pEGFPC2-GMAP-210 618-803
and 1333-1712). This phenomenon will be further examined in 2.4.2 (p. 56).
As the observed siRNA phenotype (see 2.3, p.48) in HeLa L was different compared to
the one observed in hTERT-RPE1 cells, it was necessary to check in hTERT-RPE1 cells
if GFP-tagged GMAP-210 constructs were recruited to the Golgi upon depletion of en-
dogenous GMAP-210.
hTERT-RPE1 cells were treated with GL2 control siRNA oligos or GMAP-210 siRNA oli-
gos for 72 h. After 48 h they were also transfected with GFP-tagged constructs of GMAP-
210 full-length, wild-type and GRAB domain mutant (D1780A L1783A) and GMAP-210
amino acids 1 to 1712. The cells were fixed and stained for GM130 as Golgi marker
(Fig.28). Full-length GMAP-210 wild-type (pEGFPN3-GMAP-210) or GRAB mutant
(pEGFPC2-GMAP-210 D1780A L1783A) co-localised with GM130 on the Golgi appara-
tus, independently of presence or absence of endogenous GMAP-210. The GMAP-210
construct without GRAB domain (pEGFPC2-GMAP-210 1-1712) could be found concen-
trated in the perinuclear region, but did not co-localise with GM130, neither in control
nor in GMAP-210 depleted cells. Hence, hTERT-RPE1 cells behaved differently from
HeLa L cells in relation to localisation of GMAP-210.
Depletion of GMAP-210 in HeLa L cells caused compaction of the Golgi. This effect was
not reversed by overexpression of GFP-tagged GMAP-210, although GRAB domain mu-
tant constructs of GMAP-210 were recruited to the Golgi after depletion of endogenous
GMAP-210, an effect not seen in hTERT-RPE1 cells under the same conditions.
2.3.5 Summary
An siRNA oligo against the 3’-UTR of the human GMAP-210 gene was designed and
tested for its efficiency. Endogenous GMAP-210 is depleted from HeLa L and hTERT-
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Figure 28: GMAP-210 Fragments In GMAP-210 siRNA Background In hTERT-RPE1 Cells.
hTERT-RPE1 cells were transfected for 72 h with an siRNA oligo against GMAP-210 3’-UTR or
GL2 (control); after 48 h the cells were also transfected with the indicated GMAP-210 fragments
and mutant constructs for 24 h; cells were fixed with paraformaldehyde and stained with mouse anti
GM130 antibody (red, 1:500); blue channel: DAPI staining; Bar=5 μm.
RPE1 cell extracts after 72 h as monitored by Western blotting. In immunofluorescence,
Golgi staining by GMAP-210 antibodies vanished completely. In HeLa L cells, the Golgi
apparatus showed a compacted morphology after depletion of GMAP-210, monitored
by intensified GM130 staining on the smaller and round-up Golgi. Electron microscopy
elucidated, that, on an ultrastructural level, the compacted Golgi was a cluster of swollen
vesicular fragments.
Transfection of GMAP-210 GRAB domain mutants, which were unable to bind to Golgi
in control cells, were suddenly recruited to Golgi membranes. Mapping revealed, that
GMAP-210 amino acids 855 to 1332 were responsible for this. In hTERT-RPE1 cells a
change in Golgi morphology could not be obtained.
2.4 GMAP-210 Co-Localises And Interacts With Markers From
The ER-To-Golgi Pathway
Up to date, no interaction partners are known for GMAP-210, apart from the putative
interaction with ADP-ribosylation factor 1 (Arf1), discovered with the S.cerevisiae ho-
mologue of GMAP-210 (Gillingham et al., 2004). Thus, several components from the
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secretory pathway of mammalian cells were tested for interaction and co-localisation with
GMAP-210 or for specific changes in their distribution upon GMAP-210 depletion.
2.4.1 SNARES And Golgins Remain Localised To The Compacted Golgi
Apparatus Upon GMAP-210 Knockdown
GMAP-210 is localised to the cis-Golgi (Rios et al., 1994) and is a putative interac-
tion partner of a small Arf-/Arl-GTPase, as shown in S.cerevisiae for Rud3p and Arf1p
(Gillingham et al., 2004). In order to find interaction partners of GMAP-210, which could
elucidate its function on the Golgi apparatus, siRNA against GMAP-210 3’-UTR and sub-
sequent co-staining with antibodies against a variety of Golgi markers was performed in
HeLa L cells (Fig.29). The proteins tested were the SNAREs GS15, GS27, GS28, Vti1a
and Vti1b, Golgi localised large coiled-coil proteins Golgin-245/p230, Golgin-84, TGN46
and GM130 and the cargo sorting KDEL-receptor. All these proteins had a pool on the
Golgi apparatus. Upon depletion of GMAP-210 by siRNA, the Golgi collapsed while all
examined proteins still localised to its membrane. The signal intensity for all markers
became higher, indicating the same amount of protein within a smaller area of Golgi
membranes. The only protein which showed a slightly weaker Golgi localised signal, in
comparison to other tested markers, is the SNARE Vti1b. This might indicate a partial
loss of Vti1b from the Golgi apparatus, when GMAP-210 was depleted. None of the
tested proteins co-localised with GMAP-210 on the Golgi apparatus. This is expected
and especially obvious for the trans-Golgi golgins p230 and TGN46.
None of the tested markers could be identified as candidates for GMAP-210 interaction
and apart from Vti1b, Golgi localisation was not impaired by GMAP-210 depletion.
2.4.2 GMAP-210 Interacts With The Rab GTPase Rab1
Rab GTPases are involved in a great variety of intracellular transport steps (Pfeffer, 2001).
Furthermore, Rab-GTPases have a propensity to bind to proteins with long coiled-coil
regions (Short et al., 2005).
To identify possible interaction partners for GMAP-210 amongst Rab proteins, GMAP-
210 was screened in a yeast 2-hybrid assay against the complete Rab family available as
a library in the laboratory. GMAP-210 was used as prey in the pAct2 vector, the Rab
GTPases were used as bait in the pFBT9 vector. The GTPases were used as GTP-locked,
active mutants (catalytic glutamine to alanine). The complete screen is given in Fig.30.
The yeast 2-hybrid screening showed GMAP-210 interacting with Rab1a/1b, Rab2a/2b,
Rab8a, Rab10, Rab14, Rab15, Rab35 and Rab39. Rab45 is self-activating and thus is
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Figure 29: Selected Golgi Markers And GMAP-210. HeLa L cells were transfected with an siRNA
oligo against GMAP-210 3’-UTR or GL2 (control) for 72 h and fixed with either methanol (KDEL-R)
or paraformaldehyde (all others); cells were stained with rabbit anti GMAP210 (green, 1:500) antibody;
for co-staining anti GS15 (1:100), anti GS27 (1:500), anti GS28 (1:500), anti Golgin-245/p230 (1:250),
anti Vti1a (1:100), anti Vti1b (1:100), anti GM130 (1:500), anti KDEL R (1:500) (all mouse, red), anti
Golgin-84 (1:500) or anti TGN46 (1:2000) (both sheep, red) antibodies were used; blue channel: DAPI
staining; Bar=5 μm.
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Figure 30: Yeast 2-Hybrid Screen Of GMAP-210 Against The “Rabome”. Yeast 2-Hybrid
interaction experiment, screening GMAP-210 full-length (prey in pAct2) against a complete collection
of Rab GTPases (Rabome) in GTP-bound, active mutant form (Q-A) (bait in pFBT9) -LW: leucine
and tryptophane deficient medium (growth control); QDO: leucine, tryptophane, histidine and alanine
deficient medium; numbers indicate Rab GTPase number.
used as positive control.
Of these Rab proteins, Rab1 and Rab2 are Golgi localised and involved in ER to Golgi
and intra-Golgi trafficking (Allan et al., 2000; Moyer et al., 2001; Short et al., 2001). They
have also been described to bind to several coiled-coil Golgi localised proteins (Short et al.,
2005). This made them possible candidates for further examination.
HeLa L cells were treated with GL2 control siRNA or GMAP-210 siRNA for 72 h, fixed
and stained for Rab1 or Rab2 while co-stained with an antibody against the golgin GM130
(Fig.31) Rab1 and Rab2 localised to the same perinuclear structure like GM130. Rab1
also showed a web-like structure, which might represent its localisation to the endoplasmic
reticulum. Upon GMAP-210 depletion, the Golgi became very compact and round-up.
Still Rab1 and Rab2 co-localise with GM130 and Rab1 could still be found at the endo-
plasmic reticulum. Thus, neither Rab1 nor Rab2 changed localisation when GMAP-210
was depleted in HeLa L cells.
Rab1 and Rab2 interaction with GMAP-210 was further tested by mapping the inter-
action domain by the yeast 2-hybrid method (Fig.32). Rab1a and Rab2a were used as
bait in the yeast 2-hybrid assay, whereas different GMAP-210 fragments were used as
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Figure 31: GMAP-210 And The Small GTPases Rab1 And Rab2. HeLa L cells were treated with
an siRNA oligo against GMAP-210 3’-UTR or GL2 (control) for 72 h and fixed with paraformaldehyde;
the cells were stained with mouse anti Rab1 (red, 1:5, top) or Rabbit anti Rab2 (red, 1:500, bottom)
and sheep anti GM130 (green, 1:500) antibodies; blue channel: DAPI staining; Bar=10 μm.
Figure 32: Yeast 2-Hybrid Mapping for Rab1/Rab2 Interaction Site in GMAP-210. Yeast
2-Hybrid interaction mapping experiment, testing indicated GMAP-210 fragments as prey in pAct2
vector against Rab1a and Rab2a wild-type in the pFBT9 vector; -LW: leucine and tryptophane deficient
medium (growth control); cartoons indicate tested fragments, non-interacting fragments are depicted
transparent; QDO: leucine, tryptophane, histidine and alanine deficient medium; numbers indicate
amino acid range of fragment tested.
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prey. In general Rab2a gave a stronger interaction than Rab1a. Full-length GMAP-210
interacted with both GTPases. Of the tested fragments only amino acids 855 to 1712 and
the sub-fragment 855-1332 gave a signal. With Rab2a as bait, GMAP-210 amino acids
1333 to 1712 also reacted although weaker than with amino acids 855 to 1332.
This interaction still had to be proven by biochemical interaction studies. For this
the Rab GTPases identified in yeast 2-hybrid as possible GMAP-210 partners were ex-
pressed in E.coli with an N-terminal glutathione-S-Transferase(GST)-tag and coupled
to glutathione-S-sepharose loaded with GTP and incubated with HeLa L cell extract.
Bound protein was examined by SDS-PAGE and Western blotting. Detection with anti
GMAP-210 antibodies showed binding (Fig.33, top; p.61). Coupling of recombinant Rab
proteins to beads was monitored by coomassie stained SDS-PAGE, comparing input to
supernatant of the coupling reaction (Fig.33, bottom; p.61). All proteins except Rab39
coupled efficiently, although Rab39 coupling was still sufficient for the experiment. The
Western blotting of eluted protein clearly showed binding of GMAP-210 to Rab1, but not
to Rab2 and to none of the other tested Rab GTPases Rab8a, Rab10, Rab14, Rab15,
Rab35 or Rab39.
As Rab effector, binding of GMAP-210 to Rab1 had to be dependent on the nucleotide
state of the GTPase. GMAP-210 would only bind to Rab1 in its GTP-bound, active, not
in its GDP-bound, inactive state. The pulldown experiment was repeated with the GDP-
locked, inactive (Rab1S25N) mutant in comparison to the GTP-locked, active mutant of
Rab1 (Rab1Q70L) (Fig.34, p.62). The difference in phenotype after siRNA knockdown
(2.3, p.48ff) in HeLa L compared to hTERT-RPE1 cells showed, that there seemed to be
a difference in GMAP-210 function in these two cell types. To be sure, that the different
behaviour of GMAP-210 is not related to different interactions partners, cell extracts from
both cell lines were tested in this pulldown experiment. The experiment (Fig.34, p.62),
however, showed no difference in binding behaviour or efficiency between HeLa L- and
hTERT-RPE1-derived GMAP-210. Rab1 could pull down GMAP-210 from cell extract
only in its GTP-locked, active mutant form. The GDP-locked version did not bind to
GMAP-210. The coomassie stained SDS-PAGE depicted below the Western blots showed
efficient coupling of the recombinant Rab1 proteins to the beads. GMAP-210 bound
specifically to active Rab1 but not to inactive, GDP-bound Rab1. This was independent
of cell type used.
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Figure 33: Recombinant Rab GTPase Pulldown Of GMAP-210. A HeLa L extract was made with
NL100 buffer and incubated with the respective recombinant, GST-tagged Rab GTPase, pre-coupled
to glutathione-sepharose in the presence of 100 μM GTP; beads were extracted with NE200 buffer
and TCA precipitated; protein was analysed on Western blot from 6% SDS-PAGE gels, for protein
detection rabbit anti GMAP-210 antibody (1:500) and HRP donkey anti rabbit (1:1000) secondary
antibody were used (upper row); lower gels show coomassie stained 10% SDS-PAGE gels loaded with
about 1 μg recombinant Rab GTPase input and the same amount of supernatant from above the
glutathione-sepharose after pre-binding to monitor coupling efficiency.
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Figure 34: Dependency Of The GMAP-210 Pulldown On The Nucleotide State Of Rab1.
A: HeLa L or B: hTERT-RPE1 extract was made with NL100 buffer and incubated with recombinant,
GST-tagged, mutant Rab1, pre-coupled to glutathione-sepharose in the presence of 100 μM GTP (for
Q-L mutant) or 100 μM GDP (for S-N mutant); Rab1 was either used in its active, GTP-bound
form (Q-L) or in its inactive, GDP-bound form (S-N); beads were boiled in SDS sample buffer and
samples analysed by Western blotting from 6% SDS-PAGE gels; protein was detected with rabbit
anti GMAP-210 primary antibody (1:500) and HRP donkey anti rabbit secondary antibody; C: shows
coupling efficiency of recombinant protein to glutathione-S-sepharose; 1 μg recombinant Rab1 input
and supernatant were loaded and stained with coomassie brilliant blue.
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2.4.3 GMAP-210 Overlaps With The COPII Complex On A Subpopulation
Of Vesicular Structures
As interactor of Rab1, which is found in the early secretory pathway (Cao et al., 1998;
Allan et al., 2000), GMAP-210 was likely to be a player in the ER-to-Golgi trafficking.
Thus, it might interact with other components of the early secretory pathway.
The first candidates tested were the coatomer complexes COPI and COPII. In Fig.35
HeLa L cells had been transfected with siRNA against GMAP-210 3’-UTR for 72 h and
then stained for the coatomer I component βCOP or the coatomer II component Sec31.
βCOP was concentrated at the Golgi apparatus and stained vesicular structures in the cell
periphery. These vesicular structures did not co-localise with GMAP-210 vesicular-tubular
structures observed (close-up in Fig.35). Upon depletion of GMAP-210, the peripheral
COPI vesicles were widely unchanged, the Golgi localised pool remained and appeared
more concentrated on the collapsed structure as observed for GM130 (Fig.24, p.49). The
COPII signal localised to the perinuclear region and overlapped with the signal for GM130.
COPII also showed staining on vesicular structures in the cell periphery. Upon depletion
of GMAP-210 by siRNA, vesicular structures were unchanged, however Golgi localised
signal concentrated on the now compacted Golgi. Again the signal was stronger. In
order to examine the COPII vesicles for co-localisation with GMAP-210, the pEGFPN3-
GMAP-210 plasmid was transfected into HeLa L cells for 24 h. After fixing, cells were
co-stained with the antibody against COPII. Several vesicles positive for GFP signal also
showed staining for COPII (Fig.35, white arrowheads). There were still discrete tubular
structures showing GFP and distinct COPII carrying vesicles.
2.4.4 Peripheral GMAP-210 Signals Overlap With ERGIC53
GMAP-210 partially co-localised with COPII on vesicles. This made it likely that GMAP-
210 could also be found on ER-Golgi-Intermediate-Compartments. This was tested by
co-staining for the ER-Golgi-Intermediate-Compartment protein of 53 kDa (ERGIC53).
HeLa L and hTERT-RPE1 cells were fixed and co-stained with antibodies against ER-
GIC53 and GMAP-210 (Fig.36, p.65). In both cell types, HeLa L and hTERT-RPE1, some
overlap of ERGIC53 and the GMAP-210 signal could be observed on vesicular structures
(Fig.36, p.65, “Control” and arrows in close-ups).
When GMAP-210 was depleted by siRNA treatment, ERGIC53 distribution was not dis-
turbed. The Golgi localised ERGIC53 pool remained while in HeLa L cells the signal got
stronger, due to the effect of a compact Golgi.
As ERGIC53 partially co-localised with GMAP-210, constructs for expression of GMAP-
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Figure 35: Coatomer Proteins And GMAP-210. HeLa L cells were transfected with an siRNA
oligo against GMAP-210 3’-UTR or GL2 (control) for 72 h, fixed and stained with either rabbit anti
GMAP-210 (green, 1:500, left) or mouse anti GM130 (green, 1:500, middle) and mouse anti βCOP (red,
1:500, left) or rabbit anti COPII (red, 1:500, middle); right panel shows pictures of cells transfected
for 24 h with a vector for expression of GMAP-210 full-length with a C-terminal enhanced GFP-Tag
(green) and co-stained with the rabbit anti COPII (red, 1:500) antibody; blue channel: DAPI staining;
Bar=5 μm.
210 were transfected into HeLa L and hTERT-RPE1 cells and, after fixing, co-stained with
the antibody against ERGIC53 (Fig.37, p.66). The constructs transfected were full-length
GMAP-210, amino acids 1683-1875 (GRAB domain), amino acids 1598-1979 and amino
acids 1-1712 (full-length without GRAB domain). Again the GMAP-210-GFP signal and
ERGIC53 signal overlapped on some vesicles in the cell periphery. Obviously full-length
GMAP-210 shared some structures with ERGIC53 in both cell types (pEGFPN3-GMAP-
210). GRAB domain showed no overlap (pEGFPC2-GMAP-210 1683-1875),
C-terminus (pEGFPC2-GMAP-210 1598-1979) had some co-localisation and full-length
protein without GRAB domain (pEGFPC2-GMAP-210 1-1712) shared some structures
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Figure 36: GMAP-210 And The ER-Golgi-Intermediate Compartment. hTERT-RPE1 (top)
or HeLa L (bottom) cells were transfected with an siRNA oligo against GMAP-210 3’-UTR or GL2
(control) for 72 h and then fixed and stained with rabbit anti GMAP-210 (green, 1:500) and mouse anti
ERGIC53 (red, 1:1000); right panel shows close-up of the peripheral cell region indicated by boxes; for
hTERT-RPE1 cells; HeLa L cells were transfected for 24 h with the pEGFPN3-GMAP-210 construct
for 24 h (green), fixed and stained with antibodies against ERGIC53 (red) as described above; close-
up (bottom right) shows cell periphery indicated by boxes; arrow indicate structures with overlapping
signals; blue channel: DAPI staining; Bar=5 μm.
with ERGIC53, but only in HeLa L cells.
2.4.5 Summary
GMAP-210 was tested for interaction with several different components of the ER-to-Golgi
and intra-Golgi trafficking pathways. None of the tested markers changed localisation sig-
nificantly after depletion of GMAP-210. Yeast 2-Hybrid interaction studies with the Rab
family of small GTPases identified several Rab proteins as possible interaction partners.
Pulldown experiments showed that only Rab1 could bind to GMAP-210 in vitro and did
so depending on its nucleotide state. Mapping of the interaction domain within GMAP-
210, identified amino acids 855 to 1332 as interaction domain.
Co-staining of GMAP-210 with antibodies against a COPII component or the ER-Golgi
intermediate compartment marker ERGIC53, showed several instances of overlapping sig-
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Figure 37: GMAP-210 And The ER-Golgi Intermediate Compartment. HeLa L (top) and
hTERT-RPE1 (bottom) cells were transfected with the indicated constructs for 24 h and then fixed
with paraformaldehyde and stained with the mouse anti ERGIC53 antibody (red, 1:1000); the right
side shows close-ups of highlighted areas from cells depicted on the left side; arrows indicate structures
with co-localising signals; blue channel: DAPI staining; Bar=5 μm.
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nals on vesicular structures. It could also be shown, that the GMAP-210 GRAB domain
did not co-localise with ERGIC53, although it was needed for Golgi binding (2.1.2, p.29).
2.5 GMAP-210 siRNA Depletion Does Not Impair VSV-G Or
Shiga Toxin B Subunit Trafficking
Because of its association with Rab1, COPII and ERGIC53 and its cis-Golgi localisation,
it is quite likely, that GMAP-210 is involved in ER-to-Golgi or Golgi-to-ER trafficking.
This was tested with two different experiments examining anterograde and retrograde
trafficking after knockdown of GMAP-210.
2.5.1 Vesicular Stomatitis Viral G-Protein Is Transported To The Plasma
Membrane At Normal Rates In GMAP-210 Knock-Down Cells
The Vesicular Stomatitis Virus is a member of the Rhabdoviridae family. Its G-Protein is
a ready tool in cell biology to examine transport from the ER to the plasma membrane.
Usage of its temperature sensitive mutant, VSV-Gts045, allows it to be retained in the ER
by culturing cells at 39.5◦C. Refolding happens upon incubation on ice and transport is
started when cells are brought to 32◦C (Bergmann, 1989).
HeLa L cells were treated with GMAP-210 siRNA or GL2 control siRNA for 72 h. 14 h
prior to the VSV-G transport assay, the cells were also transfected with a plasmid encoding
the temperature sensitive mutant of the vesicular stomatitis viral G-protein (VSV-Gts045)
fused to an N-terminal, enhanced GFP tag and incubated at normal growth conditions
at 37◦C for 2 h. The cells were cultured for 12 h under restrictive conditions and then
incubated on ice to allow refolding of the protein. Shifting the cells to the permissive
temperature of 32.5◦C started the export of VSV-Gts045. Cells were fixed and stained
with an antibody against the lumenal domain of VSV-G, which is exposed to the cell’s
outside when the protein reaches the plasma membrane (Fig.38). Cells were, however,
not permeabilised prior to staining. In control cells the GFP-signal of the transfected
VSV-G protein could be followed from the endoplasmic reticulum, to the Golgi after
30 min. After 60 min the protein reached the plasma membrane localisation but had
still a Golgi localised pool. The antibody against the lumenal domain of VSV-G only
stained the plasma membrane after 60 min, seldomly already after 30 min and marked
the completion of VSV-G transport through the cell. HeLa L cells depleted of endogenous
GMAP-210 also showed a GFP signal in the endoplasmic reticulum at the start of the
transport, Golgi was reached after 30 min and plasma membrane localisation was visible
after 60 min. In order to quantify the transport efficiency of GFP-VSV-G, signal intensity
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Figure 38: VSV-G Transport After GMAP-210 Depletion. HeLa L cells were transfected with
siRNA oligo against GL2 (control) or GMAP-210 3’-UTR for 72 h; 14 h before the experiment, the cells
were additionally transfected with a GFP-tagged vesicular stomatitis viral G-protein and incubated
for 2 h at 37◦C; cells were then shifted to 39.5◦C overnight; after incubation for 30 min on ice, cells
were further incubated at 32.5◦C and fixed with paraformaldehyde at the indicated time-points, but
without permeabilising; staining was done with a mouse antibody against the lumenal domain of the
VSV-G protein (red, 1:20); blue channel: DAPI staining; Bar=10 μm.
in the green and red channel after 60 min were measured with the MetaVue Software and
after correction for background the ratio of red signal to green signal (thus signal of
transported protein to overall protein) calculated and presented graphically in Fig.39.
Obviously the ratio of transported to overall protein was the same in control (4.8+/-0.9)
and GMAP-210 siRNA treated cells (4.5+/-0.8). Transport of VSV-G is not impaired by
GMAP-210 depletion.
2.5.2 Shiga Toxin B Subunit Is Internalised And Transported At Normal
Rates In GMAP-210 siRNA Treated Cells
Shiga toxin is a tool to study endocytosis and subsequent transport, via early and recycling
endosomes, to the Golgi apparatus and the endoplasmic reticulum (Johannes and Goud,
1998). Transport of the toxin holoenzyme is coordinated by the B-subunit, whereas the
A-subunit is responsible for toxicity.
For testing uptake of the shiga toxin B subunit labelled with Cy3-fluorescent dye (Fuchs
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Figure 39: Graphical Quantification Of VSV-G Transport Efficiency. The VSV-G transport
assay was performed as described above; the digital pictures were analysed with the MetaVue software
for measuring the intensity of red and green staining; background was subtracted and the ratios of red
to green calculated for both conditions; about 15 cells expressing the VSV-G protein were used for
measurement under each condition; Ratio GL2 4.8+/-0.9; Ratio GMAP-210 4.5+/-0.8.
et al., 2007), HeLa L cells were transfected for 72 h with siRNA against GL2 as control
or GMAP-210 before incubating the coverslips on ice for 30 min in a solution containing
Cy3-shiga toxin B subunit. After shifting the cells to normal growth conditions at 37◦C,
they were fixed and stained with the Golgi marker GM130 at different time-points up to
240 min (Fig.40). In control cells shiga toxin B subunit bound to the cell surface during
incubation on ice, entered the cells and showed up in vesicular structure within the first
10 min. After 60 min, the signal still localised in vesicular structures throughout the cell
but also clearly in a perinuclear area co-stained for GM130. After 120 min the perinuclear
signal became brighter, but a signal on vesicular structures started to reappear, which
was also seen after 240 min at which time the perinuclear signal became weaker again,
although it did not disappear entirely.
In cells transfected for 72 h with an siRNA oligo against GMAP-210, the shiga toxin B
subunit bound to the cell surface as seen in controls and entered the cell within the first
10 min. The toxin appeared in the perinuclear region within 60 min after incubation
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Figure 40: Shiga Toxin Uptake After GMAP-210 Depletion. HeLa L cells were transfected with
an siRNA oligos against GL2 (control) or GMAP-210 3’-UTR for 72 h before incubating the cells in a
Cy3-shiga toxin B subunit solution (red, 1:2500) on ice; cells were washed with 37◦C growth medium,
incubated at normal growth conditions and fixed at the given time-points with paraformaldehyde;
cells were stained with mouse anti GM130 antibody (green; 1:500); blue channel: DAPI staining;
Bar=10 μm.
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and became stronger within another 60 min. At this time vesicular structures, containing
shiga toxin, started to appear. The signal in the perinuclear region was not lessened after
a total of 240 min, which might have been due to the compaction of the Golgi (2.3, p.48ff)
observed in HeLa L cells. This might have masked the effect of reduction of signal at the
Golgi apparatus.
2.5.3 Summary
GMAP-210 was describe to disturb anterograde and retrograde trafficking after overex-
pression of the full-length protein (Pernet-Gallay et al., 2002). In these experiments,
GMAP-210 was depleted by siRNA and the effects on anterograde and retrograde traf-
fic evaluated by VSV-G transport and uptake of shiga toxin B subunit. VSV-G was
transported to the plasma membrane at equal rates in control cells and cells depleted
of GMAP-210. Anterograde transport was unhindered. The uptake rate of the shiga
toxin B subunit was equal until it reached the Golgi apparatus. The rate of retrograde
traffic between the Golgi apparatus to the ER was, however, difficult to compare, as Golgi
morphology had changed after GMAP-210 depletion and the compacted Golgi showed a
much higher signal intensity, than the Golgi in control cells.
2.6 GMAP-210 Remains On Golgi Remnants After Brefeldin
A Treatment And GMAP-210 Depletion Does Not Change
Brefeldin A Effect On Cells
2.6.1 Brefeldin A Effect On GMAP-210 Localisation
The fungal metabolite Brefeldin A (BFA) binds to the interface of interaction between the
Arf-GEF GBF (Kawamoto et al., 2002; Zhao et al., 2002; Garcia-Mata et al., 2003) or BIG
(Shinotsuka et al., 2002) with the GDP-bound Arf1 and creates a stable GEF-GDP-Arf
complex (Sciaky et al., 1997), making the GEF unavailable for activating any Arf1. The
Golgi subsequently breaks down and most membranes fuse with the ER. Most Golgi lo-
calised proteins, like mannosidase II redistribute to the ER (Klausner et al., 1992) whereas
others stay in distinct Golgi fragments, like the golgin GM130 (Nakamura et al., 1995).
The coatomer complex subunits redistribute to the cytoplasm. GMAP-210 was described
to act like other Golgi matrix proteins and localise to the small Golgi fragments near the
ER-exit sites (Rios et al., 1994). However, the homologue of GMAP-210 in S.cerevisiae,
Rud3p, is dependent on Arf1 to localise to the Golgi apparatus (Gillingham et al., 2004).
So far interaction of GMAP-210 with Arf1 could not be proven, but if GMAP-210 really
2 Results 72
relies on Arf1 for its Golgi localisation, it should be removed from Golgi membranes upon
Arf1 inactivation by Brefeldin A. First, HeLa L cells were cultured for 24 h under stan-
dard conditions and then treated for 10 min with 5 μg/ml Brefeldin A (Fig.41; left side).
After Brefeldin A treatment, most of the Golgi had disassembled into small fragments
distributed throughout the cell. These fragments are positive for GM130 as indicated by
antibody staining. GMAP-210, like GM130 (Nakamura et al., 1995), could be found on
small vesicular structures, matching BFA Golgi remnants. Although there were vesicular
structures, which stained for GM130 and GMAP-210 at the same time, there were others
with clear and distinct signals for only one of the two golgins.
Thus, full-length localisation of GMAP-210 does not depend on the active form of Arf1.
Still it was possible, that GMAP-210 had additional Golgi localisation motives, which kept
it bound to the Golgi, even after blocking the activation of Arf1 using BFA. If GRAB
domain interaction with Arf1 was correct, a construct only expressing the GMAP-210
GRAB domain should no longer be able to bind to the Golgi apparatus when Arf1 is
Figure 41: Brefeldin A Induced Golgi Disassembly And Effect On The GMAP-210 GRAB
Domain. HeLa L cells were transfected for 24 hours with GMAP-210 GRAB domain (amino acids
1683-1875) with an N-terminal, enhanced GFP-Tag (green); control cells were grown untransfected;
cells were fixed with paraformaldehyde either after 10 min of treatment with 5 μg/ml Brefeldin A or
untreated as indicated; cells were stained with mouse anti GM130 (red, 1:500) and, in the case of un-
transfected cells, with rabbit anti GMAP-210 (green, 1:500); blue channel: DAPI staining; Bar=10 μm.
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inactivated by Brefeldin A.
HeLa L cells, which expressed pEGFPC2-GMAP-210(1683-1875) for 24 h, were treated
with Brefeldin A for 10 min. After fixing they were stained for GM130 or GM130 and
GMAP-210 for control cells (Fig.41). In cells not treated with Brefeldin A, transfected
GRAB domain localised to the perinuclear region on the same structure as GM130. After
10 min of BFA treatment, the Golgi apparatus started to fragment as seen by GM130
staining. GMAP-210 GRAB domain still localised to the GM130 positive fragments, al-
though the diffuse cytosolic staining increased, indicating a loss of binding to the Golgi
apparatus. Therefore the GRAB domain does appear to target due to Arf1, while full-
length GMAP-210 must possess additional targeting information.
2.6.2 Brefeldin A Induced Golgi Assembly and Disassembly After
GMAP-210 Depletion
In this context, it was not only interesting if GMAP-210 localisation was influenced by
Brefeldin A treatment, but also, if GMAP-210 had any function in the processes of Golgi
fragmentation and redistribution of certain Golgi components to the endoplasmic reticu-
lum. Thus, Brefeldin A induced Golgi breakdown and the subsequent Golgi reassembly
after washout of the compound were analysed in the presence and absence of GMAP-210.
HeLa L cells were transfected with siRNA oligos against GL2 control and GMAP-210
3’-UTR for 72 h and then treated with 5 μg/ml Brefeldin A. Cells were fixed and stained
with antibodies against βCOP and GM130 at different time-points. Control and GMAP-
210 depleted cells were compared (Fig.42). In HeLa L cells, which were treated with
Brefeldin A, βCOP lost its Golgi localisation within the first 10 minutes and showed dif-
fuse cytosolic distribution. In cells treated with GMAP-210 siRNA, COPI was also lost
from the Golgi within 10 min. GM130 staining monitored the Golgi breakdown, which oc-
curred within 30 min in control cells. In GMAP-210 knockdown cells, the breakdown took
longer. Even after 45 min GM130 could be seen concentrated in the perinuclear region,
although the cisternal stacks of the Golgi had broken into vesicular structures. In this
regard it is important to remember, that the Golgi apparatus collapsed upon GMAP-210
depletion and started out from a much more compacted state than in control cells, which
could cause the slower spreading of the Golgi remnants after Brefeldin A treatment.
For reassembly studies, HeLa L cells, treated with siRNA and Brefeldin A for 20 min,
were washed and incubated at normal growth conditions. At 30 min, 60 min and 90 min
after washout, the cells were fixed and stained for GM130 and βCOP (Fig.43). After
Brefeldin A induced Golgi disassembly and washout of the compound, the Golgi ap-
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Figure 42: Effect Of GMAP-210 Depletion Upon BFA Induced Golgi Disassembly. HeLa L
cells were transfected with an siRNA oligo against GMAP-210 3’UTR or GL2 (control) for 72 hours; for
Brefeldin A treatment, growth medium was replaced by growth medium supplemented with 5 μg/ml
Brefeldin A; coverslips were fixed in Methanol at the indicated time-points; for staining mouse anti
βCOP (red, 1:500) and sheep anti GM130 (green1:500) antibodies were used; blue channel: DAPI
staining; Bar=5 μm.
paratus began to reform. GM130 staining showed, that the Golgi remnants started to
concentrate in a juxtanuclear position within 30 min and subsequently formed the Golgi
typical stacked cisternae. COPI was recruited to the remnants more slowly, but appeared
weakly 30 min after removal of Brefeldin A. After 90 min COPI showed its typical Golgi
localisation. In GMAP-210 siRNA treated cells, the Golgi reassembly started out from
an already more concentrated cluster of Golgi remnants (compare 42, p.74), which fused
quicker to form a Golgi apparatus with stacked cisternae. COPI already appeared 30 min
after compound removal at the Golgi. This may again have been an effect of the collapsed
and concentrated Golgi and might be only indirectly related to the depletion of GMAP-
210.
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Figure 43: Golgi Reassembly After BFA Wash-Out. HeLa L cells were transfected with an siRNA
oligo against GMAP-210 3’-UTR or GL2 (control) for 72 hours; for Brefeldin A treatment, growth
medium was replaced by growth medium supplemented with 5 μg/ml Brefeldin A; after 30 min of
incubation, cells were washed five times with growth medium and fixed with methanol after the in-
dicated times; for staining mouse anti COPI (red, 1:500) and sheep anti GM130 (green, 1:500) were
used as antibodies; blue channel: DAPI staining; Bar=5 μm.
hTERT-RPE1 cells did not show the compaction of the Golgi after GMAP-210 depletion
and thus Brefeldin A induced dis- and reassembly was expected to be easier to examine.
hTERT-RPE1 cells were treated for 72 h with GL2 control oligo or GMAP-210 siRNA
oligo. For disassembly the growth medium was replaced with growth medium containing
5 μg/ml Brefeldin A and fixed after 0 min, 20 min and 30 min. Then the cells were washed
and coverslips were fixed after 30 min, 60 min and 90 min. The cells were stained with
antibodies against GM130 and GMAP-210 (Fig.44). The Golgi apparatus of hTERT-
RPE1 cells dispersed within 20 min of Brefeldin A treatment. GMAP-210 and GM130
stayed on the Golgi remnants and were not redistributed to the endoplasmic reticulum,
thus hTERT-RPE1 control cells behaved similarly to HeLa L cells. In hTERT-RPE1 cells
treated with siRNA oligos against GMAP-210, the Golgi dispersed like in control cells.
No difference in localisation of GM130 or GMAP-210 or disassembly kinetics could be
observed.
After washout of Brefeldin A, the Golgi started to reassemble and already after 30 min the
Golgi formed long ribbons. After 60 min the Golgi had reached its wild-type structure,
although it was still slightly disordered. This did not change after 90 min. GMAP-210
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Figure 44: Brefeldin A Dis- And Reassembly In hTERT-RPE1 cells. hTERT-RPE1 cells were
transfected with an siRNA oligo against GMAP-210 3’-UTR or GL2 (control) for 72 hours; for
Brefeldin A disassembly, growth medium was replaced by growth medium supplemented with 5 μg/ml
Brefeldin A and coverslips were fixed in paraformaldehyde at the indicated time-points; after 30 min
the cells were washed 3 times with growth medium and incubated for another 30, 60 and 90 min
and fixed as described above; for staining mouse anti GM130 (red, 1:500) and rabbit anti GMAP-210
(green, 1:500) were used; blue channel: DAPI staining; Bar=5 μm.
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siRNA treated cells showed the same behaviour and speed of reassembly after Brefeldin A
washout.
2.6.3 Summary
GMAP-210 reacted to Brefeldin A treatment of cells (Rios et al., 1994) as described, being
localised at small stacked Golgi remnants (Klausner et al., 1992). A transfected GRAB
domain construct also localised to the Golgi apparatus, although Brefeldin A induced
inactivation of Arf1 caused reduced Golgi localisation of these constructs. Following
kinetics of Golgi disassembly by Brefeldin A treatment showed a slower dispersal speed
of the Golgi fragments in GMAP-210 depleted cells in comparison to control cells. The
reassembly of Golgi after Brefeldin A washout was also faster, starting out from less
dispersed fragments. In hTERT-RPE1 cells, where no change in morphology by GMAP-
210 depletion could be observed, Brefeldin A induced disassembly, and later reassembly,
showed no different kinetics.
2.7 GMAP-210 Shows No Microtubule Interaction
In the literature, GMAP-210 is reported to not only localise to the Golgi apparatus, but
also to interact directly with microtubule minus-ends by its C-terminus (Infante et al.,
1999). Although it had been shown, that the C-terminus comprises the Golgi interacting
GRAB domain (see Gillingham et al. (2004) and 2.1.2 in this work p.29ff.), it is still
possible, that GMAP-210 binds to microtubule minus-ends as described. Overexpression
of GMAP-210 is also supposed to disrupt the microtubule network in COS cells (Infante
et al., 1999). Microtubules do no longer show a spindle-like formation around the centro-
some, but rather a diffuse centre at the Golgi apparatus. Overexpression of a construct
missing the microtubule binding domain still localises to the Golgi apparatus, but does
not disturb the morphology of the microtubule network. Furthermore, GMAP-210 is also
described to bind γ-tubulin-containing complexes (γ-TCCs) and to recruit γ-tubulin to
the Golgi apparatus upon its overexpression (Rios et al., 2004).
2.7.1 Transfection Of GMAP-210 Constructs Does Not Change The
Microtubule Network In HeLa L
Discovery of GMAP-210 interaction with minus-ends of stable microtubules, was a sur-
prise (Infante et al., 1999), as this result would make GMAP-210 a very important golgin,
involved in Golgi morphology and would further prove, that microtubules could also be
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anchored to the Golgi rather than the centrosome (Rios and Bornens, 2003). Overexpres-
sion of GMAP-210 disturbed the arrangement of centrosomal microtubules in COS cells.
Whether or not GMAP-210 is involved in anchoring or nucleating microtubules at the
Golgi apparatus had to be elucidated.
For this HeLa L cells were transfected with various N- and C-terminal constructs of
GMAP-210 tagged with enhanced GFP and co-stained for α-tubulin, to show effects on
the microtubule network (Fig.45 left panel). As shown before (2.1.2, p.29ff), localisation
of N- and C- terminus contradicted Infante et al. (1999). The N-terminus (pEGFPC2-
GMAP-210 1-375) localised diffusely in the cytosol of HeLa L cells, whereas the C-terminus
(pEGFPC2-GMAP-210 1598-1979) localises to the perinuclear Golgi apparatus (Fig.11,
p.34). Examining the microtubule network and their centrosomal origin, showed, in cells
Figure 45: α- and γ-Tubulin In GMAP-210 Transfected HeLa L Cells. HeLa L cells were
transfected with the indicated GMAP-210 constructs or NLP with an enhanced GFP-Tag for 24 h
(green) and fixed with paraformaldehyde for staining with mouse anti α-tubulin DM1A (red, 1:1000,
left) or methanol for staining with mouse anti γ-tubulin (red, 1:1000, right); arrows indicate γ-tubulin
at the centrosomes in untransfected (white arrow) or transfected (red arrow) cells; contrast enhanced
for better visibility; blue channel: DAPI staining; Bar=10 μm.
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expressing the very N-terminus of GMAP-210(pEGFPC2-GMAP-210 1-375), a difference
between transfected and untransfected cells. However, the microtubule aster’s centre
seemed to be more defined than in untransfected cells, rather than more diffuse (Infante
et al., 1999). The effect was only marginally and GMAP-210 N-terminus showed no loca-
lisation on microtubules. A construct missing the C-terminus (pEGFPC2-GMAP-210
1-1712), showed no effect on the microtubule network, but in contrast to Infante et al.
(1999), the construct did not localise to the Golgi apparatus. It rather localised in the
cytoplasm and stained some vesicular-tubular structures. C-terminus (pEGFPC2-GMAP-
210 1598-1979) and full-length constructs of GMAP-210 did also not alter the morphology
of the microtubule network (Fig.45).
2.7.2 GMAP-210 Depletion Does Not Disturb The Microtubule Network In
HeLa L Cells
As overexpression does not disturb the microtubule network the effect of GMAP-210
depletion on microtubules had to be examined. In HeLa L cells the Golgi apparatus was
shown to fragment and scatter upon siRNA treatment against GMAP-210 (Rios et al.,
Figure 46: α- and γ-Tubulin In GMAP-210 Depleted HeLa L Cells. HeLa L cells were transfected
with siRNA oligos against GL2 (control) or GMAP-210 3’-UTR for 72 h, fixed with paraformaldehyde
and stained with mouse anti tubulin DM1A (red, 1:1000, left) or methanol for staining with mouse
anti γ-tubulin (red, 1:1000, right), arrows indicate centrosome localised γ-tubulin; contrast enhanced
for better visibility; both experiments were co-stained with rabbit anti GMAP-210 (green, 1:500); blue
channel: DAPI staining; Bar=5 μm.
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2004). The results in 2.3 (p.48) proved, however, that, although the Golgi apparatus
fragmented (Fig.26, p.52), the fragments remained in a very tight cluster, smaller than
the Golgi apparatus in control cells (Fig.24, p.49).
HeLa L cells were treated for 72 h with siRNAs against GMAP-210 and GL2 as control,
fixed and stained for GMAP-210 and α-tubulin (Fig.46). After knockdown of GMAP-210
in HeLa L cells the microtubule network was unchanged. Some cells concentrated more
tubulin in the perinuclear region and the microtubules looked more organised in an aster-
like fashion with many microtubules originating from a point in the perinuclear region.
This was, however, within the normal range of variation for HeLa L cells and thus could
not be seen as a specific effect of GMAP-210 knockdown.
2.7.3 GMAP-210 Does Not Interact With Taxol Stabilised Microtubules in
vitro
Further characterisation of GMAP-210 effect on microtubules could be tested in in vitro
experiments with taxol stabilised microtubules. For this N- and C-terminus of GMAP-
Figure 47: Purification Of GMAP-210 N- And C-Terminus From Sf9 Cells. Coomassie blue
stained SDS-PAGE gels of the purification process of GMAP-210 amino acids 1-375 and GMAP-210
amino acids 1598-1979 from Sf9 cells infected with a recombinant Baculovirus; proteins were purified
with Ni-NTA agarose and in IMAC200 buffer eluted fractions were either desalted and eluted into
PBS (GMAP-210 1-375, upper gels, fractions 1, 2, 3) or dialysed overnight against PBS (GMAP-210
1598-1979, lower gels, fractions 1, 3-6 & 2); 10 μl per sample were loaded; M: cell free culture medium
after harvesting Sf9 cells; Lys: crude lysate; SN: cleared lysate; FT: flow through after incubation with
Ni-NTA agarose; numbers show fractions eluted from beads or fraction pools after dialysis/desalting;
500/250/200/125/100/65: show μg pure BSA to judge protein concentration of samples; 10 μl of each
sample were loaded.
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210 (GMAP-210 1-375 and GMAP-210 1598-1979) were expressed and purified from Sf9
cells with the Baculovirus system. Fig.47 shows the quality and concentration of both
preparations used in the biochemical assays. Both constructs showed one distinct band
with little degradation. After desalting, the pooled and desalted or dialysed fractions were
estimated by comparison to BSA standards. GMAP-210 N-terminus concentrations were
200 μg/ml, 400 μg/ml and 100 μg/ml μg/ml. The GMAP-210 C-terminus concentrations
were lower, 10 μg /ml and 20 μg/ml.
GMAP-210 N- And C-Terminus Do Not Bundle Microtubules in vitro Pro-
teins binding to microtubules can organise and bundle them. Thus, to show binding
of GMAP-210 to microtubules, the bundling capability of the recombinant GMAP-210
fragments was tested in vitro, comparing it to the known microtubule bundling protein
Prc1sp2 (splice variant 2) (Mollinari et al., 2002) also purified from Sf9 cells (Neef et al.,
2007).
Rhodamine labelled, in vitro grown and taxol stabilised microtubules were incubated with
400 ng recombinant protein (GMAP-210 amino acids 1 to 375, GMAP-210 amino acids
1598 to 1979 or Prc1sp2) for 20 min. Microtubules were analysed by epifluorescence at a
40x magnification. Fig.48 shows unordered microtubules in the negative control (first im-
age) and highly ordered microtubules bundled by Prc1sp2 (second image). In comparison
neither the N-terminus nor the C-terminus of GMAP-210 show any propensity to order
the microtubules into bundles and microtubules look similar to the control. Neither N-
nor C-terminus of GMAP-210 have microtubule bundling capability.
Figure 48: Microtubule Bundling Assay With GMAP-210 N- And C-Terminus. Rhodamine
labelled microtubules, prepared in vitro, were incubated with buffer or 400 ng recombinant Prc1sp2,
GMAP-210 N- or C-terminus (all three prepared from Sf9 cells) for 20 min at room temperature and
analysed by fluorescence microscopy at 40x magnification; contrast enhanced for better visibility.
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GMAP-210 Does Not Associate With Microtubules In Microtubule Spin-
Down Assays Another possibility to identify microtubule association of proteins is
the microtubule spin-down assay. Taxol stabilised microtubules from pig brain were incu-
bated in vitro with 400 ng recombinant protein. After incubation at room temperature,
the microtubules were centrifuged through a glycerol cushion and the pellet analysed by
Western blotting and coomassie brilliant blue stained SDS-PAGE. Apart from GMAP-210
amino acid 1 to 375 and 1598 to 1979, Prc1sp2, as positive control, was tested for micro-
tubule binding (Fig.49). Microtubule pellets were dissolved in sample buffer and analysed
by SDS-PAGE. The coomassie blue stained SDS-PAGE gels (Fig.49, lower row) showed
good microtubule recovery under all conditions. Western blots treated with 6xHis-Tag or
Prc1 antibodies, showed protein presence or absence in the microtubule pellet. Prc1sp2
was found in the pellet with the taxol stabilised microtubules, but no protein was de-
tected in pellets without microtubules. The GMAP-210 N-terminus (amino acids 1 to
375) showed some faint, unspecific precipitation with and without microtubules, whereas
Figure 49: Microtubule Spin-Down Of Recombinant GMAP-210 N- And C-Terminus.
Microtubules grown in vitro were incubated with 400 ng recombinant GMAP-210 N- or C-terminus
or Prc1sp2 (all prepared from Sf9 cells) for 20 min; microtubule pellets were dissolved in SDS-PAGE
sample buffer and subjected to coomassie stained SDS-PAGE to check for microtubule recovery (5/6th
of sample) or Western blot (1/6th of sample); proteins were detected by rabbit anti Prc1 (right, 1:500)
and HRP donkey anti rabbit (left and middle, 1:1000) or mouse anti 6xHis (1:1000) and HRP donkey
anti mouse antibodies.
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the GMAP-210 C-terminus (amino acids 1598 to 1979) was not detected in the pellet,
irrespective of absence or presence of microtubules.
Recombinant GMAP-210 N- and C-terminus did not interact with microtubules in vitro.
2.7.4 GMAP-210 Has No Effect On Golgi Reassembly After Nocodazole
Treatment
The drug nocodazole depolymerises microtubules in cells, disturbing the cytoskeleton.
Apart from arresting the cells in G2-M phase, cells treated for a short period, lose
their Golgi integrity as a consequence of microtubule depolymerisation (Thyberg and
Moskalewski, 1999). The Golgi fragments and forms small Golgi stacks distributed
throughout the cell (Ho et al., 1989). Removal of the agent, allows microtubules to
repolymerise and the Golgi reassembles in its perinuclear position. Rios et al. (2004)
show, that nocodazole treatment of HeLa L depleted of GMAP-210, does not change
Golgi fragmentation, overexpression of GMAP-210, however, disturbs recovery of micro-
tubule asters.
Figure 50: Nocodazole Induced Golgi Disassembly In HeLa L Cells After GMAP-210 Deple-
tion. HeLa L cells were transfected with an siRNA oligo against GMAP-210 3’UTR or GL2 (control)
for 72 hours; growth medium was then replaced by growth medium containing 200 μg/ml nocodazole
and coverslips fixed at the indicated time-points with paraformaldehyde and stained with sheep anti
GM130 (red, 1:500) and mouse anti α-tubulin (green, DM1A 1:2000); blue channel: DAPI staining;
Bar=10 μm.
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The phenotype observed by Rios et al. (2004) is completely different from the pheno-
type seen with the siRNA oligo used for this work (2.3, p.48), Golgi is fragmented (Rios
et al., 2004), instead of compacted. This makes it necessary to examine microtubules and
Golgi morphology after nocodazole treatment of GMAP-210 depleted cells. HeLa L cells
were treated with an siRNA oligo against GMAP-210 3’-UTR or GL2 control for 72 h.
Cells were then treated with 200 μg/ml Nocodazole for 90 min, fixed and stained with
antibodies against GM130 and α-tubulin. (Fig.50). After 72 h siRNA treatment against
GMAP-210, the Golgi showed the compacted morphology observed before (Fig.24, p.49).
The microtubule network was not influenced by absence of GMAP-210 (compare 2.7.2,
p.79). After 90 min of nocodazole treatment, cells showed a diffuse, cytoplasmic α-tubulin
staining, as microtubules were completely depolymerised. This effect could be seen in con-
trol cells and in cells depleted of GMAP-210 alike. The Golgi apparatus was fragmented
in control cells and fragments could be found throughout the cell periphery, although a
big perinuclear clustering of fragments, reminiscent of Golgi, still existed. In cells de-
pleted of GMAP-210, small Golgi fragments were seen in the cell periphery after 90 min
of nocodazole treatment. The biggest part of GM130 staining was found on a prominent
structure near the nucleus. This big structure looked like Golgi in GMAP-210 depleted
cells before nocodazole treatment. It was, however, impossible to say, if this concentration
of Golgi membranes near the nucleus was due to a direct effect of GMAP-210 depletion.
It was also possible, that the compact Golgi, after microtubule depolymerisation, diffused
more slowly in the cell, because of purely kinetic reasons.
One possible theory could be, that GMAP-210 helps to link the Golgi apparatus to mi-
crotubules (Infante et al., 1999) and thus helps to position it near the centrosome in
a juxtanuclear position. If this was true cells depleted of GMAP-210 and treated with
nocodazole should face problems in reassembly and repositioning of the Golgi apparatus
after washout of the drug.
In order to test this, hTERT-RPE1 cells were treated with siRNA against GMAP-210 or
GL2 control for 72 h. Cells were incubated on ice for 60 min and treated with 200 μg/ml
nocodazole at 37◦C to depolymerise microtubules. Cells were then fixed and stained
for GM130 and α-tubulin 0 min, 5 min, 15 min and 30 min after nocodazole washout
(Fig.51). hTERT-RPE1 cells were used to circumvent the effect of Golgi compaction,
which has proven to make comparison of changes at the Golgi apparatus more difficult.
hTERT-RPE1 control cells showed a fragmented and scattered Golgi after treatment with
nocodazole for 60 min. This was also true for cells depleted of GMAP-210. Thus, the
starting point for reassembly was equal for GMAP-210 siRNA treated cells and control
cells. 5 min after nocodazole washout, the microtubules began to condense under both
conditions. The Golgi still remained fragmented. After 15 min, the microtubule net-
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Figure 51: Nocodazole Induced Golgi Disassembly In HeLa L Cells After GMAP-210 Deple-
tion. hTERT-RPE1 cells were transfected with an siRNA oligo against GMAP-210 3’-UTR or GL2
(control) for 72 hours; the cells were then incubated on ice for 60 min prior to exchange of the growth
medium with growth medium containing 200 μg/ml nocodazole; after 60 min, coverslips were washed 3
times with growth medium and fixed at the indicated time-points with paraformaldehyde and stained
with sheep anti GM130 (red, 1:500) and mouse anti α-tubulin (green, 1:1000); blue channel: DAPI
staining; Bar=10 μm.
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work was re-established and the Golgi fragments started to concentrate in the perinuclear
region. After 30 min the Golgi had mostly reformed its ribbon-like structure of stacked
cisternae and thus had regained its normal morphology. No difference in Golgi reassembly
could be observed between control cells and cells missing GMAP-210.
Depletion of GMAP-210 had no effect on microtubules or Golgi morphology during noco-
dazole treatment and subsequent repolymerisation of microtubules and reassembly of the
Golgi.
2.7.5 GMAP-210 Is Not Associated With γ-Tubulin
In Rios et al. (2004) GMAP-210 was shown to recruit γ-tubulin containing complexes
(γ-TCCs) to the Golgi apparatus of Cos-7 cells. Overexpression of a full-length construct
of GMAP-210 caused strong staining for γ-tubulin on the Golgi. A construct missing
the C-terminus did not cause such an effect. Due to the confusion about the interaction
and targeting domains of GMAP-210 in the literature (compare Infante et al. (1999) and
Gillingham et al. (2004) and 2.1.2, p.29ff.) it was verified if this effect could be reproduced
with the described or a different domains of GMAP-210.
HeLa L cells were transfected for 24 h with GFP-tagged constructs for GMAP-210
N-terminus (pEGFPC2-GMAP-210 1-375 and pEGFPC2-GMAP-210 1-1712), GMAP-
210 full-length or GMAP-210 C-terminus (pEGFPC2-GMAP-210 1598-1979). The cells
were fixed and stained for γ-tubulin and analysed by epifluorescence microscopy (Fig.45,
p.78, right panel). As positive control the N-terminal 702 amino acids of the ninein-like
Figure 52: Golgi Positioning Near The Centrosome After GMAP-210 Depletion. HeLa L cells
were transfected with siRNA oligos against GL2 (control) or GMAP-210 3’-UTR for 72 h and fixed
with methanol; cells were stained with mouse anti CNAP-1 (red, 1:1000) and sheep anti GM130 (green,
1:500) antibodies; blue channel: DAPI staining; Bar=5 μm.
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protein (NLP) were transfected into HeLa L cells (gift from M. Casenghi). NLP was
described to recruit γ-tubulin ring complexes (γ-TuRCs) upon overexpression (Casenghi
et al., 2003).
In untransfected cells, γ-tubulin staining could be found on two dots in the perinuclear
region, the centrosomes of G2 phase cells. Also diffuse cytoplasmic staining could be seen.
Cells transfected with the N-terminus of NLP could easily be identified by aggregates of
GFP, which at the same time stained for γ-tubulin. When GMAP-210 full-length was
transfected, GFP stained the Golgi apparatus. γ-tubulin still localised to the centrosomes
and could not be found co-localising with GMAP-210. The Golgi apparatus still localised
near the centrosome as normal. Overexpression of either N-terminus or C-terminus did
also not recruit γ-tubulin to the Golgi apparatus in HeLa L cells. As a side note, over-
expressed NLP did not disturb the microtubule network of interphase cells (Fig.45, p.78
bottom left).
It was furthermore tested if the loss of GMAP-210 in HeLa L cells disturbed the γ-tubulin
distribution or positioning of the Golgi apparatus in relation to the microtubule organis-
ing centre. For this, HeLa L cells were treated with siRNA against GMAP-210 or GL2
control for 72 h, fixed and either co-stained for GMAP-210 and γ-tubulin (Fig.46, p.79) or
GM130 and the centrosomal protein CNAP1 (Fig.52). After depletion of GMAP-210 the
antibody against γ-tubulin still stained two dots in the perinuclear region as expected.
CNAP1 staining on the centrosomes was also unchanged. GM130 staining monitors the
Golgi positioning. After GMAP-210 siRNA, the Golgi apparatus compacted (see 2.3,
p.48) but remained adjacent to the CNAP1 staining in the perinuclear region. Golgi po-
sitioning near the centrosome was not dependent on GMAP-210.
If GMAP-210 interacted with γ-tubulin, then a high concentration of γ-tubulin in the
cell, should recruit at least some GMAP-210. γ-tubulin recruitment could be achieved by
overexpression of the NLP N-terminus (Casenghi et al., 2003), as shown in Fig.45 (p.78).
Figure 53: GMAP-210 Localisation In NLP Transfected Cells. HeLa L cells were transfected
with a construct for expression of N-terminally GFP-tagged NLP (green) for 24 hours and fixed with
paraformaldehyde; cells were stained with rabbit anti GMAP-210 (red, 1:500); blue channel: DAPI
staining; Bar=10 μm.
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HeLa L cells were transfected with a GFP-tagged version of NLP amino acids 1-702 for
24 h, fixed and stained for GMAP-210 (Fig.53). Overexpression of the N-terminal half
of NLP caused aggregates of GFP to show up in HeLa L cells. These aggregates stained
strongly for γ-tubulin. The staining for GMAP-210, however, could only be found on
perinuclear Golgi membranes like in untransfected cells.
GMAP-210 is not recruited to strong concentrations of γ-tubulin.
2.7.6 Summary
GMAP-210 interaction with microtubules was tested by different methods. First the ef-
fect of GMAP-210 overexpression and depletion on the microtubule network of HeLa L
cells was examined. Overexpression of different N- and C- terminal constructs gave no
hint at disturbance of microtubules, neither at their origin, the centrosome, nor in the cell
periphery. Slight changes were observed, when a short N-terminal construct (GMAP-210
1-375) was expressed. The microtubules looked more concentrated at the MTOC. Deple-
tion of GMAP-210 had also no effect on microtubules.
Recombinant N- and C-terminal protein, purified from Sf9 cells, were tested for their
capability to bind to taxol stabilised microtubules. Bundling of microtubules by these
proteins was examined. Microtubules incubated with fragments of GMAP-210 were not
bundled, in contrast the microtubule binding protein Prc1sp2 easily organised tubules.
Microtubules were also incubated with recombinant N- and C-terminus of GMAP-210
and tested in a spin-down assay. In the microtubule pellet no GMAP-210 C-terminus and
only little, precipitated N-terminus could be found. Prc1sp2 bound microtubules in vitro.
Furthermore, the effect of GMAP-210 depletion on nocodazole induced Golgi fragmen-
tation was tested. In HeLa L cells, Golgi fragments remained more concentrated in
the perinuclear region in cells depleted of GMAP-210, if compared to control cells. In
hTERT-RPE1 cells, this effect was not observed. Reassembly of the Golgi after nocodazole
washout proceeded with similar kinetics in control cells and cells depleted of GMAP-210.
γ-Tubulin localisation was also unchanged, when GMAP-210, full-length or fragments,
were overexpressed. Ninein-like protein, however, recruited γ-tubulin visibly upon overex-
pression, but did not recruit GMAP-210 to these accumulations of γ-tubulin. GMAP-210
depletion also had no influence on the localisation of γ-tubulin and the Golgi remained
near the microtubule organising centre. In any case, γ-tubulin was found on Golgi mem-
branes.
Neither GMAP-210 interaction with microtubules nor with γ-tubulin could be proven.
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2.8 GMAP-210 Recruits The Intraflagellar Transport Protein
IFT20 To The Golgi Apparatus
IFT20 is an essential component of the intraflagellar transport machinery and is needed
to build cilia and flagella (Rosenbaum and Witman, 2002). It directly interacts with the
heterotrimeric kinesin II subunit Kif3B (Baker et al., 2003). Surprisingly, it is also found
at the Golgi apparatus (Follit et al., 2006). Thus, IFT20 is an interesting candidate for
a protein linking Golgi membranes to microtubules and thus might participate in the
function of GMAP-210 and influence Golgi morphology. The reason for IFT20’s presence
on the Golgi apparatus is only speculated about (Follit et al., 2006), and its function
in primary cilium formation of hTERT-RPE1 cells and the function at the Golgi were
examined.
2.8.1 Tools For IFT20
IFT20: Cloning In a first step, the NCBI database (www.ncbi.nlm.nih.gov) was searched
for the human version of the Chlamydomonas reinhardtii IFT20. Four version of this pro-
tein were found in the human genome (Fig.54). A fifth version was deduced from the
database sequences by adding the sequence for the elongated N-terminus to the sequence
of BC002640. This construct was later amplified successfully (BC002640+ in Fig.54) from
HeLa L cDNA.
The clone EAW51075, which has an alternative C-terminus, was only added recently to
the database and thus not examined in this work. It has the same sequence as BC002640
but replaces the last two amino acids by a 20 amino acids long sequence, which could be
identified as a flagellar P-ring protein domain by Pfam database search. These proteins
are part of the bacterial flagellum. The other four versions differ by either their N-
terminus, which is elongated by 26 amino acids, or their alternatively spliced C-terminus
after amino acid 96 or 70 respectively. Amino acids 27 to 96 or 1 to 70 (in versions
with the short N-terminus) are identical in all five versions and represent the IFT20 core
domain. Primers were designed to amplify four of the five variants (see Tab.1). These
IFT20 clones were named after the primers used in their amplification for easy reference.
They are summarized in Tab.2 (p.91), together with the respective template DNA used
or their amplification.
Database Information The IFT20 gene maps to chromosome 17 locus 17q11.2. It is
a protein of 18.1 kDa and is expressed in a wide variety of tissues, especially in soft tissue,
the uterus and the umbilical cord. It was also found in all states of human development
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Figure 54: Alignment Of The Five Identified Variants Of Human IFT20. Alignment performed
by VectorNTI10 (Invitrogen); yellow: identity of all sequences; blue: identity in a subset of sequences;
green: similarities;
Table 1: Primers used for amplification of different variants of the human IFT20 coding sequence; forward
primers inserted BamHI, reverse primers SalI restriction sites.
Primer Name DNA Sequence Description
IFT20-F2 GGGATCCCCATGGCCAAGGACATCCTGGGTGAAGCAGG 5’ short N-terminus
IFT20-R2 GGTCGACTCAACCCGATACCTTTCTAGCTGC 3’ short C-terminus
IFT20-F3 GGGATCCCCATGACACACCTCCTCCTGACTGCC 5’ long N-terminus
IFT20-R3 GGTCGACTCATTTCTGAAAAATAAATTGGTC 3’ long C-terminus
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Table 2: Overview of IFT20 variants; primers as listed in table 1; Source: DNA template used for
amplification; EAW51075 was not amplified, but F3 primer could have been used besides an applicable
reverse primer; aa: number of amino acids.
Accession No. Primer Pair Protein Length Source
AY224601 F3R2 158 aa Fetus cDNA
BC038094 F2R2 132 aa F3R2 clone
BC002640+ F3R3 174 aa HeLa L cDNA
BC002640 F2R3 148 aa F3R3 clone
EAW 51075 F3– 192 aa —-
rather equally except in embryo and juvenile (where it seems to be not present at all).
As this data was achieved by EST expression profile (www.ncbi.nlm.nih.gov; UniGene;
HS696090), it was not possible to deduce possible differences in the expression pattern
of the different IFT20 variants. This also goes beyond the scope of this work and is not
further examined.
Polyclonal Antibodies Against IFT20 Polyclonal antibodies were raised against the
shortest version of IFT20 (F2R2). Recombinant protein was expressed in E.coli trans-
formed with the pQE32-vector and purified. Overexpression of IFT20 was achieved at
37◦C with 3 h of induction. Purified protein was dialysed against 25 mM Tris/HCl pH 7.4
and 300 mM NaCl.
Immunisation of two rabbits (#5917 and #5918) was performed by Biogenes (Berlin,
Germany) with a total amount of 2 mg recombinant protein for both rabbits. Testbleeds
were evaluated at 1 month intervals and one month after the 3rd testbleed, rabbits were
bled out and about 50 ml antiserum per rabbit collected.
Affinity purification of the bleedout of rabbit #5917 was performed with 6x-His-IFT20
(F2R2 variant), purified under denaturing conditions. The antibody specificity was eval-
uated for immuno-staining of fixed cells and Western blot experiments.
IFT20 siRNA And Antibody Specificity For knockdown of IFT20 in cell culture,
an siRNA oligo was designed (Tab.5, p.122), which specifically targets the core domain
of IFT20, which all five variants have in common (Fig.54).
hTERT-RPE1 cells were transfected with the siRNA oligo against IFT20 or GL2 control
for 72 h. Cells were subsequently starved by removing growth medium and replacing it
with growth medium devoid of FCS for 48 h to stimulate primary cilium growth, while
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adding the respective siRNA oligos anew. Cells were incubated for 1 h on ice, fixed with
methanol and stained with the purified antibodies against IFT20 (Fig.55). Co-staining
was done with an antibody against acetylated tubulin. In control cells the IFT20 antibody
stained two structures. One was situated in the perinuclear region, which was shown to
co-stain with the Golgi localised GMAP-210 (Fig.56). The second structure detected
with the IFT20 antibody is the primary cilium as shown by acetylated tubulin staining.
Upon treatment with the specific IFT20 siRNA oligo, the staining for IFT20 completely
disappeared from the Golgi complex and the primary cilium.
Figure 55: Immunofluorescence And Western Blotting Of hTERT-RPE1 Cells Treated With
IFT20 siRNA. hTERT-RPE1 cells were treated for 72 h with an siRNA oligo targeting the core
domain of IFT20 or GL2 (control) and subsequently starved for 48 h by culturing in growth medium
without FCS whereas siRNA treatment was repeated; cells were then put on ice for 1 h, fixed in
methanol and stained with mouse anti acetylated tubulin (red, 1:1000) and rabbit anti IFT20 (green,
1:500); blue channel: DAPI staining; Bar=10 μm; lower pictures show close-up of the indicated region
in pictures above; arrows indicate primary cilium or centrosome, respectively; Western blotting (right)
was done by lysing cells, treated with siRNA against IFT20 or GL2, for 30 min on ice in mammalian
lysis buffer and analysing 20 μg protein extract on 12.5% SDS-PAGE; protein was detected with
rabbit anti IFT20 (1:250) and HRP donkey anti rabbit antibodies, detection with mouse anti α-tubulin
antibodies shows equal loading of both lanes.
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Depletion of IFT20 was also shown by Western blot (Fig.55). hTERT-RPE1 cells were
treated as described above, but instead of fixing, the cells were collected and lysed. The
lysate was subjected to SDS-PAGE and Western blotting. Protein was revealed with the
affinity purified antibody (2.8.1, p.91). A second SDS-PAGE gel loaded with the same
amount of protein was subjected to Western blotting. An antibody against α-tubulin,
showed equal loading.
The α-tubulin signal proved, that equal amounts of protein were loaded in each lane. A
distinct band below the 16 kDa marker revealed IFT20 protein in control cells, whereas
the band was completely absent from cell extracts treated with siRNA against IFT20. The
affinity purified antibody detected IFT20 in immunofluorescence and Western blotting.
The designed siRNA oligo results in the loss of the IFT20 protein from cells.
2.8.2 IFT20 Depletion Prevents Primary Cilium Formation
IFT20 is an important part of the intraflagellar transport complex, linking it to the
heterotrimeric kinesin II subunit Kif3B ((Baker et al., 2003)). Its depletion prevents
primary cilium formation in cells.
It was tested if depletion of IFT20 with the designed oligo had the described effect on
cilium formation. hTERT-RPE1 cells were transfected with the siRNA oligo against
Figure 56: GMAP-210 Localisation After IFT20 siRNA. hTERT-RPE1 cells were treated with
siRNA oligos against IFT20 or GL2 (control) for 72 h; cells were subsequently starved by replacing
growth medium with medium devoid of FCS for another 48 h, while retransfecting siRNA as before;
cells were incubated on ice for one hour and fixed with methanol and stained with antibodies against
acetylated tubulin (red; mouse; 1:500) and GMAP-210 (green; rabbit; 1:500); cells treated in parallel
were stained for IFT20 (rabbit; 1:500) to show depletion (right column); blue channel: DAPI staining;
Bar=5 μm.
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IFT20 or the control GL2, starved for 48 h to stimulate cilium growth and analysed by
staining with antibodies against acetylated tubulin and IFT20 (Fig.55, p.92 and Fig.56).
IFT20 is depleted efficiently from hTERT-RPE1 cells by the siRNA oligo. In control
cells the primary cilium was stained by acetylated tubulin. In cells depleted of IFT20
the acetylated tubulin antibody only labelled two dots representing the centrosomes. No
primary cilium was formed.
IFT20 was also localised on the Golgi apparatus. Its function is not elucidated yet,
but due to its direct link with the motor protein Kif3B (Baker et al., 2003) it could be
involved in establishing Golgi morphology. Thus, the effect of IFT20 depletion upon the
Golgi apparatus was examined. Cells treated with siRNA against IFT20 or the control
GL2 were stained with an antibody against GMAP-210 (Fig.56). IFT20 staining of cells
prepared in parallel showed depletion of IFT20. Acetylated tubulin staining showed the
loss of the primary cilium. Only the centrosomes were stained. The Golgi, however, was
still labelled by the GMAP-210 antibody. Neither Golgi morphology nor Golgi position
were changed after IFT20 knockdown.
2.8.3 GMAP-210 Depletion Prevents IFT20 Golgi Localisation
As Golgi localised protein, which also links to the microtubule network by binding to a
kinesin (Baker et al., 2003), IFT20 is a possible interaction partner of GMAP-210. As
shown in 2.4 (p.55) all examined Golgi localised components of the secretory pathway
stayed attached to the Golgi apparatus, even when it collapsed after GMAP-210 deple-
tion in HeLa L cells. Testing the behaviour and localisation of IFT20 after GMAP-210
knockdown will give insight into IFT20’s relation to GMAP-210.
hTERT-RPE1 and HeLa L cells were treated with siRNA against GMAP-210 or the con-
trol GL2, fixed and stained for IFT20 and GM130 (Fig.57). As GM130 staining showed,
Golgi in HeLa L cells collapses and the GM130 signal became more intense on the smaller
Golgi. In hTERT-RPE1 cells Golgi morphology was rather unchanged. The IFT20 an-
tibody labelled clearly the Golgi apparatus in hTERT-RPE1 control cells. In HeLa L
the signal was rather weak. When GMAP-210 was depleted, IFT20 antibody staining of
Golgi was significantly reduced in both cell types.
Either IFT20 did no longer bind to the Golgi apparatus and was thus localised elsewhere,
probably in the cytosol or on vesicles, or IFT20 was degraded or its expression reduced.
In order to test this, a Western blot experiment was performed to show IFT20 protein
levels in the cells.
hTERT-RPE1 cells were treated with siRNA against GMAP-210, IFT20 or GL2 for 72 h.
Cells were then collected and lysed. Equal amounts of extracts were loaded to 12.5%, 10%
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Figure 57: IFT20 Localisation After GMAP-210 siRNA. hTERT-RPE1 (left) and HeLa L (right)
cells were treated for 72 h with siRNA against GMAP-210 3’-UTR or GL2 (control), fixed in
paraformaldehyde and stained with rabbit anti IFT20 (red, 1:500) and mouse anti GM130 (green,
1:500); blue channel: DAPI staining; Bar=10 μm.
and 6% SDS-PAGE gels and subjected to Western blotting. Protein was detected with
IFT20, α-tubulin or GMAP-210 antibodies (Fig.58). The α-tubulin antibody confirmed
equal loading for all three conditions. GMAP-210 and IFT20 antibodies showed depletion
of the proteins in the respective siRNA experiments. Depletion of GMAP-210 did not
change the protein levels of IFT20, neither did IFT20 depletion change the expression
level of GMAP-210. This proved, that IFT20 lost its capability to bind to the Golgi
Figure 58: Protein Levels Of GMAP-210 And IFT20 After siRNA. hTERT-RPE1 cells were
transfected with siRNA against GL2 (control), GMAP-210 3’-UTR or IFT20 core domain for 72 h;
cells were lysed in mammalian lysis buffer for 30 min on ice and 20 μg of each extract analysed by
Western blotting; proteins were detected with rabbit anti GMAP-210 (1:500) or rabbit anti IFT20
(1:250); detection with mouse anti α-tubulin antibody DM1A (1:4000) was used as control for equal
loading.
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apparatus when GMAP-210 was not present, rather than showing a reduced protein level
in the cell.
2.8.4 GMAP-210 Does Not Localise On The Primary Cilium
IFT20 localises to the Golgi apparatus and also interacts with GMAP-210. Thus, it is
possible, that GMAP-210 is actually involved in primary cilium formation and is localised
on the cilium or at the basal body. In fact, GMAP-210 could be observed near the
cilium. It is, however, unclear if this was a GMAP-210 bearing Golgi fragment localised
coincidentally near the cilium or if it was specific targeting of GMAP-210 to the cilium.
In order to answer this question, hTERT-RPE1 cells were starved for 48 h and then stained
for acetylated tubulin, GMAP-210 and GM130, after incubation on ice and methanol
fixation (Fig.59). In this experiment, the blue channel was not used for DAPI staining of
DNA, but for AMCA secondary antibody, detecting rabbit anti GMAP-210. In the close-
up of Fig.59 a primary cilium with nearby GMAP-210 staining is shown. This pool of
GMAP-210 co-localised with GM130, which confirmed Golgi-localisation of GMAP-210.
Consequently, GMAP-210 did not localise to the primary cilium, but only to the Golgi
apparatus.
Figure 59: Localisation Of GMAP-210 And The Primary Cilium. hTERT-RPE1 cells were
starved for 48 h by growth in culture medium without FCS and then incubated for 1 h on ice; after
fixing with methanol, cells were stained with mouse anti acetylated tubulin (red, 1:500), sheep anti
GM130 (green, 1:500) and rabbit anti GMAP-210 (blue, 1:500); close-up of primary cilium region
shown, arrows indicate GMAP-210 and GM130 signal at the cilium base; Bar=10 μm.
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2.8.5 GMAP-210 siRNA Does Not Inhibit Primary Cilium Formation
GMAP-210 knockdown inhibits IFT20 targeting to the Golgi complex. IFT20 is necessary
for primary cilium formation. If GMAP-210 was also involved in primary cilium formation,
its depletion would interfere with the cells capability to form a cilium. It will now be
examined if GMAP-210 knockdown has an effect on intraflagellar transport and primary
cilium formation.
(Fig.60). hTERT-RPE1 cells were treated for 72 h with siRNA against GL2 control or
GMAP-210. They were then starved for 48 h while still keeping up siRNA conditions by
retransfecting the oligos. Cells were incubated on ice for 1 h, fixed with methanol and
stained for acetylated tubulin and IFT20.
In control cells acetylated tubulin stained the primary cilium growing from the centrosome.
IFT20 localised on the Golgi apparatus in the juxtanuclear region and co-localised with
acetylated tubulin on the primary cilium. After GMAP-210 siRNA the IFT20 antibody
only labelled the primary cilium as did the antibody against acetylated tubulin.
Obviously, IFT20 was removed only from the Golgi apparatus, but was still localised at
the primary cilium. The cilium still formed normally.
In order to quantify the capability of hTERT-RPE1 cells to form primary cilia under
various conditions, cells were treated with siRNA against GL2, GMAP-210 or IFT20 for
72 h, and starved for 48 h before incubating them for 1 h on ice, fixing them with methanol
and staining for acetylated tubulin. Cells were then counted and overall number of cells
Figure 60: Primary Cilium Formation In GMAP-210 Depleted Cells. hTERT-RPE1 cells were
transfected with siRNA oligos against GMAP-210 3’-UTR or GL2 (control) for 72 h and then cultured
an additional 48 h in growth medium without serum, whereas siRNA oligos were retransfected as
before; coverslips were placed on ice for 1 h, fixed in methanol and stained with mouse anti acetylated
tubulin (red, 1:1000) and rabbit anti IFT20 (green, 1:500); pictures in the lower row show close-ups of
indicated regions in the upper row pictures; blue channel= DAPI staining; Bar=5 μm.
2 Results 98
compared to the number of cells forming a primary cilium. For each condition, about
200 cells from three independent experiments were counted (Fig.61). In control cells 80%
(+/-8.8%) developed a primary cilium. After GMAP-210 knockdown 71% (+/-9.3%) and
after IFT20 knockdown 31% (+/-5.9%) of the cells were able to form a primary cilium.
GMAP-210 siRNA did not impair cilium formation at a significant level, whereas IFT20
siRNA reduced the capability of hTERT-RPE1 cells to form primary cilia by more than
60%.
2.8.6 GMAP-210 Directly Interacts With IFT20
IFT20 does not localise to the Golgi in absence of GMAP-210. Hence, direct interaction of
IFT20 and Golgi-localised GMAP-210 is likely. To prove direct interaction, yeast 2-hybrid
and co-immunoprecipitation experiments were performed.
Figure 61: Graphical Representation Of GMAP-210 And IFT20 siRNA Effect On Primary
Cilium Formation. hTERT-RPE1 cells were transfected for 72 h with siRNA oligos against GMAP-
210 3’-UTR, IFT20 core domain or GL2 (control) and subsequently incubated for 48 h at normal
growth conditions in serum without FCS, whereas siRNA was retransfected; cells were incubated on
ice for 1 h, fixed with methanol and stained with mouse anti acetylated tubulin (red; 1:500) and sheep
anti GM130 (green, 1:500); cells with primary cilia were counted against total cell number; GL2 80%
+/-8.8; GMAP-210 71% +/-9.3; IFT20 31% +/-5.9; (n=3); 200 cells counted per condition.
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IFT20 Interacts With A Coiled-Coil Region Of GMAP-210 In Yeast 2-Hybrid
IFT20 was tested in yeast 2-hybrid interaction studies against GMAP-210. Two other
golgins, human Golgin-84 and mouse GM130, were also tested as controls. The shortest
version of IFT20 (F2R2) was transfected as a pFBT9 construct and tested as bait against
the golgins as prey (Fig.62, left). Additionally, all four variants of IFT20 available were
tested as bait against full-length GMAP-210 (Fig.62, right).
IFT20(F2R2) only interacted with the full-length GMAP-210 construct. There was a
slight interaction with mouse GM130, but Golgin-84 did not react with IFT20. All of the
IFT20 variants interacted with GMAP-210. Thus, the shortest version could be used in
all further experiments.
To map the exact interaction domain of GMAP-210, fragments of GMAP-210 were used
as prey in a yeast 2-hybrid experiments with IFT20(F2R2) (Fig.63). IFT20 interacted
with full-length GMAP-210, the C-terminal 382 amino acids (GMAP-210 1598-1979) and
the middle part, amino acids 855 to 1712, whereas only the amino acids 855 to 1332 and
not 1333 to 1712 showed interaction. The N-terminal fragments, amino acids 1 to 375 and
618 to 803, did not bin. IFT20 interacted with GMAP-210 in yeast 2-hybrid, in a stretch
in the middle of GMAP-210 (GMAP-210 855-1332) and in the C-terminus (GMAP-210
1598-1979).
IFT20 Co-Precipitates With GMAP-210 Better proof for direct interaction of
IFT20 with GMAP-210 is co-immunoprecipitation of endogenous IFT20 and GMAP-
210. A cell extract from hTERT-RPE1 cells was prepared and incubated with Protein-G
sepharose and antibodies against IFT20 (5 μl), GMAP-210 (20 μl) or the preimmune
serum of rabbit #6130 (1 μl). The beads were extracted in SDS-PAGE sample buffer and
Figure 62: Yeast 2-Hybrid Interaction Of IFT20 With Various Golgins. Yeast 2-Hybrid in-
teraction experiment, testing GMAP-210, Golgin-84 and mouse GM130 in pAct2 vector against
IFT20(F2R2) in the pFBT9 vector (left); Yeast 2-Hybrid interaction experiment between full-length
GMAP-210 in pAct2 and the various splice variants of IFT20 (F2R2, F3R3, F3R2, F2R3) in pFBT9;
-LW: leucine and tryptophane deficient medium (growth control); QDO: leucine, tryptophane, histidine
and alanine deficient medium.
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Figure 63: Yeast 2-Hybrid Mapping Of IFT20 Interaction Site In GMAP-210.
Yeast 2-Hybrid interaction experiment, testing the indicated fragments of GMAP-210 in pAct2 vec-
tor against IFT20(F2R2) in pFBT9 vector; -LW: leucine and tryptophane deficient medium (growth
control); QDO: leucine, tryptophane, histidine and alanine deficient medium.
subjected to Western blotting. Proteins were detected with antibodies against IFT20 or
GMAP-210. HRP-coupled Protein A was used for chemiluminescence detection, in order
to reduce the background signal of the antibody light chain (Fig.64). The GMAP-210
antibody efficiently immunoprecipitated the protein and also co-precipitated IFT20. The
IFT20 antibody precipitated the protein from the hTERT-RPE1 extract and also co-
precipitated endogenous GMAP-210 protein. The pre-immune serum did not show any
affinity for either GMAP-210 or IFT20. Thus, GMAP-210 and IFT20 interact specifically
and directly in vitro.
2.8.7 Heterotrimeric Kinesin II Is Not Associated With IFT20 On The Golgi
Apparatus
IFT20 links the intraflagellar transport complex to the heterotrimeric kinesin II com-
ponent Kif3B (Baker et al., 2003) and thus is supposed to link the IFT complex to
microtubules and give it mobility. It is possible, that IFT20 and Kif3B link the Golgi
apparatus, via GMAP-210, to the microtubule network.
Overexpressed Kif3B Does Not Localise To The Golgi Apparatus There is
some evidence, that Kif3B is localised at the Golgi Apparatus (Hirokawa, 1998). Pres-
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Figure 64: Co-Immunoprecipitation Of GMAP-210 And IFT20. hTERT-RPE1 cells were lysed
in TNTE buffer and incubated with rabbit anti GMAP-210 antibody, rabbit anti IFT20 antibody or
#6130 pre-immune serum (rabbit prior to injection with GMAP-210 antigen) and Protein-G-sepharose;
beads were boiled in SDS sample buffer and analysed by Western blotting from 6% and 12.5% SDS-
PAGE gels; proteins were detected with rabbit anti GMAP-210 (1:500) or rabbit anti IFT20 antibody.
ence at the Golgi apparatus would be a first hint to its function and maybe the function
of IFT20. Kif3B targeting was tested with overexpressed proteins.
Full-length and C-terminal (aa 592-747) Kif3B were amplified from HeLa L cDNA. The
C-terminal fragment consisted of the globular tail domain and did not interact with IFT20
(Baker et al., 2003). hTERT-RPE1 cells, starved for 48 h, were transfected with the vari-
ous constructs for 24 h and their localisation examined. The cells were co-stained with an
antibody against acetylated tubulin to locate the primary cilium (Fig.65). Overexpressed
full-length Kif3B localised only to the primary cilium, to the nucleus and diffusely in the
cytoplasm in hTERT-RPE1 cells. The globular tail domain was also seen at the primary
cilium, co-localising with acetylated tubulin, and in the cytoplasm. Kif3B, localised on
the cilium, decorated the base of the cilium, although, due to high background in the
cytosol, a weak signal on the primary cilium itself would be lost. Kif3B was not found on
the Golgi apparatus in any case.
Kif3B Depletion Does Not Change Golgi Morphology The Effect of Kif3B knock-
down was examined by using siRNA. For this a SmartPool designed by Dharmacon/Perbio
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Figure 65: Localisation Of Kif3B. hTERT-RPE1 cells were cultured for 24 h with growth medium
without FCS, transfected with the indicated constructs for Kif3B full-length and C-terminal amino
acids 592 to 747 (green) and cultured for another 24 h; cells were incubated for 1 h on ice, fixed with
methanol and stained with mouse anti acetylated tubulin (red, 1:500); arrows indicate primary cilium
and basal body; blue channel= DAPI staining; Bar=5 μm.
was used, which included four different siRNA oligos targeting the same gene (Tab.5,
p.122). hTERT-RPE1 cells were transfected with the siRNA SmartPool against Kif3B
or a pool against GL2 control. After 48 h the cells were transfected with a construct for
expression of GFP tagged full-length Kif3B to monitor depletion efficiency. 24 h after
the transfection of the construct, the cells were fixed with paraformaldehyde and stained
with an antibody against IFT20 (Fig.66). Furthermore, cells treated in the same way
were collected before fixation and extracted. Cell extracts of control and Kif3B siRNA
treated cells were loaded to SDS-PAGE and examined by Western blotting. Exogenously
expressed protein was detected with a sheep anti GFP antibody or an antibody against
α-tubulin (Fig.66). Immunofluorescence and Western blotting showed, that the expres-
sion of the GFP-tagged Kif3B protein was completely abolished by treatment with the
siRNA SmartPool. Localisation of IFT20 on the Golgi apparatus was not changed by the
absence of Kif3B in immunofluorescence.
If Kif3B was involved in Golgi positioning and morphology by its putative link with IFT20
and GMAP-210, its depletion would change the Golgi apparatus.
hTERT-RPE1 cells were treated for 72 h with the siRNA SmartPool against GL2 or Kif3B
and subsequently starved for another 48 h under siRNA conditions. Cells were incubated
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Figure 66: Effects Of Kif3B siRNA Treatment In hTERT-RPE1 Cells. hTERT-RPE1 cells were
transfected with an siRNA SmartPool against Kif3B or GL2 (control) for 72 h; after 48 h the cells
were also transfected with a construct for expression of full-length Kif3B with an N-terminal, enhanced
GFP-tag for 24 h (green) without removing the siRNA; cells were fixed with paraformaldehyde and
stained with rabbit anti IFT20 (red, 1:500) antibody (upper left panel). From the same cells an
extract was made by lysis in mammalian lysis buffer on ice; 20 μg were applied to a 6% SDS-PAGE gel
and analysed by Western blotting; protein was detected with sheep anti GFP antibody (1:1000); the
mouse anti α-tubulin antibody controlled equal loading (upper right panel). hTERT-RPE1 cells were
transfected with an siRNA SmartPool against Kif3B or GL2 (control) for 72 h after which the cells
were cultured for another 48 h in growth medium without FCS; siRNA was retransfected; cells were
incubated on ice for 1 h, fixed with methanol and stained, as indicated, with mouse anti acetylated
tubulin (red, 1:500) and rabbit anti GMAP-210 (green, 1:500, left) or rabbit anti IFT20 (green, 1:500,
right) antibodies (lower left and right panel); arrows indicate the primary cilium; blue channel= DAPI
staining; Bar=5 μm.
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on ice for 1 h, fixed with methanol and stained for acetylated tubulin and GMAP210
(Fig.66, lower left). After depletion of Kif3B, GMAP-210 was still localised on the Golgi
apparatus in hTERT-RPE1 cells and Golgi morphology was not changed. Acetylated
tubulin still stained the cilium, positioned near the Golgi apparatus.
The influence of Kif3B depletion on primary cilium formation was further examined. Cells
were treated as described above, but stained for acetylated tubulin and IFT20 instead
(Fig.66, lower right). In cells depleted of Kif3B, a primary cilium had, nevertheless,
formed and was stained by the acetylated tubulin and IFT20 antibody. IFT20 was also
found at the Golgi apparatus.
Depletion of Kif3B by siRNA did not inhibit primary cilium formation in hTERT-RPE1
cells and IFT20 localises normally.
2.8.8 Summary
The intraflagellar transport protein IFT20 was localised on the Golgi apparatus and the
primary cilium. When IFT20 was depleted from starved hTERT-RPE1 cells, their ability
to form a primary cilium was significantly impaired and only about 30% of cells formed
a cilium, in comparison to 80% in control cells. Depletion of GMAP-210 removed IFT20
from the Golgi apparatus, but not from the primary cilium. Western blotting of cells,
depleted of GMAP-210, showed, that protein levels of IFT20 were the same as in control
cells. Direct interaction of GMAP-210 and IFT20 was proven by yeast 2-hybrid and co-
immunoprecipitation studies. GMAP-210 localisation and Golgi morphology, however,
were not changed by IFT20 depletion. GMAP-210 itself was not involved in primary
cilium formation. No GMAP-210 was found at the centrosome and depletion of GMAP-
210 inhibited primary cilium formation only slightly (71% of cells instead of 80% in
controls).
The IFT20 associated subunit Kif3B of the heterotrimeric kinesin II was not associated
with Golgi localised IFT20, although GFP-tagged Kif3B protein was found at the basal
body of the primary cilium in hTERT-RPE1 cells. Depletion of Kif3B with an siRNA
SmartPool, did neither change Golgi morphology, nor localisation of IFT20. Primary
cilium formation was also not inhibited.
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3 Discussion
In this work, I studied the localisation of the protein GMAP-210. I examined its tar-
geting motives and tried to elucidate its function in the cell. To this end I set out to
discover interaction partners of GMAP-210 and studied the effects of overexpression and
knockdown on Golgi morphology, transport pathways and behaviour to treatment with
different drugs.
3.1 GMAP-210 Localises To The Golgi Apparatus And Vesicu-
lar Tubular Structures Of The Early Secretory Pathway
3.1.1 The C-Terminal GRAB Domain Is The Golgi Targeting Domain Of
GMAP-210
The golgin GMAP-210 was discovered by screens with antisera from patients with the
Sjoegren’s autoimmune disorder (Rios et al., 1994). GMAP-210 localises to the cis-Golgi
apparatus and has extensive coiled-coil structural elements. Treatment of cells with the
fungal compound Brefeldin A displaces GMAP-210 to Golgi mini-stacks near the ER-exit
sites (Fig.41, p.72). Consequently, GMAP-210 qualifies as a golgin (Barr and Short, 2003;
Gillingham and Munro, 2003). Publications on GMAP-210 are, however, contradictory
in regards to its Golgi localising domain. Infante et al. (1999) describe the N-terminus as
Golgi binding portion, others claim the C-terminus to target to Golgi membranes (Chen
et al., 1999; Gillingham et al., 2004).
Studies on Rud3p, the S.cerevisiae homologue of human GMAP-210, revealed a putative
binding domain in the C-terminus (Gillingham et al., 2004) of all Rud3p homologues,
which was termed GRAB domain. This domain is reminiscent of the GRIP domain, which
mediates recruitment of certain golgins to the trans-Golgi by binding to Arl1 (Panic et al.,
2003b; Wu et al., 2004). The GRAB domain from S.cerevisiae Rud3p interacts with the
small GTPase Arf1p and disruption of the GRAB domain, by mutation of the essential
residues aspartate 407 and leucine 410, prevents interaction with Arf1p and abolishes
Golgi binding of Rud3p.
To identify the GMAP-210 Golgi targeting motif (Fig.67, p.106), overexpression experi-
ments were performed with fragments of GMAP-210. N-terminal fragments and fragments
from the GMAP-210 middle-part display only weak Golgi binding, if any (Fig.11, p.34).
C-terminal fragments transfected into HeLa L cells show Golgi localisation (Fig.8, p.29),
whereas targeting depends on the GRAB domain (amino acids 1757-1875). Constructs
which only contain the GRAB and GA1 domain, however, (aa 1757-1979, aa 1778-1979)
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target less clearly (Fig.6, p.23), also showing a diffuse cytosolic localisation. Mutation
of the essential aspartate and leucine residues (D1780 and L1783) inhibits Golgi binding
significantly (Fig.9, p.30). The minimal GRAB domain without a coiled-coil element (aa
1757-1875) shows a diffuse cytosolic signal apart from Golgi targeting. Adding a coiled-
coil element (GMAP-210 1683-1875) improves targeting. In analogy to GRIP domain
(Fig.4, p.15), the coiled-coil structure seems to enable the GRAB domain to dimerise,
which is necessary for binding the Golgi localised recruitment factor.
This proves without any doubt, that the C-terminal GRAB domain of GMAP-210 is the
domain, which targets the protein to the Golgi apparatus. Weak Golgi targeting of
N-terminal constructs (Fig.11, p.34) could partially explain results from Infante et al.
(1999), but how they missed Golgi targeting of their C-terminal fragments is not easily
explained. In HeLa L, GMAP-210 fragments containing the amino acids 855 to 1332 are
found at Golgi membranes after depletion of endogenous GMAP-210 (Fig.27, p.53). The
same fragment of GMAP-210 (Fig.67) binds to Rab1 in in vitro pulldown assays and in
yeast 2-hybrid studies (2.4.2, p.56ff).
GMAP-210 is targeted by its C-terminal GRAB domain to the cis-Golgi (Fig.67). A
second targeting signal, which interacts with the small GTPase Rab1 can be found in the
middle part of GMAP-210, although Golgi targeting is conditional as this fragment binds
only weakly to Golgi in HeLa L cells and is recruited to the Golgi only when endogenous
GMAP-210 is depleted.
Figure 67: GMAP-210 Fragments And Their Localisation In HeLa L. Overview of the complete
array of tested constructs and their localisation to different compartments and interaction with Rab1
(after GMAP-210 depletion). VTS= vesicular tubular structures; “+” = does localise, “-” = does
not localise; GRAB mutant = localisation of the construct with mutated GRAB domain; n/a = not
applicable; n/t = not tested; data compiled from Fig.8, 9, 10, 11 and section 2.3.4.
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3.1.2 GMAP-210 Localises To Vesicular Tubular Structures
Staining of endogenous GMAP-210 and transfection of various constructs shows signals for
GMAP-210 on vesicular tubular structures in the cell periphery (2.1.2, p.29ff). Especially
D1780A L1783A mutations of GMAP-210 or fragments without the GRAB domain target
to vesicular tubular structures, which are more pronounced than those seen with staining
of endogenous GMAP-210 (Fig.9, p.30). Constructs expressing the C-terminus (GMAP-
210 1598-1979) or the GRAB domain and some adjacent coiled-coil structure (GMAP-210
1683-1875) can also be found on vesicular structures (Fig.67).
Most Golgi markers tested, like GM130 and p115, do not overlap with GMAP-210 on these
structures (Fig.7, p.28 and Fig.29, p.57). Two markers from the ER-to-Golgi secretory
pathway partially co-localise with GMAP-210 on the vesicular tubular structures (Fig.35,
p.64 and Fig.36, p.65): the coat protein complex COPII (1.2.2, p.8) and the cargo receptor
ERGIC53 (1.2.2, p.9). Nevertheless, there are discrete structures, stained for GMAP-210
but not for COPII or ERGIC53.
3.1.3 Conclusion
GMAP-210 is a Golgi localising protein, which is targeted to the Golgi by the GRAB
domain in its C-terminus. Two residues in the GRAB domain, D1780 and L1783, are
necessary for this interaction (Fig.10, p.32). Dimerisation of GMAP-210, comparable to
the GRIP domain, is also necessary for GRAB domain targeting. Without dimerisation,
the GRAB domain has only a weak affinity for the Golgi apparatus. The N-terminus
shows only weak Golgi targeting capability, which is probably due to dimerisation with
coiled-coil domains of endogenous protein and not due to a specific targeting motif. The
middle-part of GMAP-210 binds to Golgi localised Rab1.
GMAP-210 is also found at vesicular tubular structures, which are distributed throughout
the cell. GMAP-210 targets to these tubules independently of the GRAB domain, and
the structures get more pronounced if GMAP-210, without a GRAB domain or with a
mutant GRAB domain, is transfected. Some of the GMAP-210 positive structures are
also positive for ERGIC53 or the coat protein COPII. This is consistent with data from
D.melanogaster (Friggi-Grelin et al., 2006), where dGMAP co-localises with Sec23 at ER
exit sites in electron microscopy studies. This and the interaction of Rud3p with Arf1p
(and the putative interaction of GMAP-210 and Arf1) imply GMAP-210’s involvement
in the early secretory pathway.
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3.2 GMAP-210 Depletion Does Not Block Intracellular
Transport
GMAP-210 localises at the cis-Golgi (Rios et al., 1994) and on vesicular tubular structures,
which are partially labelled for markers of the ER-to-Golgi pathway. It was described, that
overexpression of GMAP-210 blocks the anterograde transport of C-terminally truncated,
secreted alkaline phosphatase (Pernet-Gallay et al., 2002), and also transport of influenza
virus hemagluttinin A between the ER and cis-Golgi. Furthermore, retrograde transport
of the shiga toxin subunit B, containing a KDEL signal for effective export from the
Golgi apparatus, is also inhibited and shiga toxin is trapped in GMAP-210 positive Golgi
fragments.
Here, VSV-G anterograde trafficking was tested (Fig.38, p.68) in GMAP-210 depleted
cells. Transport rates do not change after GMAP-210 siRNA, as measured by comparing
the signal of VSV-G transported to the plasma membrane against total signal of VSV-G
in the cell (Fig.39, p.69). To test retrograde transport, the uptake efficiency of shiga
toxin B subunit and its transport to the ER was monitored in GMAP-210 depleted cells
(Fig.40, p.70). The uptake of shiga toxin B subunit and its transfer to the Golgi is not
impaired. Retention in the Golgi apparatus is hard to evaluate, as the signal intensity
in the collapsed Golgi is stronger than in control cells with normal Golgi ribbons. This
is consistent with results from Kim (2003), which show that depletion of the S.cerevisiae
homologue of GMAP-210, Rud3p, does not block intracellular trafficking. Its deletion
from S.cerevisiae causes glycosylation defects, implying that Rud3p is necessary for Golgi
function.
3.3 GMAP-210 And The Microtubule Network
3.3.1 GMAP-210 Does Not Bind Directly To Microtubules
GMAP-210 is also described as microtubule associated protein (Infante et al., 1999), which
binds to microtubule minus-ends, probably even nucleating them at the cis-Golgi by its
capability to recruit γ-tubulin containing complexes (Rios et al., 2004). Extensive studies
in this work, however, do not reveal any direct association of GMAP-210 with the micro-
tubule network.
In vitro binding assays do not uncover interactions of the GMAP-210 N- or C-terminus,
purified from Sf9 cells, with microtubules (Fig.49, p.82) and neither are these protein frag-
ments able to bundle taxol stabilised microtubules (Fig.48, p.81). GMAP-210 full-length
and fragments overexpressed in HeLa L cells do not disturb the microtubule network sig-
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nificantly (Fig.45, p.78). Disturbances of centrosomal microtubules, as shown by Infante
et al. (1999), cannot be seen. Cos-7 cells were used in this previous study instead of
HeLa L cells, and since these show a more defined microtubule network, subtle changes in
microtubule organisation might be more readily visible. Also knockdown of GMAP-210
with siRNA does not change the microtubule network in HeLa L cells (Fig.46, p.79).
3.3.2 Nocodazole Induced Disassembly Of The Golgi Is Only Slightly Altered
By GMAP-210 Depletion
Depolymerisation of the microtubule network by the drug nocodazole causes reversible
Golgi fragmentation and dispersal of Golgi mini-stacks. These are still able to fulfil
intracellular transport as normal (Thyberg and Moskalewski, 1999). Washout of the drug
allows the Golgi apparatus to reform in the perinuclear region. These effects are linked to
the microtubule network and a disturbance of the link between Golgi and microtubules
should change the progress of dis- and reassembly. GMAP-210 depletion in HeLa L cells
causes the Golgi apparatus to collapse, becoming more compact and lose its ribbon-like
structure. Treatment with nocodazole for 90 min fragments the Golgi and disperses it
in control cells. In GMAP-210 depleted cells, the Golgi dispersal is slower and after
90 min there is still a cluster of Golgi fragments in the perinuclear region, which greatly
resembles the compacted Golgi apparatus before treatment (Fig.50, p.83). In hTERT-
RPE1 cells no compacted Golgi is observed and treatment with Nocodazole fragments the
Golgi apparatus at equal rates in control and GMAP-210 depleted cells (Fig.51, p.85).
Reassembly is also not changed by GMAP-210 depletion. This hints at the fact, that
GMAP-210 function is possibly different in the two cell types. hTERT-RPE1 cells might
also be less sensitive to depletion of GMAP-210.
3.3.3 GMAP-210 Is Not A γ-Tubulin Binding Protein
Rios et al. (2004) show, that GMAP-210 can recruit γ-tubulin to the Golgi apparatus
upon overexpression. Furthermore, GMAP-210 localises to the centrosome itself, when
its Golgi localising domain is removed. This displaces the pericentriolar marker CTR453
from the centrosome, which is attributed to interaction of γ-tubulin with GMAP-210. A
model is presented, where GMAP-210 recruits γ-tubulin and short, stable microtubules
to the Golgi apparatus and nucleates microtubules on that organelle.
As no γ-tubulin has been found at the Golgi apparatus before (Murphy et al., 1998;
Khodjakov and Rieder, 1999), constructs of GMAP-210 were transfected into HeLa L
cells and γ-tubulin distribution was examined. γ-Tubulin is not recruited to the Golgi
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apparatus, but antibodies against γ-tubulin stain two dots in the perinuclear region. No
construct of GMAP-210 localises at the two centrosomal dots stained with γ-tubulin.
However, overexpression of the N-terminus of the ninein-like protein readily accumulates
γ-tubulin (Casenghi et al., 2003), but no GMAP-210 or Golgi membranes (Fig.45, 53,
p.78 and 87).
3.3.4 Conclusion
This shows, that GMAP-210 is unlikely to be involved in microtubule nucleation at the
Golgi apparatus. First, no in vitro interaction of GMAP-210 with microtubules can
be detected. Secondly, the microtubule network of HeLa L cells is not disturbed by
GMAP-210 overexpression or depletion. Third, no link to γ-tubulin, which is necessary
for microtubule nucleation, can be established and endogenous GMAP-210 does not co-
localise with γ-tubulin under any circumstances. It is possible, that GMAP-210 attaches
the Golgi apparatus to the microtubule network by mediating the interaction between
a motor protein and Golgi membranes. This would explain the morphological changes
visible after depletion and overexpression of GMAP-210 in HeLa L cells. The impaired
dispersal of Golgi fragments after GMAP-210 depletion could also hint at a function of
GMAP-210 in mediating Golgi microtubule interaction. However, GMAP-210 does not
have the properties expected of a Golgi MAP.
3.4 GMAP-210 Shows Interaction With Several Golgi Localised
Proteins
Not much is known about GMAP-210 interactors. The S.cerevisiae homologue of GMAP-
210, Rud3p, is shown to bind to the Golgi apparatus via its interaction with the small
GTPase Arf1p (Gillingham et al., 2004).
3.4.1 Binding Of The GRAB Domain To Arf1 Is Regulated
The whole family of small ADP-ribosylation factor and ribosylation factor-like proteins
was tested for interaction in yeast 2-hybrid experiments (Fig.13, p.37). Full-length GMAP-
210 interacts with the small GTPases Arl4A, B and C and Arl16. Arl16 does not interact
with the GMAP-210 GRAB domain, but Arl4A, B and C do and the interaction is abol-
ished by the mutation of the two essential residues aspartate and leucine in the GRAB
domain (Fig.14, p.38). However, further studies reveal, that the Arl4 family does not
localise to the Golgi apparatus, but is found on the plasma membrane (Fig.16, p.40)
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(Hofmann et al., 2007). Arl4 recruits the guanine nucleotide exchange factor cytohesin
and thus activates Arf6. Pulldown experiments with recombinant Arl4 (Fig.18, p.43) and
immunoprecipitation (Fig.19, p.44) show no binding of GMAP-210 and Arl4. Surprisingly,
the active mutant of Arf1 interacts in yeast 2-hybrid with a fragment, which contains only
the GMAP-210 GRAB domain and mutation of the GRAB domain abolishes this. Arf1
does, however, not interact with full length GMAP-210 (Fig.12, p.35). Yeast 2-hybrid
mapping of GMAP-210 shows, that Arf1 interaction is inhibited by a part N-terminally
from the GRAB domain (Fig.22, p.47). This hints at regulation of Arf1 binding to the
GMAP-210 GRAB domain in full-length GMAP-210. The GRAB domain is activated for
Arf1 binding upon interaction with a yet unidentified factor.
3.4.2 GMAP-210 Interacts With The Small GTPase Rab1
Rab GTPases are involved in all transport steps and give identity to membrane compart-
ments (Pfeffer, 2001; Zerial and McBride, 2001; Short et al., 2005). They are essential
components of intracellular trafficking. GMAP-210 was screened against a yeast 2-hybrid
library of the complete Rab GTPase family (Fig.30, p.58). Several Rab GTPases show
interaction with GMAP-210, including Rab1 and Rab2. Rab1 co-localises with GMAP-
210 on the cis-Golgi of HeLa L cells (Fig.31, p.59), Rab2 is clearly localised on a different
compartment, the medial Golgi (Short et al., 2001). Pulldown experiments with all pos-
itive Rab GTPases found in the yeast 2-hybrid screen (Fig.33, 34, p.61, 62) confirm,
that Rab1 interacts with GMAP-210 in a nucleotide dependent manner. Yeast 2-Hybrid
experiments were further used to map down the interaction domain for Rab1 on GMAP-
210 (Fig.32, p.59). Amino acids 855 to 1332 can bind Rab1. Interaction with Rab2 is
stronger, but due to the localisation of Rab2 and its inability to pull down GMAP-210,
this is likely of no importance. Even more interesting is the fact, that GRAB mutant
GMAP-210 is recruited to the Golgi of HeLa L cells, when endogenous GMAP-210 is
depleted by siRNA. This targeting capability also maps to the same fragment as Rab1
binding (Fig.27, p.53). It is thus possible, that GMAP-210 binds to Rab1, but only in
combination with GRAB domain targeting (Fig.68). Without the GRAB domain bind-
ing signal, the Rab1 interaction domain is too weak or structurally blocked for bringing
GMAP-210 to the membrane. Alternatively, it is competed by endogenous GMAP-210.
Depletion of endogenous GMAP-210 frees Rab1 for binding mutant GMAP-210. However,
this effect is not visible in hTERT-RPE1 cells.
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Figure 68: Model Of Competition Between Endogenous And GRAB Domain Mutant
GMAP-210 For Rab1 Binding On The Golgi Apparatus. Endogenous GMAP-210 binds the
GRAB domain binding factor “X” (allegedly Arf1), which causes a conformational change in GMAP-
210 and enables Rab1 binding. Exogenously expressed GMAP-210 is sterically hindered to bind Rab1,
but can do so, if no endogenous GMAP-210 is present to compete for Rab1 on the Golgi apparatus.
A factor “Y” might label a GMAP-210 specific pool of Rab1; not drawn to scale.
3.4.3 Conclusion
GMAP-210 is a large coiled-coil domain protein targeted to the Golgi apparatus by its
C-terminal GRAB domain (Fig.69). Studies in S.cerevisiae show, that the GRAB domain
of Rud3p binds to Arf1p on the Golgi apparatus. In this work, no interactor from the
Arf- and Arl-family could be identified for GMAP-210 with certainty. Candidates from
a yeast 2-hybrid screening with all Arf family members are not Golgi proteins but are
found at the plasma membrane or do not interact with the GRAB domain. Pulldown
experiments do also not confirm interaction. Arf1, however, interacts with the GMAP-
210 GRAB domain, when the minimal domain is tested in yeast 2-hybrid. This raises
the possibility, that binding of Arf1 to GMAP-210 is regulated by different factors, which
induce a structural change in GMAP-210 and thus expose the GRAB domain for Arf1
interaction.
A screen with the Rab GTPase family identifies Rab1 as a small GTPase binding GMAP-
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210 (Fig.69). In HeLa L cells GRAB mutant GMAP-210 is recruited to the Golgi appara-
tus, when endogenous GMAP-210 is depleted. It is further shown, that this recruitment is
mediated by the same region Rab1 binds to. It is thus possible, that GMAP-210 interacts
with a small GTPase by its GRAB domain and with Rab1 by a domain in the middle
part in a synergistic way. GRAB mutants cannot compete with endogenous GMAP-210
for Rab1 binding (Fig.68). Only in the absence of endogenous GMAP-210, these GRAB
mutants are recruited to the Golgi. For interaction of GMAP-210 and Arf1 a regulation
of the binding domain could likewise be proposed. GMAP-210 can only interact with
Arf1 when an additional factor causes a conformational change and exposes the GRAB
domain for binding. This could explain, why Arf1 cannot interact with full-length GMAP-
210 in vitro, but shows up in a yeast 2-hybrid experiment, which uses the minimal GRAB
domain. Further testing will be necessary.
3.5 IFT20: An Unexpected GMAP-210 Interactor
3.5.1 GMAP-210 Interacts With IFT20 But Is Not Involved in Primary
Cilium Formation
The most surprising interaction partner of GMAP-210 discovered in this work is IFT20.
IFT20 is described as Golgi localising protein of the intraflagellar transport machinery
(Follit et al., 2006). Depletion of GMAP-210 and staining for IFT20 shows a loss of the
protein from the Golgi apparatus (Fig.57, p.95). This effect is clearly visible in hTERT-
RPE1 cells, but also in HeLa L cells, which have only very little IFT20. The overall
amount of IFT20 in the cell, after it is lost from the Golgi apparatus, is not changed
(Fig.58, p.95) and IFT20 depletion by siRNA has no effect on Golgi morphology or lo-
calisation of GMAP-210 (Fig.56 p.93). However, loss of IFT20 significantly reduces the
ability of the cell to form a primary cilium. When IFT20 is depleted from the cell, 60%
less primary cilia are observed in hTERT-RPE1 cells in comparison to control cells. De-
Figure 69: Binding Domains Of GMAP-210 Interaction Partners. Identified domains in GMAP-
210 and their recruited binding partners; green: coiled-coil; blue: GRAB domain; red: GA1 domain;
yellow: proline rich sequence.
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pletion of GMAP-210 and the subsequent loss of IFT20 from the Golgi apparatus does
not significantly alter the capability of hTERT-RPE1 cells to grow a primary cilium,
indicating, that the Golgi localisation of IFT20 is not necessary for primary cilium forma-
tion. IFT20 interacts directly with GMAP-210 in yeast 2-hybrid (Fig.62, p.99), but not
with other golgins. Endogenous IFT20 is also co-immunoprecipitated with GMAP-210
antibodies from hTERT-RPE1 extract and vice versa (Fig.64, p.101). Mapping of the
interaction domain of GMAP-210 by yeast 2-hybrid (Fig.63, p.100) identifies two regions
of GMAP-210, which bind to IFT20: the middle part, amino acids 855 to 1332, and the
C-terminus, amino acids 1598 to 1979 (Fig.69). Rather than binding to two separate re-
gions in GMAP-210, it can be expected, that the tertiary structure of GMAP-210 brings
these two regions closely together for binding of IFT20.
IFT20 interacts with the kinesin Kif3B subunit of the heterotrimeric kinesin. This ki-
nesin is responsible for microtubule plus-end directed motility within the primary cilium.
Although it is described to localise to the Golgi apparatus, protein can only be found at
the primary cilium when overexpressed in hTERT-RPE1 cells (Fig.65, p.102). Depletion
of Kif3B by an siRNA gene pool does neither alter IFT20 nor GMAP-210 localisation at
the Golgi (Fig.66, p.103). Cilia form normally, although Kif3B function in intraflagellar
transport would indicate otherwise (Kozminski et al., 1995).
3.5.2 Conclusion
The IFT complex particle IFT20 is essential for formation of flagella and cilia and is
required for cargo transport within the cilium (Baker et al., 2003). Its localisation at
the Golgi apparatus is unexplained. Follit et al. (2006) observed a stream of IFT20
particles from the Golgi apparatus to the cilium and moderate knockdown of IFT20
significantly reduces the levels of the transmembrane protein polycystin-2 in the primary
cilium. GMAP-210 depletion removes the Golgi localised pool of IFT20 from the organelle,
but does not prevent primary cilium formation in hTERT-RPE1 cells. This raises the
question of IFT20 function at the Golgi apparatus and the involvement of GMAP-210 in
the intraflagellar transport. From the collected data we propose the following model about
IFT20 and GMAP-210 function in transport of cargo to the cilium. The cargo transported
to the cilium by this means is not needed for assembly of the cilium itself, but for the
function of this structure, for example components of cellular signalling localised to the
primary cilium (Scholey and Anderson, 2006).
The IFT-cargo is exported from the ER exit sites in GMAP-210 positive COPII vesicles
(Fig.70), which travel to cis-Golgi. IFT20 particles are recruited and the IFT-cargo
is “handed over” by GMAP-210, which dissociates from the complex. The IFT-cargo
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Figure 70: Model For Functions Of Golgi Localised IFT20 And Its Interaction With
GMAP-210. Cargo destined to the cilium leaves the ER exit sites (ERES) in specialised COPII
vesicles, on cis-Golgi GMAP-210 recruits IFT20 and performs a “hand-over” of the IFT-cargo to IFT20;
the IFT-cargo-IFT20 complex travels through the Golgi stack and is packed into vesicles destined to
the cilium, maybe assisted by Rab8a; alternatively, the IFT-cargo-IFT20 complex leaves the cis-Golgi
in special IFT-vesicles after dissociation from GMAP-210 and travels directly to the cilium.
proceeds through the Golgi stack and is transported to the cilium by vesicles, maybe with
assistance of Rab8a (Nachury et al., 2007; Yoshimura et al., 2007) and other factors. As
IFT20 is only proven to localise to the cis-Golgi by its interaction with GMAP-210 (Rios
et al., 1994; Friggi-Grelin et al., 2006), another possible pathway can be proposed. The
IFT-cargo-IFT20 complex would leave the Golgi by vesicles budding directly from the
cis-Golgi. This would be necessary if the transported cargo does not need medial- and
trans-Golgi processing. In this scenario, IFT20 and GMAP-210 could even function as
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cargo receptor and coat protein as it has been hypothesised, that IFT evolved from the
clathrin- and COPI-coat systems (Jekely and Arendt, 2006). To verify either of the two
hypotheses, the exact cisternal localisation of IFT20 on the Golgi needs to be determined.
Furthermore, identification of a specific cargo of this transport pathway and examination
of its glycosylation pattern would help much to pin down the exact function of GMAP-210
and IFT20 in the intraflagellar transport.
It is however obvious, that there is more to GMAP-210 than its role in intraflagellar
transport. HeLa L cells express only little IFT20 in comparison to hTERT-RPE1 cells and
HeLa L cells are also not able to grow a primary cilium, which is consistent with their lack
of IFT20. Nevertheless, they express a significant amount of GMAP-210 and its depletion
changes Golgi morphology. Furthermore, organisms without cilia, like S.cerevisiae and
plants, have homologues to GMAP-210, but supposedly none to IFT20.
3.6 GMAP-210 And Golgi Morphology
3.6.1 Golgi Grows Tubules Upon GMAP-210 Overexpression
Overexpression of a wide array of N- and C-terminal constructs of GMAP-210 has no effect
on Golgi morphology (Fig.8, 9, 11, p.29ff). After overexpression of full-length GMAP-210
in HeLa L, however, tubules grow from the Golgi (Fig.8, p.29). These structures are part
of the Golgi membrane, as they also stain for GM130.
3.6.2 GMAP-210 Depletion Shrinks Golgi In HeLa L
The phenotype of GMAP-210 overexpression is consistent with the effect of GMAP-210
depletion by siRNA (2.3, p.48ff). A siRNA oligo was designed, which targets a sequence
in the 3’-untranslated region of the human GMAP-210 gene. In HeLa L cells, depletion
of GMAP-210 causes the Golgi apparatus to shrink to about half its normal size (Fig.25,
p.50) and to lose its ribbon-like structure (Fig.24, p.49). All Golgi markers tested remain
at the Golgi apparatus (Fig.29, p.57) and, although the volume of Golgi membranes is
decreased, staining of Golgi resident proteins increases in intensity, signifying, that Golgi
resident proteins are concentrated on a smaller amount of Golgi membranes (Fig.29, p.57).
ERGIC53 and COPII are affected in the same way (Fig.35 and 36, p.64 and 65). The
distribution of the vesicles, they localise to, is not altered significantly, although this is
not surprising as co-localisation with GMAP-210 is only partial and depletion of GMAP-
210 would only affect a subset of COPII- and ERGIC53-positive vesicular structures. Of
course it is impossible to follow the fate of vesicular tubular structures after GMAP-210
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depletion, until a unique marker for these is identified. Electron microscopical analysis of
the Golgi apparatus in HeLa L cells treated with siRNA against GMAP-210 reveals, that
the Golgi remains in the perinuclear region, but fragments into swollen compartments,
which show neither stacking of cisternae nor a Golgi ribbon (Fig.26, p.52). Strangely
enough, in hTERT-RPE1 cells the Golgi apparatus is not at all affected by GMAP-210
siRNA (Fig.24 and Fig.25, p.49f), although the protein is depleted, as shown by Western
blotting (Fig.23, p.49). This could be due to two reasons. Either GMAP-210 depletion
in HeLa L cells is more effective than in hTERT-RPE1 cells and even undetectable levels
of GMAP-210 can keep up Golgi morphology or hTERT-RPE1 cells are able to compen-
sate for the loss of GMAP-210 by a different, unknown factor, which is not available to
HeLa L cells. Total Golgi fragmentation as observed by Rios et al. (2004) was not caused
by a more effective depletion of GMAP-210 from HeLa L cells, as their Western blots and
immunofluorescence images show incomplete depletion of GMAP-210 from cells. Addi-
tionally, they see different populations of cells, some have reduced levels of GMAP-210,
others are unaffected by the siRNA. The siRNA oligo against the 3’-UTR of GMAP-210
used in this work gives a complete knockdown in all cells. The Golgi dispersal witnessed
by Rios et al. (2004) could be due to off-target effects, which often cause Golgi dispersal
(AH, SY, JE, FAB, personal observation).
3.6.3 Conclusion
GMAP-210 overexpression and depletion has consistently opposite effects in HeLa L cells.
Whereas GMAP-210 overexpression causes the Golgi membranes to grow out into fine
tendrils, depletion of the protein collapses the Golgi and it concentrates in the perinuclear
region. EM studies make it likely that the Golgi is fragmented into swollen vesicles.
This could indicate one of two functions for GMAP-210 in Golgi: Either GMAP-210
tethers incoming vesicles (Fig.71A) or it links the Golgi to the cytoskeleton by plus-end
directed microtubule motors (Fig.71B). As a tether, GMAP-210 could capture vesicles
of the early secretory pathway, being recruited by Rab1 and binding to their membrane
with the proposed ALPS (ArfGAP1 lipid packing sensor) domain. The GRAB domain
would be protected against Arf1 binding until it is released by a yet unknown factor.
The GRAB domain then tethers the vesicle to the Golgi for subsequent membrane fusion
by SNARE proteins. Overexpression improves capturing, thus building tubules made
from freshly fused vesicles. When GMAP-210 is depleted, capturing is impaired, and
Golgi volume decreases. However, to cause such a severe effect, GMAP-210 had to be
involved in an important transport pathway and the decrease of Golgi material would also
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Figure 71: Models for Molecular Function Of GMAP-210 At The Golgi Apparatus.
A: GMAP-210 as tethering factor. GMAP-210 binds vesicles with its alleged ALPS domain at the
C-terminus after being recruited by Rab1. The GRAB domain is blocked until the factor “X” frees
it for binding to Arf1 on the Golgi membrane. IFT20 could link to a microtubule minus-end directed
motor protein and cause vesicle movement. Cartoon not drawn to scale. B: GMAP-210 as microtubule
linker protein. GMAP-210 binds to Golgi membranes by its Rab1 and Arf1 interaction and links Golgi
membranes to the microtubule network by microtubule plus-end directed motor proteins. This causes
enlargement of the Golgi apparatus. Position of interaction of the motor with GMAP-210 chosen
arbitrarily. Not drawn to scale.
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decrease the amount of Golgi resident proteins, as they are transported to the ER and
cannot return. This would result in a phenotype reminiscent of Brefeldin A treatment.
Additionally, depletion of GMAP-210 has little effect on intracellular transport (Powers
and Barlowe, 1998) and does not alter VSV-G transport rates (2.5.1, p.67). Thus, GMAP-
210 is most likely not involved in basal protein transport, but rather in a specialised
transport pathway as proposed for flagellar cargo transport (3.5, p.113). Another possible
function of IFT20, which might even be independent of flagellar cargo transport, could
be imagined (Fig.71A). Binding of IFT20 to GMAP-210 could link the protein and the
bound vesicle to microtubule minus-end directed motors, thus enabling the complex to
travel to the Golgi apparatus. This would, however, make it necessary, that IFT20 is able
to bind to two different motor proteins, plus-end directed Kif3B in intraflagellar transport
and a microtubule minus-end directed protein for vesicle transport to the Golgi. Due to
the small size of IFT20 this is unlikely.
Thus, the second model for GMAP-210 function is more compelling. GMAP-210 might
set up a link to the microtubule network (Fig.71B), probably via plus-end directed motor
proteins. A likely candidate could be the kinesin Kif5B, as its depletion also causes Golgi
collapse (Feiguin et al., 1994), although in astrocytes, which show a different wild-type
Golgi morphology. Upon overexpression of GMAP-210 Golgi membranes would be drawn
along microtubules, thus forming the Golgi tubules observed (Fig.8, p.29). In this model,
Rab1 and Arf1 play the role of anchoring points for GMAP-210 and could regulate Golgi
size and position, by regulated release of GMAP-210 from the membranes.
3.7 Outlook
This work settles some important questions about GMAP-210 localisation at the Golgi
apparatus. It identifies binding partners and implies it in different functions in Golgi
morphology and intracellular trafficking. But all these findings raise further questions
about GMAP-210.
How is it involved in intracellular trafficking? Is this role linked to primary cilium forma-
tion and function or does its interaction with IFT20 serve a completely different purpose?
If not, why is this protein conserved, even in plants, which do not have cilia? What role
does it fulfil in formation of cilia and flagella?
GMAP-210 might not to be essential for survival of cells in cell culture, but in multi-
cellular organisms things might look different and the next step in unravelling GMAP-
210’s elusive purpose should not in the least be to study its function in vivo beyond the
test tube and cell culture.
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4 Materials And Methods
4.1 Materials And Reagents
Buffers and general solutions were prepared by Marianne Siebert from the Department of
Cell Biology. Suppliers for commercially available chemicals, reagents and materials were
Amersham Pharmacia (Freiburg, Germany), Becton Dickinson (Heidelberg, Germany),
Invitrogen (Paisley, UK), Merck (Darmstadt, Germany), Nunc (Wiesbaden, Germany),
Qiagen (Hilden, Germany), Roche/Boehringer (Mannheim, Germany), Roth (Karlsruhe,
Germany) and Sigma (Taufkirchen, Germany). Oligonucleotides were obtained from
Metabion (Martinsried, Germany). DNA sequencing was done by Medigenomix (Mar-
tinsried, Germany) or the core facility of the Max-Planck-Institute for Biochemistry in
Martinsried. Restriction enzymes and buffers were obtained from New England Bio-
labs (NEB) (Frankfurt, Germany). Commercial antibodies were purchased from Abcam
plc. (Cambridge, UK), Cell Signaling Technology (Frankfurt, Germany), Dianova (Ham-
burg, Germany), NEB (Frankfurt, Germany), Santa Cruz Biotech (Heidelberg, Germany),
Sigma-Aldrich (Taufkirchen, Germany) and Upstate Biotechnologies (Biomol, Hamburg,
Germany).
Often used buffers are summarised in Tab.3.
Table 3: General buffer solutions used
Solution Composition
DNA Loading Dye (6x) 0.25%(w/v) bromophenol blue, 40%(w/v) sucrose,
in TE
LB 10 g/l Bacto-tryptone, 5 g/l Bacto-yeast extract,
10 g/l NaCl
LB-Agar LB plus 15 g/l Bacto-agar
Milk-PBS (Blocking Buffer) 4% (w/v) milk powder in PBS plus 0.2%(w/v)
Tween-20
PBS 8 g/l NaCl, 0.2 g/l KCL , 1.44 g/l Na2HPO4,
0.24 g/l KH2PO4, pH 7.4
SDS-PAGE Lower Buffer (4x) 181.72 g/l Tris, 4 g/l Sodiumdodecylsulphate
SDS-PAGE Running Buffer (10x) 30.2 g/l Tris, 188 g/l glycine, 10 g/l Sodiumdode-
cylsulphate
SDS-PAGE Sample Buffer (3x) 2.3 g Tris/HCl pH 6.9, 9.0 g Sodiumdodecylsul-
phate, 50 mg bromophenol blue in 100 ml; 10%
β-mercaptoethanol
continued next page
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Solution Composition
SDS-PAGE Upper Buffer (4x) 60.6 g/l Tris, 4 g/l Sodiumdodecylsulphate
TAE(50x) 242.4 g/l Tris, 57.2 ml/l glacial acetic acid,
100 ml/l 0.5 M EDTA pH 8.0
TE 10 mM Tris/HCl pH 7.4 , 1 mM EDTA
4.1.1 Vectors And Plasmids
Parental Vectors The vectors used for this study are all based on commercially avail-
able vectors which were modified as appropriate. Modifications were done by Francis
A. Barr (pFAT2, pMAL-Tev, pAcHis and pFBT9), Herman Silljé (pcDNA3.1-MycA),
Xiumin Yan (pcDNA3.1+ cFLAG) and myself (pFBT10). The parental vectors used are
listed in Tab.4.
Table 4: Parental Vectors (Amp = Ampicilin; Kan = Kanamycin)
Vector Name Organism Description(resistance/selection)
pCRIITOPO E.coli Topoisomerase cloning (Amp, Kan)
pFAT2 E.coli N-terminal 6xHis-GST-Tag for bacterial
expression (Amp)
pQE32Tev E.coli N-terminal 6xHis-Tag for bacterial expres-
sion, Tev-cleavage site in front of MCS
(Amp)
pMAL-Tev E.coli N-terminal MBP-Tag for bacterial expres-
sion, Tev cleavage site in front of MCS
(Amp)
pAcHis E.coli, insect cells N-terminal 6xHis-Tag for expression in in-
sect cells (Sf9) (Amp)
pcDNA3.1+ E.coli, mammalian cells Mammalian expression (Amp)
pcDNA3.1+
cFLAG
E.coli, mammalian cells C-terminal FLAG-Tag, Mammalian ex-
pression (Amp)
pEGFPC2 E.coli, mammalian cells N-terminal, enhanced GFP-Tag, Mam-
malian expression (Kan)
pEGFPN3 E.coli, mammalian cells C-terminal, enhanced GFP-Tag, Mam-
malian expression (Kan)
pcDNA3.1+
MycA
E.coli, mammalian cells N-terminal myc-Tag, mammalian expres-
sion Amp
continued on next page
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Vector Name Organism Description(resistance/selection)
pAct2 E.coli, S.cerevisiae Yeast 2-hybrid Gal4 transactivator do-
main fusion (Leu)
pFBT9 E.coli, S.cerevisiae Yeast 2-hybrid Gal4 DNA binding domain
fusion on N-terminus of MCS (Trp)
pFBT10 E.coli, S.cerevisiae Yeast 2-hybrid Gal4 DNA binding domain
fusion on C-Terminus of MCS (Trp)
Plasmids The Plasmids used for these studies were created by the methods described in
section 4.4.1 (p.130), using the parental vectors in Tab.4. Vectors named “pJE” were done
by myself, vectors named differently were created by the respective person (see Appendix
A, p.148ff).
4.1.2 siRNA Oligos
The siRNA oligos used to deplete specific mRNAs were synthesised by Dharmacon Inc.
Their names and the target sequence are listed in Tab.5. They were designed with a
sequence, following: NN(N19)dTdT, with the sense oligo reading (N19)dTdT and the
antisense reading (N19 reverse complemented)dTdT (Elbashir et al., 2001).
Table 5: siRNA oligonucleotides
Target Gene Target Sequence
Human Lamin A AACTGGACTTCCAGAAGAACATC
GL2 AACGUACGCGGAAUACUUCGAUU
siGENOME SMARTpool GL2 sequences not published by supplier
Human GMAP-210 3’-UTR AAGCCAGAGACAATCTAGCAC
Human IFT20# 1 NNGGAAGAGTGCAAAGACTTT
siGENOME SMARTpool Human Kif3B sequences not published by supplier
4.1.3 Antibodies
Primary Antibodies In Tab.6 the primary antibodies used for immunofluorescence,
immunoprecipitation and/or Western blotting are listed.
4 Materials And Methods 123
Table 6: Primary Antibodies used; aa = amino acids; Sα =
Sheep anti; Rα = Rabbit anti; Mα = Mouse anti;
Name Description Organism Dilution Supplier
IF WB
RαGMAP-210 polyclonal antibody
against human 6xHis-
GMAP-210 aa 1-375;
affinity purified from
bleedout animal #
6130; purified with
native GST-6xHis-
GMAP-210 1-375
Rabbit 1:500 1:500 Biogenes, Berlin
RαIFT20(1.2) polyclonal antibody
against human 6xHis-
IFT20; denatured in
8M Urea; affinity pu-
rified from bleedout
animal # 5918
Rabbit 1:500 1:250 Biogenes, Berlin
RαPrc1 – Rabbit – 1:500 R. Neef
FAB35 6xHis-GFP affinity pu-
rified
Sheep 1:2000 1:1000 FAB, ICRF
FAB36 human Golgin-97
aa 589-769 affinity
purified
Sheep 1:500 1:500 FAB, ICRF
FAB37 6xHis-rat p115 aa 772-
959, serum
Sheep 1:500 1:500 FAB, ICRF
FAB40 6xHis-rat GM130 serum
or affinity purified
Sheep 1:500 1:500 FAB, ICRF
9E10 c-myc, affinity purified Mouse 1:1000 1:1000 -
DM1A α-tubulin, affinity puri-
fied
Mouse 1:1000 1:4000 Sigma-Aldrich
MαGolgin-97
clone CDF4
unknown Mouse 1:1000 – Dianova
SαTGN46 polyclonal human
TGN46, affinity puri-
fied
Sheep 1:2000 – AbD Serotec
continued on next page
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Name Description Organism Dilution Supplier
IF WB
MαLAMP1
CD107a
human LAMP1, affinity
purified
Mouse 1:250 – Becton-Dickinson
MαGM130
clone 35
rat GM130 aa, affinity
purified 869-98
Mouse 1:250 1:250 Becton-Dickinson
MαGolgin-84
clone 26
human Golgin-84
aa 510-713 affinity
purified
Mouse – 1:500 Becton-Dickinson
MαGS15
clone 19
rat GS15 aa 1-85, affin-
ity purified
Mouse 1:100 – Becton-Dickinson
MαGS27
clone 25
human GS27 aa 5-124,
affinity purified
Mouse 1:500 – Becton-Dickinson
MαGS28
clone 1
rat GS28 aa 3-108, affin-
ity purified
Mouse 1:500 – Becton-Dickinson
Mαp115
clone 15
rat p115 aa 843-955,
affinity purified
Mouse 1:50 – Becton-Dickinson
Mαp230
clone 15
human p230 aa 2063-
2179, affinity purified
Mouse 1:250 – Becton-Dickinson
MαSyntaxin 6
clone 30
rat Syntaxin 6 aa 6-136,
affinity purified
Mouse 1:2500 – Becton-Dickinson
MαVti1a
clone 45
mouse Vti1a aa 114-
217, affinity purified
Mouse 1:500 – Becton-Dickinson
MαVti1b
clone 7
mouse Vti1b aa 9-121,
affinity purified
Mouse 1:500 – Becton-Dickinson
Mα Histidine 6xHis-Tag clarified as-
cites fluid
Mouse – 1:5000 GE Healthcare
MαVSV-G lumenal domain of the
vesicular stomatitis
virus G-protein
Mouse 1:20 – Ira Mellmann
MαEEA1
clone 14
human EEA1 aa 3-281 Mouse 1:50 – Becton-Dickinson
MαCaveolin
clone 56
purified mouse 1:100 – Becton-Dickinson
Mα-βCOP
clone maD
– mouse 1:500 – Sigma
continued on next page
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Name Description Organism Dilution Supplier
IF WB
MαSec31a
clone 32
– mouse 1:250 – Becton-Dickinson
RαCOPII sec31 rabbit 1:500 – ABR/Abcam
MαKDEL-R
KR-10
peptide from bovine
KDEL sequence
mouse 1:500 – Stressgen (USA)
MαRab1 1E7 – mouse 1:5 – Weide et al. (1999)
RαRab2 Peptide of c-terminus rabbit 1:500 – Santa Cruz
MαERGIC53 human ERGIC53 mouse 1:1000 – Alexis Biochemicals
Mα-acetylated
Tubulin
6/11B/1
acetylated α-tubulin
from the outer arm
of sea urchin sperm
axonemes
Mouse 1:500 – Sigma-Aldrich
RαCNAP1 clone 2-6 Rabbit 1:1000 – E.A. Nigg
Mα-γ-tubulin
GTU88
synthetic peptide aa 38-
53
Mouse 1:1000 – Sigma-Aldrich
ShαGolgin-84 – Sheep 1:500 – Martin Lowe
Secondary Antibodies The conjugated antibodies listed in Tab.7) were used for im-
munofluorescence and Western blotting studies.
Table 7: Secondary Antibodies used
Name Antigen Organism Dilution Supplier
IF WB
Alexa-488
α-mouse
Mouse IgG Donkey 1:1000 – Molecular Probes(dye)/
Jackson Laboratories
Alexa-488
α-rabbit
Rabbit IgG Donkey 1:1000 – Molecular Probes(dye)/
Jackson Laboratories
Alexa-488
α-sheep
Sheep IgG Donkey 1:1000 – Molecular Probes(dye)/
Jackson Laboratories
Cy2-α-sheep Sheep/Goat IgG Donkey 1:1000 – Jackson Laboratories
Cy3-α-mouse Mouse IgG Donkey 1:1000 – Jackson Laboratories
Cy3-α-rabbit Rabbit IgG Donkey 1:1000 – Jackson Laboratories
Cy3-α-sheep Sheep/Goat IgG Donkey 1:1000 – Jackson Laboratories
continued on next page
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Name Description Antigen Dilution Supplier
IF WB
HRP-α-mouse Mouse IgG Donkey – 1:1000 Jackson Laboratories
HRP-α-rabbit Rabbit IgG Donkey – 1:1000 Jackson Laboratories
HRP-α-sheep Sheep/Goat IgG Donkey – 1:1000 Jackson Laboratories
HRP-ProteinA Mouse/Rabbit IgG – – 1:1000 Amersham-Pharmacia
4.2 Bacterial Methods
4.2.1 Growth And Maintenance Of E.coli Bacteria
The bacterial strain Escherichia coli was grown in LB medium supplemented with the
proper amount of antibiotics (100μg/ml Ampicilin, 50μg/ml Kanamycin or 100 μg/ml
Ampicilin plus 34 μg/ml Chloramphenicol) depending on the resistance marker of the
transformed plasmids. Short-term storage of transformed bacteria was done at 4◦C on
LB-agar with antibiotics.
4.2.2 Bacteria Strains
The Escherichia coli strains used in this work and their genotypes are listed in Tab.8.
4.2.3 Expression And Purification of Recombinant Protein From E.coli
Culturing Of E.coli Escherichia coli strain JM109 or BL21pRIL were grown in LB
medium supplemented with antibiotics suitable for selecting the transformed plasmid.
For BL21pRIL chloramphenicol had to be added to select for the pRIL plasmid. pMAL-
transformed bacteria were cultured in presence of 0.2% Glucose. Bacteria cultures were
inoculated with either a 25 ml overnight culture, grown at 37◦C in the appropriate medium
or with a single colony picked from an LB-agar plate. The cultures were grown under
constant shaking at a rate of 180 rpm. The culture was induced at an OD600 of 0.5-0.8 with
0.5 mM Isopropyl β-D-thiogalactoside (IPTG) and then grown for 2-4 h at 37◦C or 14-18 h
at 18◦C. The bacteria were harvested at 3000 g (Sorval RC5C) at a temperature of 4◦C
for 20 min. The supernatant was discarded and the pellet either processed immediately
or frozen on dry ice and kept at -20◦C.
Purification Of Recombinant, His-Tagged Protein Under Native Conditions
The cell pellet was resuspended in chilled IMAC5 buffer (all buffers used are listed in
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Table 8: E.coli strains and function.
Strain Genotype Description
XL1-blue F’::Tn proA+B+ lacIq Δ(lacZ)M15/
recA1 endA1 gyrA96 (NaIr) thi hsdR17
(r−Km
+
K) glnV44 relA1 lac
General cloning
GM2163 F− ara-14 leuB6 fhuA31 lacY1 tsx78
glnV44 galK2 galT22 mcrA dcm-
6 hisG4 rfbD1 rpsL136 dam13::Tn9
xy1A5 mtl-1 thi-1 mcrB1 hsdR2
Cloning of non-methylated DNA
for digestion with Dam or Dcm-
sensitive restriction enzymes
BL21(DE3)a F− ara-14 leuB6 fhuA31 lacY1 tsx78
glnV44 galK2 galT22 mcrA dcm-
6 hisG4 rfbD1 rpsL136 dam13::Tn9
xylA5 mtl-1 thi-1 mcrB1 hsdR2
Recombinant protein expression
JM109 a F’ traD36 proA+B+ lacIq Δ(lacZM15/
Δ(lac-proAB) thi hsdR17
Recombinant protein expression
TOP10 F’ mcrA Δ (mrr-hdsRMS-mcrBC) Φ80
lacZΔlacX74 recA1 deoR araD139
Δ(ara-leu)7697 galU galK rpsL (StrR)
amdA1 nupG
TA-cloning of PCR products
a sometimes transformed with the pRIL plasmid (Stratagene), which provides tRNAs for rare codons:
arginine, isoleucine and leucine, selective marker: chloramphenicol
Tab.9, p.128) supplemented with 0.5 mg/ml Lysozyme (Amersham, Freiburg), 1mM PMSF
(Sigma, Taufkirchen) and 1 tablet/10 ml Protease Inhibitor Cocktail (Roche, Mannheim).
The suspended bacteria were incubated for 10 min at 37◦C to lyse the cells. The lysate
was sonicated at 4◦C four times 30 s with 30 s rest periods in between with a Bandelin
Sonopuls sonicator (Bandelin, Berlin). In order to clear the lysate of cell debris ultra-
centrifugation was performed in a Beckman Optima LE-80K Ultracentrifuge (Beckman,
USA) with a SW28 or SW40 rotor at 27000rpm and 4◦C for 35 min. The cleared lysate
was incubated with 0.5 ml Ni-NTA Agarose (Qiagen, Hilden) per 1 l of original culture in
an empty 50 ml Falcon tube for 2 h at 4◦C. The Ni-NTA agarose was pelleted for 5 min
at 400 g and 4◦C and washed four times in batch with IMAC20-TX supplemented with
1 mM ATP and 1 mM MgCl2 (Tab.9). Resident Triton-X100 was removed by washing
with IMAC20. The beads were transferred to a column with a volume of 3 ml. The pro-
tein was eluted from the beads with IMAC200 while collecting fractions of 0.5 ml-1 ml.
Protein yield was analysed by SDS-PAGE and Coomassie blue staining and peak fractions
dialysed overnight against 5 l of an appropriate buffer at 4◦C. The dialysed protein was
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frozen at -80◦C.
Table 9: Buffers used for native recombinant protein purification with Ni-NTA-Agarose
Buffer Composition
IMAC5 20 mM Tris/HCl pH 8.0, 300 mM NaCl, 5 mM Imidazole
IMAC20 20 mM Tris/HCl pH 8.0, 300 mM NaCl, 20 mM Imidazole
IMAC20-TX 20 mM Tris/HCl pH 8.0, 300 mM NaCl, 20 mM Imidazole, 0.1% Triton-X100
IMAC200 20 mM Tris/HCl pH 8.0, 300 mM NaCl, 200 mM Imidazole
Purification Of Recombinant, His-Tagged Protein Under Denaturing Condi-
tions Bacteria were grown as described. The pellet was re-suspended in 8 M Urea (in
PBS pH 8.0) at room temperature. The suspension was sonicated 3 times for 1 min and
then centrifuged at 27000 rpm for 45 min in a SW28 or SW40 rotor (Beckmann, USA)
at room temperature. The supernatant was then incubated for 2 h under constant rota-
tion with 1 ml Ni-NTA-agarose beads per 1 l of original bacteria culture. The beads were
transferred to a 3 ml column, washed with 40 ml 8 M Urea and then eluted with 8 M Urea
and 200 mM Imidazole in PBS. Five 1.5 ml fractions were collected and analysed with
SDS-Page and Coomassie staining. Peak fractions were pooled and dialysed overnight at
room temperature against PBS with 0.1% Sodium-Dodecylsulphate (SDS).
Purification of Recombinant Protein With GST- Or MBP-Tag The Purifica-
tion of these proteins was analogous to purification of 6xHis-tagged proteins except for
the usage of different buffers and affinity beads. Lysis buffer was PBS supplemented with
0.5 mg/ml lysozyme and protease inhibitor cocktail. After sonication and ultracentrifuga-
tion different resins were added to the cleared bacterial lysate. For GST-tagged proteins
0.5 ml glutathione-sepharose (GE Healthcare, Sweden or Amersham, Freiburg) per 1 l of
original culture, for MBP-tagged proteins 5 ml amylose resin (NEB, Frankfurt) per 30 ml
lysate were used. Binding was allowed for 2 h at 4◦C. The resin was washed once in batch
with wash solution (PBS + 1 mM ATP + 1 mM MgCl2) and then transferred to a new
column. After washing 4 times with wash buffer, GST-tagged proteins were eluted with
GST-elution buffer (100 mM Tris/HCl pH 7.4 + 150 mM NaCl + 15 mM reduced glu-
tathione) and collected in 1 ml fractions. MBP-tagged proteins were eluted with 20 mM
maltose in PBS and collected in 500 μl fractions. After analysis on Coomassie stained
SDS-PAGE, the most concentrated fractions were pooled and dialysed against PBS or
10 mM Tris/HCl pH 7.5 at 4◦C. After dialysis overnight, protein was aliquoted, shock
frozen on dry ice and stored at -80◦C.
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4.3 Yeast Methods
4.3.1 Yeast Strain, Growth Medium and Culture
The Saccharomyces cerevisiae strain PJ69-4A was used for all experiments in this work
(James et al., 1996).
Genotype of PJ69-4A
MATα, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1UAS−
GAL1TATA−HIS3, GAL2UAS−GAL2TATA−ADE2, MEL1 met2=GAL7-lacZ
Yeast were grown at 30◦C on one of two media, depending on experimental purpose.
Either YPDA or SC dropout medium, which selects for the appropriate transformed
plasmids, was used. YPDA medium includes 10 g/l yeast extract, 20 g/l peptone (both
Difco/Becton-Dickinson, Heidelberg) and 20 g/l glucose (20 g/l Bacto-agar was added for
solid medium plates). After dissolving the components, the media was sterilised at 121◦C
for 20 min, cooled down to 55◦C and sterile filtered adenine hemisulphate 0.2% (w/v)was
added before plates were poured.
Amino acid base(-Leu/-Trp/-His/-Ura) for SC medium was prepared by mixing 20 g
of each alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid,
glycine, inositol, isoleucine, lysine, methionine, phenylalanine, proline, serine, threonine,
tyrosine and valine with 5 g adenine and 2 g p-aminobenzoic acid. For the dropout mix,
36.7 g of amino acid base were supplemented with either 2 g histidine, 4 g leucine, 2 g
tryptophane or 2 g uracil, depending on the desired selectivity of the medium. SC medium
included 6.7 g/l yeast nitrogen base (Difco), 2 g/l of the appropriate dropout mix and
20 g/l glucose (and 20 g/l Bacto-agar for solid medium plates). The pH was adjusted
to 6.5 and buffered with 20 mM Tris/HCl. Autoclaving and pouring of the plates was
performed as described above for YPDA medium, whereas Adenine was only added, if
not used as selectivity marker.
4.3.2 Transformation Of Yeast By The Frozen Cell Method
Competent yeast cells were prepared by picking several colonies from a freshly grown plate.
From these, overnight cultures of liquid YPDA medium were grown at 30◦C under shaking.
The overnight culture was then diluted to an OD600 of 0.15 in fresh YPDA medium and
grown to an OD600 of 0.6 (i.e. 1.2-1.5x10
7 cells). After harvesting at 3000 rpm for 2 min
at room temperature the cells were washed in half a culture volume of sterile dH2O and
spun again. The pellet was resuspended in 1/8th of the original culture volume of Lithium-
Sorbitol: 100 mM LiOAc, 10 mM Tris/HCl pH 8.0, 1 M Sorbitol (molecular biology grade;
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filter sterilized) and incubated for 5 min at room temperature. All resident Lithium-
Sorbitol was removed by centrifuging twice as described above. The pellet was again
resuspended in Lithium-Sorbitol (600 μl per 100 ml of original culture) and 10 mg/ml
salmon sperm DNA (Gibco) were added as carrier DNA. After heat-treatment at 95◦C
for 5 min, the yeast was aliquoted and stored at -80◦C until used.
For transformation, the competent yeast cells were thawed at room temperature and
mixed with 0.2 μg plasmid DNA per 10 μl of yeast. Each reaction was overlaid with 150 μl
Lithium-Polyethylenglycol (LiPEG: 100 mM LiOAc pH 8.0, 1 mM EDTA pH 8.0, 40%
PEG3350, filter sterilised) and mixed by vortexing for 5 s. After 20 min of incubation
at room temperature, 17.5 μl Dimethylsulfoxide (DMSO) were added, mixed again by
vortexing and incubated for 15 min at 42◦C. The reaction mix was centrifuged for 3 min
at 400g, the supernatant removed and the cell pellet resuspended in 200 μl sterile dH2O.
100 μl were then plated onto the appropriate selective media and incubated for 3-4 days
at 30◦C.
4.3.3 Yeast 2-Hybrid Method
For yeast 2-hybrid experiments, PJ69-4A yeast was transformed with bait and prey plas-
mids as described above and grown on SC-Leu/-Trp medium plates. Colonies were picked
and restreaked on quadruple dropout medium plates (SC-Leu/-Trp/-His/-Ade) and grown
for another 2-3 days at 30◦C. Growth on selective medium indicated interaction. Its
strength could be estimated by colour.
4.4 DNA Methods
Standard work with DNA, especially agarose gel electrophoresis and restriction digest
were performed as described (Sambrook et al., 1989). Preparation of DNA from bacteria
by the Mini-, Midi or Maxiprep method and extraction of DNA from agarose gels was per-
formed using the kit systems provided by Qiagen(Hilden) according to the manufacturer’s
instructions.
4.4.1 Cloning Strategies
Whenever applicable, a standard cloning strategy was used. This strategy is called the
“Shortway”-system and provides PCR-products, which could be subcloned into a wide
variety of vectors (all vectors on Tab.4, p.121 are compatible to this system). For this
strategy, a BamHI, BglII or BclI restriction site on the 5’-end and a SalI or XhoI re-
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striction site on the 3’-end were generated during amplification of the gene by PCR. The
ATC-Sequence of the BamHI/BglII/BclI restriction site was designed to be in frame with
the start codon of the insert as shown here:
GGG ATC CCC ATG BamHI
GAG ATC TCC ATG BglII
GTG ATC ACC ATG BclI
The restriction site is underlined and the start codon in italics. The PCR product was
TA-TOPO cloned (see 4.4.3, p.132) into the pCRIITOPO-vector (Invitrogen). The insert
was then sequenced and subcloned into the respective shortway vectors (Tab.4, p.121).
For vectors which add a C-terminal tag to the insert, a clone without a stop codon was
amplified. In the rare case that the amplified sequence included one of the mentioned
restriction sites either an individual cloning strategy had to be devised or the restriction
site was removed by silent mutation (see 4.4.4, p.132).
4.4.2 Polymerase Chain Reaction (PCR)
For Polymerase Chain Reaction either Pfu Turbo Polymerase (Stratagene, Amsterdam)
or the KOD-Hotstart-Polymerase (Novagene, Darmstadt) were used. The reaction was
performed in a volume of 50 μl. The reaction mixture composition is given on Tab.10.
Composition in regard to MgSO4, Polymerase, DMSO and dNTPs concentrations could
be varied, depending on the template, its size and its GC-content. Buffers were provided
Table 10: Reaction mix composition for PCR
PCR from cDNA library
Pfu Turbo Polymerase KOD Hotstart Polymerase
Volume Component Volume Component
5 μl marathon-ready cDNA library 5 μl marathon-ready cDNA library
Clontech, Palo Alto, CA, USA Clontech, Palo Alto, CA, USA
2.5 μl 4 μM Forward Primer 3 μl 5 μM Forward Primer
2.5 μl 4 μM Reverse Primer 3 μl 5 μM Reverse Primer
5 μl 10x Pfu-Buffer 5 μl 10x Buffer
2 μl 25 mM MgSO4
1 μl 10 mM dNTPs(NEB) 5 μl 2 mM dNTPs(Novagene)
1 μl Pfu Turbo Polymerase 1 μl KOD Hotstart Polymerase
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with the enzymes from the respective supplier, primers were synthesised by Metabion
(Martinsried).
Usually a second round of PCR was performed, substituting the cDNA with the purified
PCR product of the first run as template. Different PCR programs were used for the two
different polymerases:
Pfu Polymerase KOD Polymerase
Time Temperature Time Temperature
30 s 94◦C 120 s 94◦C 1 cycle
30 s 94◦C 15 s 94◦C 25 cycles
60 s 55◦Ca 30 s 60◦Ca 25 cycles
2 min/1kb 68◦C 30 sec/1kb 72◦C 25 cycles
2 min/1kb 68◦C 30 sec/1kb 72◦C 1 cycle
a The annealing temperature could be changed for GC-rich templates
The reaction was performed in a GeneAmp PCR System 2400 thermocycler (Perkin-
Elmer, USA). PCR products were either purified with the Qiagen PCR product purifica-
tion protocol or subjected to agarose gel electrophoresis.
4.4.3 TA-TOPO Cloning
After Polymerase Chain Reaction and agarose gel electrophoresis, the amplified DNA
was extracted from the gel with the QiaQuick Gel Extraction Kit (Qiagen, Hilden). The
PCR product was inserted into the pCRIITOPO vector by using the TA-TOPO cloning
system (Invitrogen, UK). A single adenosine overhang was added to the 3’-ends of the
DNA double-strand. To this end the extracted PCR product (50 μl volume) was incubated
with 1 μl Taq Polymerase (NEB, Frankfurt) at 72◦C for 30 min in the presence of 5 μl
buffer as provided by the manufacturer (10x concentration) and 0.25 mM dNTPs. 2 μl
of the mix were added to 0.5 μl TA-TOPO cloning mix and incubated for 5 min at room
temperature. The complete reaction mix was then transformed into TOP10 bacteria
(Tab.8, p.127).
4.4.4 Site-Specific Mutagenesis
Quickchange mutagenesis was used to introduce a 1-3 basepair mutation into a DNA
sequence. For this the Quickchange protocol from Stratagene was used in combination
with Pfu-Turbo-Polymerase or KOD-Hotstart-DNA-Polymerase (Novagene, Darmstadt).
33 basepairs long forward and reverse primers were designed, in which the changed codon
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was in the centre, flanked by 15 nucleotides on both sides. For the reaction 30 ng template
DNA, 1 pM of each primer, 0.25 μM dNTPs, 5 μl 10x Pfu-Buffer and 1 μl (2.5U) Pfu
turbo polymerase (both Stratagene) or KOD Polymerase (Novagene, Darmstadt) were
mixed in a total volume of 50 μl. The PCR cycling programs were as follows:
Pfu Polymerase KOD Polymerase
Time Temperature Time Temperature
30 s 94◦C 120 s 94◦C 1 cycle
30 s 94◦C 15 s 94◦C 18 cycles
60 s 55◦Ca 30 s 60◦Ca 18 cycles
2 min/1kb 68◦C 30 sec/1kb 72◦C 18 cycles
2 min/1kb 68◦C 30 sec/1kb 72◦C 1 cycle
a The annealing temperature could be changed for GC-rich templates
After that, 1 μl restriction enzyme DpnI was added and the mix incubated for one hour
at 37◦C, which totally degraded the methylated template DNA. 5-10 μl of the mix were
then transformed into XL1-blue bacteria and plated on the appropriate selective plates.
4.5 Protein Methods
4.5.1 Determination of Protein Concentration
For determining of protein concentration the BioRad Protein Assay Kit (BioRad, Munich)
was used. It uses a modified Bradford assay protocol. The dye reagent was diluted 1:5
with water and 1 ml mixed with 10 μl protein solution. After vortexing, the mixture was
incubated for 5-10 min at room temperature, transferred to disposable 1 ml cuvettes and
absorption at 595 nm measured in an Ultrospec 3000 Pro spectrophotometer (Amersham
Pharmacia, Freiburg). Samples of bovine serum albumin (BSA) (Sigma, Taufkirchen)
with known concentrations were recorded as standard curve.
4.5.2 Protein Precipitation
For protein precipitation trichloroacetic acid (TCA) was used. Protein solutions were di-
luted to 500 μl with water, if necessary, then mixed with 50 μl 0.15% sodium-deoxycholate
and vortexed thoroughly. After 5 min of incubation at room temperature, 100 μl of 72%
TCA were added, the mix vortexed and incubated on ice for 60 min. The precipitated
protein was pelleted by centrifugation at 20000 g for 5 min. The pellet was washed twice
with 1 ml Acetone pre-cooled to -20◦C. It was then redissolved in an appropriate amount
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of SDS-PAGE sample buffer, wherein a small amount of 1 M Tris/HCl pH 8.5 was added
for neutralising resident acid.
4.5.3 SDS-PAGE (Polyacrylamide Gel Electrophoresis)
Small SDS polyacrylamide gels (8x6.5 cm) were prepared. SDS-PAGE sample buffer was
added to the samples and boiled for 5 min at 95◦C. Gels were run in a BioRad Mini
Protean II or III gel chamber (BioRad, Munich) in SDS-PAGE running buffer at 180 V
and 50 mA per two gels for 1 h.
4.5.4 Coomassie Staining of SDS-PAGE Gels
Staining of SDS-PAGE gels was done by immersion for 15 min in fresh 0.01% Coomassie
Brilliant Blue R-250 in 50% Methanol, 10% acetic acid, while rocking. The gels were
destained in 20% iso-propanol and 20% acetic acid. In order to estimate protein masses,
an NEB Protein Broad Range Marker (NEB, Frankfurt) was run side-by-side with protein
samples.
4.5.5 Western Blotting
Proteins were separated on SDS-PAGE gels and subsequently transferred to 45 μm Hybond-
C Extra Nitrocellulose (Amersham, Freiburg) by semi-dry blotting in transfer buffer (SDS-
PAGE running buffer with 10% methanol). This was done on a Trans-Blot SD Transfer
Cell (BioRad, Munich) at 15 V and 200 mA for 40 min. The membranes were then blocked
in milk solution (4% milk powder (w/v) in PBS with 0.1% Tween-20) for 1-2 h at room
temperature or alternatively overnight at 4◦C. After blocking, the primary antibody was
applied for 1-2 h at room temperature or overnight at 4◦C. The membranes were subse-
quently washed 5 times in milk solution for 3-5 min and then treated with the secondary
antibody for 1 h at room temperature. Antibodies were diluted in milk solution. Mem-
branes were again washed three times in milk solution and three times in PBS. The bound
depletion can interfere with the cells capability to form a cilium.antibodies were detected
by chemiluminescence, using ECL Western Blot Detection Reagent (Amersham, Freiburg)
or SuperSignal West Femto Maximum Sensitivity Substrate (Pierce Biotechnology, Bonn)
for higher sensitivity (at 30-100% concentration), according to the manufacturers’ instruc-
tions. The membranes were exposed to Kodak X-Omat XAR-5 film (Sigma-Aldrich) until
a clear signal could be detected. The films were developed with the Kodak X-OMAT 2000
Processor developer. For estimation of protein masses, an NEB Protein Prestained Marker
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or Protein Broad Range Marker were run side-by-side with protein samples.
4.5.6 Antibody Production And Purification
In the course of this work, two antibodies were raised. Immunisation and preparation of
test serums were done by Biogenes (Berlin) in two rabbits.
For affinity purification of antibodies, 1 mg of recombinant protein was coupled to 1 ml
of Affigel-15 (BioRad, Munich) in an appropriate volume of PBS and incubated for 2 h at
4◦C. The resin was then washed three times in 10-15 ml PBS and subsequently in 15 ml
0.2 M glycine pH 2.8, followed by another three washes with PBS. The coupling efficiency
was analysed on coomassie stained SDS-PAGE gels.
5-10 ml of antiserum were then incubated with the prepared Affigel-15 for 2 h at 4◦C,
washed four times in PBS and transferred to a fresh column. The isolated antibody
was eluted with 10 times 1 ml 0.2 M glycine pH 2.8 and analysed on 10% coomassie
stained SDS-PAGE. Most concentrated fractions were pooled and dialysed overnight at
4◦C against PBS. Dialysed antibodies were collected and frozen on dry ice and stored at
-80◦C.
4.6 Cell Culture Methods And Microscopy
4.6.1 Mammalian Cell Culture
Cell Lines For this work the following cell lines were used:
• HeLa L, cervix adenocarcinoma, adherent
• HeLa S3, cervix adenocarcinoma, grown in suspension
• HS68, human foreskin fibroblast, adherent, propagate for 40 passages
• hTERT-RPE1, human retinal pigment epithelial, immortalized with telomerase re-
verse transcriptase, adherent, Clontech
• Sf9, Spodoptera frugiperda (fall armyworm) ovary, adherent, for Baculovirus expres-
sion
All cell lines, except hTERT-RPE1 were obtained from the American Type Culture Col-
lection (ATCC).
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Cell Growth Conditions And Growth Media HeLa and HS68 cell lines were cul-
tured at 37◦C and 5% CO2 atmosphere in Dulbecco’s Modified Eagle Medium (DMEM)
with 10% foetal calf serum (FCS). 100 U/ml penicillin and 100 μg/ml Streptomycin (all
Invitrogen, Gibco, UK) could be added during transfections. hTERT-RPE1 cells were
grown at the same environmental conditions, but in a 1:1 mixture of Dulbecco’s Modified
Eagle Medium (DMEM) with HAM’s F-12 Nutrient Mix, 10% foetal calf serum (FCS),
2.5 mM L-glutamine and 1.2 g/l sodium bicarbonate. For serum starvation the same
medium without foetal calf serum was used and the adherent cells were washed three
times with the serum-free medium. For splitting cells, old medium was removed and the
cells washed with PBS, then incubated for 15 min at 37◦C and 5% CO2 in PBS and 1 mM
EDTA (HeLa L and RPE1) or 0.25% trypsin with 1 mM EDTA (HS68 cells) (Invitrogen,
Gibco, UK). Cells not detached after this treatment were suspended by rinsing the culture
dish several times by pipetting up and down. The cell suspension was then added to fresh
medium in a fresh or rinsed recycled culture dish.
Sf9 cells were cultured in TC100 insect cell medium (Pan, Aidenbach) containing 10%
foetal calf serum, 100 U/ml penicillin and 100 μg/ml Streptomycin (Invitrogen, Gibco,
UK) at 27◦C. Splitting was done by gentle rinsing the culture dish with the resident
medium. Detached cells were added to fresh medium on a fresh culture dish.
4.6.2 Transient Transfection Of DNA Into Mammalian Cells
HeLa L and hTERT-RPE1 cells were transiently transfected with DNA constructs for
expression in mammalian cells (Tab.4, p.121) by a lipid based method. As transfection
reagent FUGENE 6 (Roche, Mannheim) or TransIt-Lt1 (Mirus Bio Corporation, USA)
were used. The reagents were applied following the manufacturers’ protocols. In short a
6-well plate (Corning, Falcon or Nunc) with 50000-100000 cells per well in 2 ml of growth
medium were prepared 24 h in advance. For one well on a 6-well plate, 97 μl Optimem
(Invitrogen, Gibco, UK) were mixed with 3 μl transfection reagent and incubated at room
temperature for 5-10 min. After addition of 0.5 μg to 1 μg plasmid DNA, the mix was
incubated for another 20 min and then added drop-wise to the cells. They were then
grown for 24-36 h. For larger culture dishes, the protocol was scaled up in relation to the
increased amount of culture medium used.
4.6.3 RNA Interference
Specific knockdown of protein expression levels was obtained by transfecting small interfer-
ing RNA oligonucleotide duplexes (siRNA) into HeLa L or hTERT-RPE1 cells as described
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(Elbashir et al., 2001). The siRNA oligo sequence was chosen to lie in the coding region,
more than 100bp downstream of the start codon, or the 3’-UTR and followed the sequence
NN(N19)dTdT, so that sense and antisense strand had an overlap of 21 nucleotides and a
2 nucleotide overhang on the 3’-end (Tab.5, p.122). siGENOME SmartPools were designed
by the rules devised by the supplier Dharmacon (Perbio, Bonn). Some single oligo du-
plexes were designed with a software provided on their homepage (www.dharmacon.com).
BLAST searches Altschul et al. (1997) made sure, that the siRNA oligo sequence was spe-
cific for the intended target mRNA.
If not supplied already pre-annealed, oligos were diluted to a concentration of 20 μM
(15 μM for GMAP-210 3’-UTR) in a volume of 100 μl with provided buffer and RNAse-
free water also provided by the supplier. For annealing, the mix was heated to 90◦C for
1 min and then incubated for 60 min at 37◦C. The annealed oligos were stored at -80◦C.
For transfection of HeLa L or hTERT-RPE1 cells, 20000-40000 cells were plated per well of
a 6-well plate (Corning, Falcon or Nunc) 24 h prior to transfection. In sterile and RNAse
free plastic test tubes, 200 μl Optimem (Invitrogen, Gibco, UK) were mixed with 3 μl
Oligofectamine (Invitrogen, UK) and incubated for 10 min at room temperature. In the
meantime, 50 μl Optimem were mixed with 3 μl annealed siRNA duplex or siGENOME
SmartPool. After combining both volumes and 20 min of incubation at room tempera-
ture, 38 μl Optimem were added and everything added drop-wise onto the 2 ml culture
medium in the well. After 24 -96 h of culturing the transfected cells were processed further
for immunofluorescence (see 4.6.4, p.137) or lysed for Western blotting (see 4.5.5, p.134).
4.6.4 Indirect Immunofluorescence
For immunofluorescence microscopy cells were grown on glass coverslips, sterilised by
flaming with ethanol in 6-well plates (Falcon, Nunc or Corning). Cell numbers plated
depended on cell line and time until fixation. Cells were fixed in either paraformaldehyde
(PFA) or methanol.
Paraformaldehyde Fixation PFA(4%) was prepared by dissolving 4 g PFA in 100 ml
PBS at 80◦C in a fume hood under continuous stirring. 10 μl 1 M CaCl2 and 10 μl 1 M
MgCl2 were added before cooling to room temperature. The pH was adjusted to 7.4 and
the clear solution vacuum filtered through a 0.45 μm filter.
The cells on coverslips were either washed three times with PBS or fixed immediately.
The coverslips were incubated for 20 min at room temperature in 4% paraformaldehyde
and then washed and quenched for 10 min with 50 mM NH4Cl (prepared freshly in PBS).
The coverslips were then washed three times with PBS and permeabilised with 0.1-0.2%
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Triton-X100 in PBS for 5 min at room temperature. Triton-X 100 was removed by washing
three times with PBS.
Methanol Fixation The coverslips were either washed three times with PBS or fixed
immediately with methanol pre-cooled to -20◦C. The fixation was performed for 4 min in
a -20◦C freezer and the cells washed afterwards.
PTEMF Fixation The coverslips were washed three times with PBS and then fixed
and permeabilised at the same time with 50 mM PIPES buffer pH 6.8, 0.2% Triton X-100,
1 mM MgCl2, 10 mM EGTA and 4%(w/v) formaldehyde for 15 min at room temperature.
Cells were washed again three times with PBS.
Antibody Labelling Of Fixed Cells After washing, the coverslips were removed from
the wells, excess liquid removed with 3MM filterpaper and put upside down onto 50 μl
drops of antibody solution in PBS on parafilm (American Can Company, USA). The
antibody was centrifuged hard (20000 g, 3 min) and the parafilm stuck flat to the working
surface with a water-film. The coverslips were incubated with the antibody for 45-90 min
in a dark moisture chamber. The coverslips were transferred back to the culture dish and
washed three times with PBS. Then incubation with secondary antibody was performed
identically to the procedure described above. After another 45-90 min the coverslips were
transferred back and washed again for three times with PBS and then mounted on 10 μl
Mowiol mounting medium (containing, in most cases, 1 μg/ml DAPI for DNA staining)
on glass slides for microscopy and left to dry in a dark place for several hours.
Mowiol was prepared by mixing 2.4 g 4-88 Mowiol to 6 g of analytical grade glycerol
under continuous stirring. 6 ml of dH2O were added and the mixture left for 2 h at room
temperature. After addition of 12 ml of 0.2 M Tris/HCl pH 8.5 it was heated to 50◦C for
10 min and centrifuged for 15 min at 3000 g.
Immunofluorescence Microscopy Images were collected with an Axioskop-2 with a
63x Plan Apochromat oil immersion objective of NA 1.4, standard filter sets (Carl Zeiss
GmbH, Jena), a 1300 by 1030 pixel cooled-CCD camera model CCD-1300-Y (Princeton
Instruments, USA) and MetaVue software (Visitron Systems GmbH, Puchheim). Images
were cropped in Adobe Photoshop CS2 then sized and placed in figures using Adobe
Illustrator CS2 (Adobe Systems Inc., USA).
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Delta Vision Microscope Cell samples prepared as described above (see 4.6.4, p.137)
were processed with an APPLIED PRECISION DeltaVision RT Life Cell Imaging System
with a 60x Olympus PlanApo objective (Aperture 1.4 with immersion oil). Images were
processed with the softWoRx software (Applied Precision, USA). Stacks of 20-40 pictures
were taken and deconvolved in 10 cycles with standard parameters and merged into a
single picture. Cropping and placing of images was done using the Adobe Creative Suite 2
(Adobe Systems Inc., USA).
4.6.5 Electron Microscopy
Fixing of cells, embedding and imaging was done by Dr. Thomas Keil (Department
of Molecular Biology, Max-Planck-Institute of Biochemistry, Martinsried). Cells were
treated with siRNA as described above (see 4.6.3, p.136). For fixing, the growth medium
was exchanged for 37◦C-warm PBS and 1 mM EDTA for 15 min at 37◦C. The cell sus-
pension was collected and pelleted at 400 g. The cell pellet was then washed twice in PBS
(first warm then room temperature) and fixed in 2.5% glutaraldehyde in 0.1 M cacodylate
buffer containing 5% sucrose, pH 7.1-7.2, at room temperature for 30-40 min. The cells
were then incubated in the same fixative containing 1% tannic acid at 4◦C for 30-60 min,
postfixed in 1% OsO4 for 1-2 h, stained en bloc in 1% aqueous uranyl acetate at 60
◦C
overnight and dehydrated in ethanol and then embedded in Spurr’s medium. Thin sec-
tions were taken on a Leica Ultracut with a Diatome diamond knife and investigated in
a Philips (FEI) CM 12 operated at 120 kV.
4.6.6 Transport Assays
For transport assays, cells were grown and transfected as described (4.6.2, p.136 and 4.6.3,
p.136).
VSV-G Transport Assay For vesicular stomatitis virus G-protein transport, cells
were transfected as described (4.6.2, p.136) with a construct expressing a GFP-tagged
version of the VSV-Gts45 protein (Bergmann, 1989) 14 h before the experiment. The
transfected cells were grown for 2 h at normal cell culture conditions and then shifted to
39.5◦C and 5% CO2. After 12 h the culture medium was replaced by ice-cold medium
and the cells were placed on ice for 30 min. While a set of coverslips was fixed with PFA
(see 4.6.4, p.137), the cells were shifted to 32◦C (medium replaced with 32◦C pre-warmed
medium) and 5% CO2 for 30 min and 60 min, when additional sets of coverslips were
fixed. Fixing by PFA was done as described (see 4.6.4, p.137), whereas the cells were
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not permeabilised with Triton-X100. The antibody against the lumenal domain of the
VSV-G-Protein (Tab.6, p.123ff) revealed protein transported to the plasma membrane
(incubation time for both antibodies was 30 min). Pictures were taken and the ratio of
transported protein (red channel) against overall GFP-tagged protein (green channel) was
measured with the MetaVue Software (Visitron Systems GmbH, Puchheim).
Shiga Toxin Uptake Cells were cultured and prepared as described above. For shiga
toxin uptake, the cells were first washed three times in ice-cold PBS and then transferred
upside down onto 50 μl of shiga toxin mix on a parafilm on ice. The incubation was
performed in the dark and prior to incubation, excess liquid was removed with 3MM filter
paper. The shiga toxin mix was composed of 2% BSA (ultra-pure, Jackson Immunore-
search, UK) and 25 mM Hepes-KOH pH 7.2 in DMEM (Invitrogen, Gibco, UK) mixed
with Cy3 conjugated, recombinant B subunit of Shigella sp. toxin at a dilution of 1:1000.
After incubation with labelled shiga toxin B-subunit, the coverslips were transferred back
to the culture wells and washed three times with ice-cold PBS. The first time-point was
fixed with PFA as described and the rest of the coverslips washed three times with 37◦C
pre-warmed DMEM and put back to normal culture conditions. Further time-points were
fixed after 10, 30, 60, 120 and 240 min (Fuchs et al., 2007).
4.6.7 Drug Treatment
Cells were grown on coverslips for 24 h before transfection and further growth for an
appropriate amount of time (see 4.6, p.135). Drug treatment was performed by removing
growth medium and replacing it by washing three times with growth medium supple-
mented with the appropriate amount of the respective drug. Cells were then put back to
standard culture conditions.
Drug Concentration Supplier
Brefeldin A 5 μg/ml Sigma-Aldrich, Taufkirchen
Nocodazole 200 ng/ml Calbiochem, Darmstadt
For washout experiments, culture wells were washed 3-5 times with drug-free culture
medium and put back to normal culture conditions. A set of coverslip was fixed at
appropriate time-points.
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4.7 Mammalian Biochemical Methods
4.7.1 Protein Expression And Purification From Sf9 Cells With The
Baculovirus System
This method consists of two steps, first the preparation of the recombinant baculovirus in
Sf9 cells and second the infection of Sf9 cells with the recombinant virus and subsequent
purification of the recombinant protein.
For the generation of the virus the BaculoGold Kit from Pharmingen (Becton-Dickinson,
Heidelberg) was used. 0.25 μg BaculoGold DNA (2.5 μl) were mixed with 2.5 μg pAcHis
vector construct for expression of the appropriate protein (see Tab.4, p.121). While
incubating for 5 min, the growth medium on a 3 cm culture dish with 5·105 Sf9 cells,
prepared 6-24 h before, was replaced by 0.5 ml buffer A (included in the kit). Then
0.5 ml buffer B were added to the DNA and the mixture added drop-wise to the cells
under continuous rocking. After incubation for 4 h at 27◦C, the culture dish was washed
once with TC100 and the cells grown in 2.5 ml TC100 at 27◦C.
After 5 days the supernatant was taken and centrifuged for 5 min at 1000 g at room
temperature. The supernatant (P0-virus) was kept for further amplification.
Next, 200 μl of P0 mixed with 1 ml TC100 were used to infect a 10 cm dish of 5·106 Sf9
cells. The cells were incubated for 1 h at 27◦C and then the infection mix was replaced by
10 ml TC100 and the cells grown for 4 days. The supernatant was collected as described
above (P1-virus) and stored at 4
◦C. For amplifying the P1-virus, 500 μl were mixed with
1 ml TC100 and 5·106 cells on a 10 cm dish infected for 1 h and, after replacing the virus
with 10 ml TC100, grown for 4 days. The P2-virus was recovered like the P1-step. In
order to get the final P3-virus, 2·107 cells on a 15 cm culture dish were infected with 100 μl
P2-virus, diluted in 3 ml TC100, for 1 h. The cells were then grown in 25 ml TC100 for
4 days and the virus was collected, when cell lysis reached 50%. The P3-virus was stored
at 4◦C in the dark. After each step, the cells were collected and the protein expression
assayed by Western blot and coomassie stained SDS-PAGE.
For protein expression ten 15 cm dishes with 2·107 Sf9 cells were each infected with
1 ml P3-virus in 2 ml TC100 each. After 1 h, 30 ml TC100 were added. Three days
later, cells were harvested by pipetting up and down in the culture medium. The cell
suspension was then centrifuged at room temperature for 8 min at 400 g. The pellet
was washed in 200 ml PBS and after centrifugation as above lysed for 30 min on ice
in 20 ml lysis buffer (IMAC5, Protease Inhibitor Cocktail, 0.2 mM PMSF, 0.1% Triton-
X100, see 4.2.3, p.126 for IMAC5). The crude lysate was ultracentrifuged for 35 min at
27000 rpm and 4◦C in a SW40 rotor (Beckman Optima LE-80K) and the supernatant
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applied to 300 μl Ni-NTA-Agarose (Qiagen, Hilden). After incubation for 2 h at 4◦C
and constant rolling, the beads were pelleted at 1000 g and washed in 20 ml lysis buffer
before they were transferred to a 3 ml disposable column. The beads were then washed
again with IMAC20-TX and IMAC20. The protein was eluted with three times 1 ml
of IMAC200 buffer into 8 fractions. After analysis on coomassie stained SDS-PAGE,
fractions with highest concentrations were pooled as appropriate and dialysed (see 4.2.3,
p.126) or desalted.
For desalting, a desalting column was prepared by piercing the bottom of an Eppendorf
tube with a syringe needle and filling it with 100 μl glasswool. This was overlaid with
desalting Gel P-6 DG (BioRad, Munich) in several steps of centrifugation (1500 g, 2 min,
4◦C) and addition of gel until the Eppendorf tube was filled up to the 1 ml marking.
The desalting column was then washed four times with PBS and the protein solution was
applied. Elution was done with the same volume of the appropriate buffer. Protein was
frozen in liquid Nitrogen and stored at -80◦C.
4.7.2 Preparation Of Rat Liver Golgi Membranes
The preparation of rat liver Golgi membranes was done as described in Hui et al. (1998).
In brief, three 2-3 months old male or female Wistar rats (Chbb: THOM, MPI for Bio-
chemistry, Martinsried) were anaesthetised with CO2 gas and killed by breaking their
necks. The liver tissue (between 45 g and 60 g in total) was removed with surgeon scis-
sors at 4◦C and placed into ice-cold 0.5 M K/S (K/S buffer: 0.1 M potassium phosphate
pH 6.7, 5 mM MgCl2, varied Molarity of sucrose as indicated), supplemented with EDTA-
free Protease Inhibitor Cocktail (Roche Diagnostics, Mannheim). The liver tissue was cut
to small pieces with surgeon scissors and subsequently forced through a 150 μm steel
mesh sieve. The homogenate was transferred to 14 ml Beckman centrifuge tubes. Each
of the 6 tubes used was filled with 6.5 ml 0.86 M K/S and overlaid with 4 ml of the liver
homogenate in 0.5 M K/S. A layer of 2 ml 0.25 M K/S was applied on top. The gradient
was centrifuged for 60 min at 29000 rpm at 4◦C in a SW40 rotor in a Beckman Optima
LE-80K Ultracentrifuge (Beckman, USA). The cloudy interphase (crude Golgi fraction)
at the border of the 0.5 M K/S and 0.86 M K/S layer was collected for further processing.
The 0.5 M K/S fraction contained the cytosol. The crude Golgi fraction was adjusted to
a sucrose concentration of 0.25 M with 0.1 M Potassium phosphate pH 6.7, 5 mM MgCl2
and placed on top of a cushion of 1.3 M K/S in a fresh 14 ml Beckman centrifuge tube.
The mixture was centrifuged for 20 min at 7000 rpm at 4◦C (SW40, Beckman Optima
LE-80K). The Golgi membranes could be collected from the top of the cushion and were
frozen in aliquots on dry ice and stored at -80◦C. The quality and yield of the prepara-
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tion process was assayed by spectroscopic methods (see 4.5.1, p.133) and Western blot
with 10 μg of each homogenate, rat liver cytosol, interphase and purified membranes for
enrichment and possible degradation of GM130.
For experiments, Golgi membranes were often extracted with detergents. Golgi mem-
branes were thawed on ice and then centrifuged for 5 min at 20000 g and 4◦C and the
sucrose containing buffer removed. The pelleted Golgi membranes were then resuspended
in extraction buffer (50 mM Hepes/KOH pH 7.2, 200 mM NaCl, 0.5% Triton-X100 +
Protease Inhibitor Cocktail, Roche) for 30 min on ice and then centrifuged for 15 min at
20000 g and 4◦C.
4.7.3 Preparation Of Mammalian Cell Extracts
For mammalian cell extracts, cells were grown on 15 cm culture dishes to 80-90% conflu-
ency and, after washing with PBS, either scraped with a silicon cell scraper into 5-10 ml
ice-cold PBS or detached by 15 min of treatment with PBS/1 mM EDTA at 37 ◦C. The
cell suspension was centrifuged at 400 g at 4◦C for 5 min and the cell pellet resuspended
in the appropriate buffer (see Tab.11) for 30 min on ice for lysis. The cell extract was
centrifuged for 15 min at 20000 g, 4◦C in order to remove cell debris. The protein con-
centration in the supernatant was assayed (see 4.5.1, p.133).
Alternatively, cell extracts could be fractionated into membrane and cytosolic fraction.
For this cells were harvested as described above and resuspended into TMK-buffer (25 mM
Tris/HCl pH 7.3, 130 mM KCl, 5 mM MgCl2 + Inhibitor Cocktail), centrifuged again
and resuspended again in TMK. The cell suspension was passed through a 27 Gauge
syringe needle 20 times and centrifuged for 5 min at 20000 g and 4◦C. The supernatant
was ultracentrifuged in a Beckman TLA55 rotor at 50000 rpm and 4◦C for 30 min. The
supernatant comprised the cytosolic fraction, the pellet the membranous fraction. The
Table 11: List of Lysis Buffers used
Buffer Composition
TNTE 10 mM Tris/HCl pH 7.5, 150 mM NaCl, 0.3% Triton-
X100, 5 mM EDTA
RIPA 10 mM Tris/HCl pH 7.5, 150 mM NaCl, 1% Triton-
X100, 0.1% SDS, 1% sodium deoxycholate
Mammalian Lysis Buffer 50 mM Tris/HCl pH 7.5, 150 mM NaCl, 0.1% Triton X-
100
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membranes were then extracted for 30 min on ice in TMK plus 1% Triton-X100 and
processed as described above.
4.7.4 Preparation Of Tubulin From Pig Brain
As raw material about 25-50 fresh pig brains were acquired from the slaughter house
and transported in ice-cold PBS until further processing. The preparation of the brain
homogenate was done in the cold room at 4◦C. As a first step, the blood vessels and brain
skin were removed with normal paper towels and a scalpel. The brain matter was weighed
and the same volume of depolymerisation buffer added. Then the brain was mixed harsh
in a standard kitchen mixer to homogenise the tissue. The homogenate was cleared by
centrifugation in an SLA 1500 rotor at 13600 rpm for 1 h at 4◦C (Sorval RC3-C, Thermo
Scientific, USA). The supernatant was collected in a 5 l Erlenmeyer tube and the same
amount of HMPB (pre-warmed to 37◦C), 0.8265 mg/ml final volume ATP, 0.262 mg/ml
final volume GTP and 1 g/ml starting volume Glycerol were added and polymerisation
was allowed for 1 h in a 37◦C water bath with gentle shaking every 15 min. The mixture
was centrifuged at 37◦C in a Ti45 rotor at 44000 rpm for 30 min (Beckmann Optima
LE-80K). The pellets were collected in 100 ml/kg brain of depolymerisation buffer and
kept for 30 min at 4◦C. The next centrifugation step was done again in the Ti45 rotor
pre-cooled to 4◦C, at 30000 rpm for 30 min. The supernatant was mixed with its volume
37◦C-warm HMPB, 0.8265 mg/ml final volume ATP, 0.262 mg/ml final volume GTP and
1 g/ml starting volume Glycerol and incubated for 30 min at 37◦C with gentle shaking
every 5 min. The polymerised tubulin solution was again centrifuged for 30 min in a Ti45
rotor at 44000 rpm (151000 g) at 35◦C. The pellet was resuspended in 15 ml/kg brain
ice-cold BRB80 buffer and incubated on ice for 30 min. The last centrifugation step was
carried out twice in a TLA100.4 rotor for 10 min, 4◦C at 49000 rpm. The supernatant was
pooled, its concentration assayed by OD280 measurement and coomassie blue SDS-PAGE,
aliquoted and snap-frozen on dry-ice.
4.8 General Biochemical Methods
4.8.1 Small GTPase Effector Pulldown From Cell Extracts
For pulldown experiments a protein was immobilized on resin and incubated with cell
extract. Bound proteins were analysed by Western blotting. The methods used were dif-
ferent for Rab-effectors and Arl-/Arf-effectors as described below. Pulldown experiments
for Rab-effectors followed the description of Christoforidis and Zerial (2000), pulldown
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Table 12: Buffers for Tubulin Preparation from Pig Brain
Buffer Composition
Depolymerisation Buffer 50 mM MES/KOH pH 6.6; 1 mM CaCl2
HMPB (High Pipes) 1 M Pipes/KOH pH 6.9; 10 mM MgCl2;
20 mM EGTA
5xBRB80 (Brinkley BR buffer 1980) 400 mM Pipes/KOH pH 6.8; 5 mM MgCl2;
5 mM EGTA
with Arl-/Arf-GTPases followed Panic et al. (2003a) and Lu et al. (2005).
Rab Effector Pulldown 500 μg of GST-6xHis-tagged Rab protein was coupled to
50 μl of glutathione-S-sepharose beads (GE Healthcare, Sweden) in a volume of 500 μl
PBS for 1 h at 4◦C. Then, beads were washed three times in 500 μl NE100 buffer
(20 mM HEPES/NaOH pH 7.5, 100 mM NaCl, 10 mM EDTA, 0.1% Triton-X100); cen-
trifugation was done at 400 g, 4◦C for 5 min. In the meantime, the cell extract was
prepared as described (see 4.7.3, p.143), whereas NL100 buffer (20 mM HEPES/NaOH
pH 7.5, 100 mM NaCl, 5 mM MgCl2, 0.1% Triton-X100) was used for lysis. Cell extract
(1-5 mg protein) and glutathione-S-sepharose bound Rab-proteins were mixed and GDP
or GTP was added to a concentration of 100 μM and incubated for 2 h at 4◦C under
constant rolling. The beads were washed three times in NL100 buffer (centrifugation at
400 g, 4◦C, 5 min) and then either boiled in 50 μl SDS-sample buffer or extracted with
500 μl NE200 buffer (20 mM HEPES/NaOH pH 7.5, 200 mM NaCl, 20 mM EDTA, 0.1%
Triton-X100) for 10 min at 4 ◦C. The beads were centrifuged (400 g, 4◦C, 5 min) and the
supernatant was treated with fresh glutathione-S-sepharose beads for 10 min at 4◦C. This
step was repeated up to three times. The cleared supernatant was then TCA-precipitated
(see 4.5.2, p.133) and analysed by Western blotting (see 4.5.5, p.134).
Arf-/Arl-Effector Pulldown For Arf-/Arl-Effector Pulldown, 100 ml E.coli trans-
formed with the appropriate pFAT2-construct were grown and induced with IPTG for 2 h
at 22 ◦C. The bacteria were harvested, lysed (PBS, 5 mM MgCl2, 5 mM βMercaptoethanol,
200 μM GTP or GDP, 1% Triton-X100 and PIC) and bound for 30 min to 200 μl
glutathione-S-sepharose beads as described in 4.2.3 (p.126). The beads were washed three
times in wash buffer (lysis buffer w/o Triton-X100) and then the cell extract (see 4.7.3,
p.143) was directly applied to 50 μl of protein bound to beads and supplemented with
200 μM GDP or GTP. After 2 h of incubation at 4 ◦C and constant rolling, the beads
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were washed three times in lysis buffer containing 200 μM GDP or GTP and then boiled
in 50 μl SDS-PAGE sample buffer.
4.8.2 Co-Immunoprecipitation From Cell Extracts
A cell extract was prepared as described (see 4.7.3, p.143) and mixed with 2-20 μl of
the appropriate antibody (depending on antibody concentration and affinity) or 2 μl of
pre-immune serum as control and 20 μl packed Protein-A- or Protein-G-sepharose beads
(Amersham, Freiburg) The mix was incubated for 2 h at 4◦C under constant rolling. The
beads were centrifuged for 5 min at 400 g and 4◦C in order to pellet the beads. The
beads were washed three times with 500 μl lysis buffer and then boiled for 5 min in 30 μl
SDS-sample buffer and analysed by Western blotting (4.5.5, p.134).
4.8.3 Microtubule Assays
Microtubules were grown in vitro from tubulin purified from pig brain (see 4.7.4, p.144).
In vitro Preparation Of Microtubules 25 μl tubulin from pig brain (4 mg/ml;
40 μM) were mixed with 43.1 μl BRB80 buffer (Tab.12) containing 10 μM Taxol and with
3.1 μl 100 mM MgCl2, 3.1 μl 100 mM GTP and 3.7 μl DMSO and incubated for 30 min at
37◦C. The polymerised microtubules were then pipetted on top of a 40% glycerol cushion
(in BRB80 buffer) in a TLA100 rotor centrifuge tube (Beckman, USA) and centrifuged
in a Beckman Optima TLX-120 microcentrifuge for 15 min at 55000 rpm and 35◦C. The
supernatant was removed and the pellet washed with 50 μl BRB80 and 10 μM Taxol and
centrifuged again for 10 min. The pellet was then resuspended in 50 μl BRB80 buffer
and 50 μM Taxol by incubating for 30 min at room temperature and subsequent gentle
pipetting. The final microtubule concentration was 20 μM (2 mg/ml).
Microtubule Bundling For microtubule bundling experiments, microtubules were pre-
pared as described above whereas 1.5 μl rhodamine-labelled tubulin was added. For
bundling, 400 ng of purified, recombinant protein were incubated for 20 min at room tem-
perature with 1 μl rhodamine-labelled microtubules in BRB80 buffer and 10 μM Taxol.
One drop of the mixture was then applied to an objective slide, covered with a glass cover
slip and examined under an Axioskop-2 with a 40x Plan Apochromat objective of NA 1.3,
standard filter sets (Carl Zeiss GmbH, Germany), a 1300 by 1030 pixel cooled-CCD cam-
era model CCD-1300-Y (Princeton Instruments, USA) and MetaVue software (Visitron
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Systems GmbH, Puchheim). Images were cropped in Adobe Photoshop CS2 then sized
and placed in figures using Adobe Illustrator CS2 (Adobe Systems Inc., USA).
Microtubule Spin-Down Assays 400 ng of purified, recombinant protein were mixed
with 2 μl (4 μg) microtubules and 5 μl BRB80 buffer containing 50 μM Taxol in a
total volume of 20 μl. The mix was incubated for 20 min at room temperature and
then centrifuged in a Beckman Optima TLX-120 (Beckman, USA) in a TLA100 rotor at
55000 rpm, 25 ◦C for 20 min. A 75 μl 40% glycerol cushion was used to improve separation.
The pellet was washed with 50 μl BRB80 buffer and 50 μM Taxol and centrifuged again
for 20 min. The pellet was resuspended in 30 μl SDS-PAGE sample buffer and analysed
on coomassie stained SDS-PAGE (24 μl) and Western blotting (6 μl).
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Table 13: Plasmids used; abbreviations: pAH=Alexander Haas, pBS=Benjamin Short, pCP=Christian
Preisinger, pEF=Evelyn Fuchs, pFB=Francis Barr, pRK=Robert Kopajtich
pFB # Creator # Short Name Description
GMAP-210 Constructs
pFB2037 pJE001 pCRIITOPO-GMAP210 human GMAP210, BamHI-EcoRI/EcoRI-XhoI
has BamHI site in sequence (Nr.2)
pFB2037 pJE002 pCRIITOPO-GMAP210 human GMAP210, BamHI-EcoRI/EcoRI-XhoI
has BamHI site in sequence (Nr.11) K1827G ver-
sion
pFB2040 pJE004 pCRIITOPO-GMAP210(1-375) human GMAP210 N-Term aa 1-375, BamHI-
XhoI; derived from pFB2037
pFB2041 pJE005 pCRIITOPO-GMAP210(1598-1979) human GMAP210 C-Term aa 1598-1979, BamHI-
XhoI; S1827G version
pFB2215 pJE014 pCRIITOPO-GMAP210(618-803 Human GMAP210 aa 618-803 with STOP codon,
BamHI-XhoI, derived from pFB2037
pFB2216 pJE015 pCRIITOPO-GMAP210(855-1712) Human GMAP210 aa 855-1712 with STOP
codon, BglII-XhoI, derived from pFB2037
pFB2232 pJE031 pCRIITOPO-GMAP210(855-1332) Human GMAP210 aa 855-1332 with STOP
codon; BglII-XhoI, derived from pFB2037
pFB2233 pJE032 pCRIITOPO-GMAP210(1333-1712) Human GMAP210 aa 1333-1712 with STOP
codon; BamHI-XhoI, derived from pFB2037
pFB2710 pJE092 pCRIITOPO-GMAP210(1-375)’ human GMAP210 aa 1-375; no stop codon;
BamHI XhoI
pFB2711 pJE093 pCRIITOPO-GMAP210(1598-
1979)’
human GMAP210 aa 1598-1979; no stop codon;
BamHI XhoI
pFB2712 pJE094 pCRIITOPO-GMAP210’ human GMAP210; no stop codon, BamHI XhoI
pFB2713 pJE095 pCRIITOPO-GMAP210(1598-1778) human GMAP210 aa 1598-1778; BamHI XhoI
pFB2714 pJE096 pCRIITOPO-GMAP210(1779-1979) human GMAP210 aa 1779-1979, BamHI XhoI
pFB2717 pJE099 pCRIITOPO-GMAP210(1598-1979)
D1780A L1783A
human GMAP210 aa 1598-1979; D1780A and
L1783A mutation; BamHI XhoI; S1827G
pFB2721 pJE103 pCRIITOPO-GMAP210(1779-1838) human GMAP210 aa 1779-1838, BamHI XhoI
pFB2849 pJE143 pCRIITOPO-GMAP210 D1780A
L1783A
human GMAP210; mutation D1780A and
L1783A; BamHI-EcoRI/EcoRI-XhoI
pFB2857 pJE151 pCRIITOPO-GMAP210(1757-1979) human GMAP210 aa 1757-1979; BamHI XhoI
pFB2858 pJE152 pCRIITOPO-GMAP210(1757-1838) human GMAP210 aa 1757-1838; BamHI XhoI
pFB3019 pJE154 pCRIITOPO-GMAP210(1757-1875) human GMAP210 aa 1757-1875; BamHI XhoI
pFB3291 pJE225 pCRIITOPO-GMAP-210(1598-
1979)
human GMAP-210 aa 1598-1979; S1827 version;
BamHI XhoI
pFB3292 pJE226 pCRIITOPO-GMAP-210(1598-
1979)DALA
human GMAP-210 aa 1598-1979; D1780A
L1783A mutant; S1827 version; BamHI XhoI
pFB4183 pJE292 pCRIITOPO-GMAP-210ΔBamHI human GMAP-210 without BamHI (silent muta-
tion) in the sequence; BamHI XhoI
pFB4184 pJE293 pCRIITOPO-GMAP-210(1-1712) human GMAP-210 aa 1-1712 (PCR from
pFB4183; no internal BamHI); BamHI XhoI
pFB4185 pJE294 pCRIITOPO-GMAP-210(1683-
1875)
human GMAP-210 aa 1683-1875; BamHI XhoI;
GRAB domain plus coiled-coil
pFB4364 pJE316 pCRIITOPO-GMAP-210(1-1332) human GMAP-210 aa 1-1332; BamHI XhoI; has
internal BamHI: cut BamHI-EcoRI EcoRI-XhoI
pFB2226 pJE025 pAct2-GMAP210 Human GMAP210; BamHI-XhoI, derived from
2037
pFB2227 pJE026 pAct2-GMAP210(1-375) Human GMAP210 aa 1-375 with STOP codon,
BamHI-XhoI, derived from pFB2040
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pFB2228 pJE027 pAct2-GMAP210(1598-1979) Human GMAP210 aa 1598-1979 with STOP
codon, BamHI-XhoI, derived from pFB2041;
S1827G
pFB2229 pJE028 pAct2-GMAP210(855-1712) Human GMAP210 aa 855-1712 with STOP
codon, BglII-XhoI, derived from pFB2037
pFB2230 pJE029 pAct2-GMAP210(618-803) Human GMAP210 aa 618-803 with STOP codon,
BamHI-XhoI, derived from pFB2037
pFB2234 pJE033 pAct2-GMAP210(855-1332) Human GMAP210 aa 855-1332 with STOP
codon; BglII-XhoI, derived from pFB2037
pFB2235 pJE034 pAct2-GMAP210(1332-1712) Human GMAP210 aa 1333 712 with STOP codon;
BamHI-XhoI, derived from pFB2037
pFB2737 pJE119 pAct2-GMAP210(1779-1979) human GMAP210 aa 1779-1979, from pFB2714
pFB2844 pJE138 pAct2-GMAP210(1598-1979)
D1780A L1783A
human GMAP210 aa 1598-1979; D1780A and
L1783A mutation; from pFB2717; S1827G
pFB3361 pJE242 pAct2-GMAP210(1598-1979) S1827 human GMAP210 aa 1598-1979; derived from
pFB3291
pFB3362 pJE243 pAct2-GMAP210(1598-1979)
D1780A L1783A S1827
human GMAP210 aa 1598-1997; D1780A L1783A
mutant; from pFB3292
pFB4472 pJE334 pAct2-GMAP-210(1683-1875) human GMAP-210 aa 1683-1875; from pFB4185
pFB4473 pJE335 pAct2-GMAP-210(1683-
1875)D1780A L1783A
human GMAP-210 aa 1683-1875; GRAB mutant
pFB2043 pJE006 pQE32Tev-GMAP210(1-375) human GMAP210 N-Term aa 1-375, BamHI-
XhoI; derived from pFB2040 ; expression in
JM109; protein insoluble
pFB2739 pJE121 pFAT2-GMAP210(1-375) human GMAP210 aa 1-375, from pFB2040
pFB2846 pJE140 pAcHis-GMAP210 human GMAP210; from pFB2037; sequenced
pFB3295 pJE229 pAcHis-GMAP-210(1-375) human GMAP-210 aa 1-375; from pFB2040; se-
quenced
pFB3352 pJE233 pAcHis-GMAP210(1598-1979) S1827 human GMAP210 aa 1598-1979; derived from
pFB3291
pFB2220 pJE019 pEGFPC2-GMAP210(1598-1979) Human GMAP210 aa 1598-1979 with STOP
codon, BamHI-XhoI, derived from pFB2041;
S1827G
pFB2221 pJE020 pEGFPC2-GMAP210d(1-375) Human GMAP210 aa 1-375 with STOP codon,
BamHI-XhoI, derived from pFB2040
pFB2740 pJE122 pEGFPN3-GMAP210 human GMAP210; from pFB2712
pFB2746 pJE128 pEGFPC2-GMAP210(1779-1979) human GMAP210 aa 1779-1979; from pFB2714
pFB2747 pJE129 pEGFPN3-GMAP210(1-375) human GMAP210 aa 1-375; from pFB2710
pFB2748 pJE130 pEGFPN3-GMAP210(1598-1979) human GMAP210 aa 1598-1979; from pFB2711
pFB3145 pJE206 pEGFPC2-GMAP210/1757-1979) human GMAP210 aa 1757-1979; from pFB2857
pFB3149 pJE210 pEGFPC2-GMAP210(1757-1838) human GMAP210 aa 1757-1838; from pFB2858
pFB3159 pJE220 pEGFPC2-GMAP210(1757-1875) human GMAP210 aa 1757-1875 from pFB3019
pFB4186 pJE295 pEGFPC2-GMAP-210(1598-1979)
DALA
human GMAP-210 C-Terminus aa 1598-1979;
D1780A L1783A mutation;
pFB4187 pJE296 pEGFPN3-GMAP-210 DALA human GMAP-210 D1780A L1783A mutation
pFB4188 pJE297 pEGFPC2-GMAP-210 human GMAP-210; derived from pFB4183
pFB4189 pJE298 pEGFPC2-GMAP-210(1757-1875)
DALA
human GMAP-210 aa 1757-1875; GRAB domain
with D1780A L1783A mutation
pFB4190 pJE299 pEGFPC2-GMAP-210(1-1712) human GMAP-210 aa 1-1712; dervied from
pFB4184
pFB4366 pJE318 pEGFPC2-GMAP-210(1598-1778) human GMAP-210 aa 1598-1778; derived from
pFB2713
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pFB4367 pJE319 pEGFPC2-GMAP-210(1683-1875) human GMAP-210 aa 1683-1875; GRAB domain
plus coiled-coil; derived from pFB4185
pFB4372 pJE324 pEGFPC2-GMAP-210(855-1712) human GMAP-210 aa 855-1712; derived from
pFB2216
pFB4469 pJE331 pEGFPC2-GMAP-210(1598-
1979)S1827
human GMAP-210 aa 1598-1979; S1827 variant;
derived from pFB3291
pFB4470 pJE332 pEGFPC2-GMAP-210(1-1332) human GMAP-210 aa 1-1332; derived from
pFB4364
pFB4471 pJE333 pEGFPC2-GMAP-210(1683-
1875)D1780A L1783A
human GMAP-210 aa 1683-1875; D1780A
L1783A mutant; GRAB mutant
pFB4820 pJE418 pdsRed-GMAP-210 human GMAP-210; derived from pFB4183; weak
exp. in HeLaL
pFB4821 pJE419 pdsRed-GMAP-210(1-1712) human GMAP-210; aa 1-1712; derived from
pFB4184; weak exp. in HeLaL
pFB4822 pJE420 pdsRed-GMAP-210(1683-1875) human GMAP-210; aa 1683-1875; coiled-coil plus
GRAB; derived from pFB4185; weak exp. in
HeLaL
pFB4970 pJE472 pEGFPC2-GMAP-210(618-803) human GMAp-210; aa 618-803; derived from
pFB2215
pFB4971 pJE473 pEGFPC2-GMAP-210(855-1332) human GMAP-210; aa 855-1332; derived from
pFB2232
pFB4972 pJE474 pEGFPC2-GMAP-210(1333-1712) human GMAP-210; aa 1333-1712; derived fom
pFB2233
Rud3p Constructs
pFB391 pCRII-
GRP1
G RP1/RUD3 fl Full length GRP1/RUD3 (yeast golgin-160 homo-
logue) BamHI cassette
pFB393 pACT2
GRP1.1
Gal4AD GRP1.1 Gal4AD full-length GRP1/RUD3 fusion
pFB3153 pJE214 pCR2.1TOPO-Rud3 S.cerevisiae Rud3p; BamHI SalI
pFB3351 pJE232 pAct2-Rud3 S.cerevisiae Rud3p from pFB3153
pFB4192 pJE301 pMyc-Rud3 S.cerevisiae Rud3; derived from pFB3153
Golgins
pFB2722 pJE104 pCRIITOPO-Golgin97 human Golgin97, BclI SalI; from dam+ bacteria
(BclI resistant)
pFB2856 pJE150 pCRIITOPO-Golgin97 Y697A human Golgin97 Y697A GRIP mutation;
BclI/SalI
pFB3436 pJE247 PCRIITOPO-Golgin-84 human Golgin-84; with stop codon; BamHI SalI
pFB2845 pJE139 pAct2-Golgin97 human Golgin97; from pFB2722
pFB3141 pJE202 pAct2-Golgin97Y697A human Golgin97 GRIP Arl1 binding mutation
pFB3020
pFB3441 pJE252 pAct2-Golgin-84 human Golgin-84; from pFB3436
Golgin-84
pFB3436 pJE247 PCRIITOPO-Golgin-84 human Golgin-84; with stop codon; BamHI SalI
pFB3441 pJE252 pAct2-Golgin-84 human Golgin-84; from pFB3436
IFT20 Constructs
pFB2048 pJE011 pCRIITOPO-IFT20 human IFT20, BamHI-SalI; only bp 1-213(aa 1-
71), then gap and frame-shift, seems to exist, with
longer 3’-end; seems to function in plasmids with
stop-codon!
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pFB4889 pJE437 pCRIITOPO-IFT20(F2R2) human IFT20; F2 R2 Primer used; BamHI SalI
pFB4890 pJE438 pCRIITOPO-IFT20(F2R2)’ human IFT20; nostop; F2 R2’ Primer used;
BamHI SalI
pFB4891 pJE439 pCRIITOPO-IFT20(F2R3) human IFT20; F2 R3 Primer used; BamHI SalI
pFB4892 pJE440 pCRIITOPO-IFT20(F2R3)’ human IFT20; nostop; F2 R3’ Primer used;
BamHI SalI
pFB4893 pJE441 pCRIITOPO-IFT20(F3R3) human IFT20; F3 R3 Primer used; BamHI SalI
pFB4894 pJE442 pCRIITOPO-IFT20(F3R3)’ human IFT20; nostop; F3 R3’ Primer used;
BamHI SalI
pFB4895 pJE443 pCRIITOPO-IFT20(F3R2) human IFT20; F3 R2 Primer used; BamHI SalI
pFB4896 pJE444 pCRIITOPO-IFT20(F3R2)’ human IFT20; nostop; F3 R2’ Primer used;
BamHI SalI
pFB4957 pJE459 pAct2-IFT20old human IFT20; derived from pFB2048
pFB4952 pJE454 pFBT10-IFT20(33)’ human IFT20; F3 R3’ primer used; derived from
pFB4894
pFB4953 pJE455 pFBT9-IFT20(32) human IFT20; F3 R2 Primer used; derived from
pFB4895
pFB4954 pJE456 pFBT9-IFT20(23) human IFT20; F2 R3 Primer used; derived from
pFB4891
pFB4955 pJE457 pFBT9-IFT20(33) human IFT20; F3 R3 Primer used; derived from
pFB4893
pFB4956 pJE458 pFBT9-IFT20old human IFT20; derived from pFB2048
pFB2049 pJE012 pQE32Tev-IFT20 human IFT20, BamHI-SalI; expresses in JM109
only 3h/37Â̊ C; dialyse protein in Tris/300mM
NaCl; derived from pFB2048
pFB2051 pJE013 pEGFPC2-IFT20 human IFT20, BamHI-SalI, derived from
pFB2048
pFB4943 pJE445 pEGFPC2-IFT20(22) human IFT20; F2 R2 Primer used; derived from
pFB4889
pFB4944 pJE446 pEGFPN3-IFT20(22)’ human IFT20; F2 R2’ Primer used; derived from
pFB4890
pFB4945 pJE447 pEGFPC2-IFT20(23) human IFT20; F2 R3 Primer used; derived from
pFB4891
pFB4946 pJE448 pEGFPN3-IFT20(23)’ human IFT20; F2 R3’ Primer used; derived from
PFB4892
pFB4947 pJE449 pEGFPC2-IFT20(32) human IFT20; F3 R2 Primer used; derived from
pFB4895
pFB4948 pJE450 pEGFPN3-IFT20(32)’ human IFT20; F3 R2’ Primer used; derived from
pFB4896
pFB4949 pJE451 pEGFPC2-IFT20(33)’ human IFT20; F3 R3’ Primer used; insert has no
stop codon, but vector; derived from pFB4894
pFB4950 pJE452 pEGFPN3-IFT20(33)’ human IFT20; F3 R3’ Primer used; derived from
pFB4894
pFB4951 pJE453 pEGFPC2-IFT20(33) human IFT20; F3 R3 Primer used; derived from
pFB4893
Heterotrimeric Kinesin II Kif3B
pFB4877 pJE425 pCRIITOPO-Kif3B human Kif3B; BclI XhoI
pFB4879 pJE427 pCRIITOPO-Kif3B’ human Kif3B; nostop; BclI XhoI
pFB4885 pJE433 pCRIITOPO-Kif3B(592-747) human Kif3B; aa 592-747; BclI XhoI
FB4887 pJE435 pCRIITOPO-Kif3B(592-747)’ human Kif3B; aa 592-747; nostop; BclI XhoI
pFB4963 pJE465 pEGFPN3-Kif3B’ human Kif3B; derived from pFB4880
pFB4967 pJE469 pEGFPN3-Kif3B(592-747)’ human Kif3B; aa 592-747; derived from pFB4888
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pFB4962 pJE464 pEGFPC2-Kif3B human Kif3B; derived from pFB4878
pFB4966 pJE468 pEGFPC2-Kif3B(592-747) human Kif3B; aa 592-747; derived from pFB4886
ADP-Ribosylation Factor Constructs
pFB2191 pRK pCRIITOPO-Arf1 Human Arf1, BamHI+XhoI
pFB3619 pJE264 pCRIITOPO-Arf1ΔN14Q71L human Arf1; deleted AA 1-14; GTP-locked;
BamHI XhoI
pFB3635 pJE280 pCRIITOPO-Arf1Q71A human Arf1; GTP-locked by Q to A mutation;
BamHI XhoI
pFB4195 pJE304 pCRIITOPO-Arf1ΔN14 human Arf1; without aa 1-14; BamHI XhoI
pFB4195 pJE304 pCRIITOPO-Arf1ΔN14 human Arf1; without aa 1-14; BamHI XhoI
pFB2192 pRK pCRIITOPO-Arf3 human Arf3, BamHI+XhoI
pFB2273 pRK pCRIITOPO-Arf3Q71L Human Arf3, BamHI+XhoI, GTP mutant, de-
rived from pFB2192
pFB2193 pRK pCRIITOPO-Arf4 human Arf4, BamHI+XhoI
pFB2274 pRK pCRIITOPO-Arf4Q71L Human Arf4, BamHI+XhoI, GTP mutant, de-
rived from pFB2193
pFB2194 pRK pCRIITOPO-Arf5 human Arf5, BamHI+XhoI
pFB2275 pRK pCRIITOPO-Arf5Q71L Human Arf5, BamHI+XhoI, GTP mutant, de-
rived from pFB2194
pFB2195 pRK pCRIITOPO-Arf6 human Arf6, BglII+XhoI
pFB2276 pRK pCRIITOPO-Arf6Q67L Human Arf6, Bgl II+XhoI, GTP mutant, derived
from pFB2195
pFB2282 pRK pFBT9-Arf1Q71L Human Arf1, BamHI+XhoI, GTP mutant, de-
rived from pFB2272
pFB2571 pRK pFBT9-Arf1wt Human Arf wt, derived from pFB 2191
pFB4200 pJE309 pFBT9-Arf1Q71A human Arf1; GTP-locked (QA); derived from
pFB3635
pFB4204 pJE313 pFBT9-Arf1ΔN14 Q71L human Arf1; GTP-locked (QL); without aa 1-14;
derived from pFB3619
pFB2283 pRK pFBT9-Arf3Q71L Human Arf3, BamHI+XhoI, GTP mutant, de-
rived from pFB2273
pFB2572 pRK pFBT9-Arf3wt Human Arf wt, derived from pFB 2192
pFB2284 pRK pFBT9-Arf4Q71L Human Arf4, BamHI+XhoI, GTP mutant, de-
rived from pFB2274
pFB2573 pRK pFBT9-Arf4wt Human Arf wt, derived from pFB 2193
pFB2285 pRK pFBT9-Arf5wt Human Arf5, BamHI+XhoI, derived from
pFB2275
pFB2574 pRK pFBT9-Arf5QL Human Arf Q71L, derived from pFB 2275
pFB2286 pRK pFBT9-Arf6Q67L Human Arf6, Bgl II+XhoI, GTP mutant, derived
from pFB2276, same as pFB2410
pFB2409 pRK pFBT9-Arf6 wt Human Arf6 wt, derived from pFB2195
pFB3624 pJE269 pFAT2-Arf1 human Arf1; dervied from pFB2191
pFB3625 pJE270 pFAT2-Arf1Q71L human Arf1; GTP-locked; derived from pFB2272
pFB4202 pJE311 pFAT2-Arf1Q71A human Arf1; GTP-locked (QA); derived from
pFB3635
FB4203 pJE312 pFAT2-Arf1ΔN14 Q71L human Arf1; GTP-locked (QL); without aa 1-14;
derived from pFB3619
pFB4363 pJE315 pFAT2-Arf1ΔN14 human Arf1; without aa 1-14; derived from
pFB4195
pFB4817 pJE415 pFAT2-Arf3 human Arf3; derived from pFB2192
pFB4716 pJE381 pFAT2-Arf6 human Arf6; derived from pFB2195
pFB4717 pJE321 pFAT2-Arf6QL human Arf6; GTP-locked; derived from pFB2276
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pFB2400 pRK pEGFPN3-Arf1 wt Human Arf1 wt, derived from pFB2390
pFB2405 pRK pEGFPN3-Arf1 Q71L Human Arf1 Q71L, GTP mutant, derived from
pFB2395
pFB2401 pRK pEGFPN3-Arf3 wt Human Arf3 wt, derived from pFB2391
pFB2406 pRK pEGFPN3-Arf3 Q71L Human Arf3 Q71L, GTP mutant, derived from
pFB2396
pFB2402 pRK pEGFPN3-Arf4 wt Human Arf4 wt, derived from pFB2392
pFB2403 pRK pEGFPN3-Arf5 wt Human Arf5 wt, derived from pFB2393
pFB2407 pRK pEGFPN3-Arf5 Q71L Human Arf5 Q71L, GTP mutant, derived from
pFB2398
pFB2404 pRK pEGFPN3-Arf6 wt Human Arf6 wt, derived from pFB2394
pFB2408 pRK pEGFPN3-Arf6 Q67L Human Arf6 Q67L, GTP mutant, derived from
pFB2399
pFB4115 pAH600 pCRIITOPO-Sar1a WT Human Sar1a WT from HeLa cDNA, BamHI,
XhoI
pFB4116 pAH601 pCRIITOPO-Sar1a H79G Human Sar1a H79G, GTP locked, from pFB4115,
BamHI, XhoI
pFB4119 pAH604 pFBT9-Sar1a H79G Human Sar1a H79G, GTP locked, from pFB4116.
pFB3021 pJE156 pCRIITOPO-ScArf1 yeast Arf1; BamHI XhoI
pFB3037 pJE168 pCRIITOPO-ScArf1Q71L S.cerevisiae Arf1 with Q71L mutation GTP-
locked; BamHI XhoI
pFB3294 pJE228 pCRIITOPO-ScArf1ΔN14 S.cerevisiae Arf1 deleted aa 1-14; BamHI XhoI
pFB3443 pJE254 pCRIITOPO-ScArf1Q71LΔN14 S.cerevisiae Arf1 deleted aa 1-14; GTP-locked;
BamHI XhoI
pFB3617 pJE262 pCRIITOPO-ScArf1Q71L’ S.cerevisiae Arf1; GTP-locked; no stop codon;
BamHI XhoI
pFB3618 pJE263 pCRIITOPO-ScArf1’ S.cerevisiae Arf1; no stop codon; BamHI XhoI
pFB3038 pJE169 pFBT9-ScArf1Q71L S.cerevisiae Arf1 with Q71L mutation GTP-
locked; BamHI XhoI; sequenced
pFB3085 pJE191 pFBT9-ScArf1 S.cerevisiae Arf1 wt; from pFB3021;
pFB3444 pJE255 pFBT9-ScArf1Q71LΔN14 S.cerevisiae Arf1 deleted aa 1-14; GTP-locked;
from pFB3443
pFB3147 pJE208 pFAT2-ScArf1 S.cerevisiae Arf1 wt; from pFB3021;
pFB3148 pJE209 pFAT2-ScArf1QL S.cerevisiae Arf1 GTP-locked; from pFB3037
pFB3359 pJE240 pFAT2-ScArf1ΔN14 S.cerevisiae Arf1 deleted aa 1-14; from3294
pFB3446 pJE257 pFAT2-ScArf1Q71LΔN14 S.cerevisiae Arf1 deleted aa 1-14; GTP-locked;
from pFB3443
pFB4193 pJE302 pEGFPN3-ScArf1 S.cerevisiae Arf1; derived from pFB3618
pFB4194 pJE303 pEGFPN3-ScArf1QL S.cerevisiae Arf1; GTP-locked; derived from
pFB3617
ADP-Ribosylation Factor-Likes Constructs
pFB2623 pJE035 pCRIITOPO.Arl1 Human Arl1, BamHI XhoI
pFB2626 pJE038 pCRIITOPO.Arl1Q71L human Arl1Q71L, GTP-locked BamHI XhoI
pFB3293 pJE227 pCRIITOPO-Arl1ΔN14 human Arl1 deleted aa 1-14; BamHI XhoI
pFB3442 pJE253 pCRIITOPO-Arl1Q71LΔN14 human Arl1 deleted aa 1-14; GTP-locked; BamHI
XhoI
pFB3616 pJE261 pCRIITOPO-Arl1’ human Arl1; BamHI XhoI; no stop codon
pFB3634 pJE279 pCRIITOPO-Arl1Q71L’ human Arl1; GTP-locked, no stop codon; BamHI
XhoI
pFB3882 pJE282 pCRIITOPO-Arl1Q71A human Arl1; GTP-locked (QA); BamHI XhoI
pFB4675 pJE340 pCRIITOPO-Arl1T31N human Arl1 GDP-locked; BamHI XhoI; derived
from pFB2623
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pFB4676 pJE341 pCRIITOPO-Arl1ΔN14 T31N human Arl1 deletion 1-14; GDP-locked; derived
from pFB3293
pFB2628 pJE040 pCRIITOPO-Arl2 human Arl2, BamHI XhoI
pFB2704 pJE086 pCRIITOPO-Arl2Q70L human Arl2, GTP-locked; BamHI XhoI
pFB4677 pJE342 pCRIITOPO-Arl2’ human Arl2 no-stop codon; derived from
pFB2628
pFB4678 pJE343 pCRIITOPO-Arl2QL’ human Arl2 no-stop codon; GTP-locked; derived
from pFB2704
pFB2631 pJE043 pCRIITOPO-Arl3 human Arl3, BamHI XhoI
pFB2705 pJE087 pCRIITOPO-Arl3Q71L human Arl3, GTP-locked; BamHI XhoI
pFB4679 pJE344 pCRIITOPO-Arl3’ human Arl3 no-stop; derived from pFB2631
pFB4680 pJE345 pCRIITOPO-Arl3QL’ human Arl3 no-stop; GTP-locked; derived from
pFB2705
pFB2634 pJE046 pCRIITOPO-Arl4A human Arl4A, BamHI XhoI
pFB2635 pJE047 pCRIITOPO-Arl4A’ human Arl4A, BamHI XhoI, no stop codon
pFB2636 pJE048 pCRIITOPO-Arl4A Q79L human Arl4A Q79L, GTP-locked, BamHI XhoI;
pFB2702 pJE084 pCRIITOPO-Arl4A Q79L’ human Arl4A, GTP-locked; no stop codon
pFB3133 pJE194 pCRIITOPO-Arl4A T34N human Arl4 GDP-locked; BamHI XhoI
pFB4463 pJE325 pCRIITOPO-Arl4A ΔN14 human Arl4A aa 1-14 deleted, BamHI XhoI
pFB3022 pJE157 pCRIITOPO-Arl4B human Arl4B; BamHI XhoI
pFB3032 pJE163 pCRIITOPO-Arl4B’ human Arl4B without stopcodon; BamHI XhoI
pFB2648 pJE059 pCRIITOPO-Arl4C’ human Arl4C, no stop codon, BamHI XhoI
pFB2649 pJE060 pCRIITOPO-Arl4C Q72L human Arl4C, GTP-locked, BamHI XhoI
pFB2650 pJE061 pCRIITOPO-Arl4C Q72L’ human Arl4C, GTP-locked, no stop codon,
BamHI XhoI
pFB3131 pJE192 pCRIITOPO-Arl4C T27N human Arl4C GDP-locked, BamHI XhoI
pFB4464 pJE326 pCRIITOPO-Arl4C ΔN14 human Arl4C aa 1-14 deleted, BamHI XhoI
pFB4681 pJE346 pCRIITOPO-Arl4D human Arl4D (ARF4L); BamHI XhoI
pFB4682 pJE347 pCRIITOPO-Arl4D’ human Arl4D no-stop; derived from pFB4681
pFB2641 pJE052 pCRIITOPO-Arl5A human Arl5A, BamHI XhoI
pFB2706 pJE088 pCRIITOPO-Arl5A Q70L human Arl5A, GTP-locked; BamHI XhoI
pFB4683 pJE348 pCRIITOPO-Arl5A’ human Arl5A nostop; derived from pFB2641
pFB4684 pJE349 pCRIITOPO-Arl5A QL’ human Arl5A nostop; GTP-locked; derived from
pFB2706
pFB2657 pJE068 pCRIITOPO-Arl5B human Arl5B, BamHI XhoI
pFB2708 pJE090 pCRIITOPO-Arl5B Q70L human Arl5B, GTP-locked; BamHI XhoI
pFB2644 pJE055 pCRIITOPO-Arl6 human Arl6, BamHI XhoI
pFB2707 pJE089 pCRIITOPO-Arl6Q73L human Arl6, GTP-locked; BamHI XhoI
pFB4685 pJE350 pCRIITOPO-Arl6’ human Arl6 nostop; derived from pFB2644
pFB4686 pJE351 pCRIITOPO-Arl6QL’ human Arl6 nostop; GTP-locked; derived from
pFB2707
pFB3023 pJE158 pCRIITOPO-Arl8A human Arl8A; BamHI XhoI
pFB3033 pJE164 pCRIITOPO-Arl8A’ human Arl8A without stopcodon; BamHI XhoI
pFB3024 pJE159 pCRIITOPO-Arl8B human Arl8B; BamHI XhoI
pFB3034 pJE165 pCRIITOPO-Arl8B’ human Arl8B without stopcodon; BamHI XhoI
pFB2660 pJE071 pCRIITOPO-Arl11 human Arl11, BamHI XhoI; C148R mutant: EST
clones exist
pFB4694 pJE359 pCRIITOPO-Arl11’ human Arl11 nostop; derived from pFB2660
pFB4689 pJE354 pCRIITOPO-Arl14 human Arl14; BamHI XhoI
pFB4690 pJE355 pCRIITOPO-Arl14’ human Arl14 nostop; derived from pFB4689
pFB4691 pJE356 pCRIITOPO-Arl15 human Arl15; BamHI XhoI
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pFB4692 pJE357 pCRIITOPO-Arl15’ human Arl15 nostop; derived from pFB4691
pFB4693 pJE358 pCRIITOPO-Arl16 human Arl16; BamHI XhoI
pFB4789 pJE387 pCRIITOPO-Arl16’ human Arl16; nostop; BamHI XhoI;
pFB4785 pJE383 pCRIITOPO-ARD1’ human ARD1; nostop; BamHI XhoI, Arl-Related-
Domain
pFB4786 pJE384 pCRIITOPO-ARD1 human ARD1; BamHI XhoI, Arl-Related-Domain
pFB4695 pJE360 pCRIITOPO-ARD2 human ARD2; BamHI XhoI
pFB4787 pJE385 pCRIITOPO-ARD2’ human ARD2; nostop; BamHI XhoI; Arl-Related-
Domain; also Arl13B
pFB4696 pJE361 pCRIITOPO-ARD3 human ARD3; BamHI SalI
pFB4788 pJE386 pCRIITOPO-ARD3’ human ARD3; nostop; BamHI SalI; Arl-Related-
Domain; also Arl13A
pFB2663 pJE074 pCRIITOPO-AFRP1 human AFRP1, BamHI XhoI
pFB2664 pJE075 pCRIITOPO-AFRP1’ human AFRP1, BamHI XhoI, no stop codon
pFB2703 pJE085 pCRIITOPO-AFRP1Q79L human AFRP1, GTP-locked; BamHI XhoI
pFB2855 pJE149 pCRIITOPO-AFRP1Q79L’ human AFRP1 Q79L GTP-locked; no stop codon
pFB2624 pJE036 pFBT9-Arl1 human Arl1, from pFB2623
pFB2627 pJE039 pFBT9-Arl1Q71L human Arl1Q71L, GTP-locked
pFB2661 pJE072 pFBT9-Arl11 human Arl11, from pFB2660
pFB3349 pJE230 pFBT9-Arl1ΔN14 human Arl1 deleted aa 1-14; derived from
pFB3293
pFB4199 pJE308 pFBT9-Arl1Q71A human Arl1; GTP-locked (QA); derived from
pFB3882
pFB4205 pJE314 pFBT9-Arl1ΔN14 Q71L human Arl1; without aa 1-14; GTP-locked (QL);
derived from pFB3442
pFB4697 pJE362 pFBT9-Arl15 human Arl15; derived from pFB4691
pFB4811 pJE409 pFBT9-Arl14 human Arl14; derived from pFB4689
pFB4812 pJE410 pFBT9-Arl16 human Arl16; derived from pFB4693
pFB2629 pJE041 pFBT9-Arl2 human Arl2, from pFB 2628
pFB2837 pJE131 pFBT9-Arl2Q70L human Arl2Q70L GTP-locked; from pFB2704
pFB2632 pJE044 pFBT9-Arl3 human Arl3, from pFB2631
pFB2839 pJE133 pFBT9-Arl3Q71L human Arl3 Q71L; GTP-locked; from pFB2705
pFB2637 pJE049 pFBT9-Arl4A human Arl4A, from pFB2634; now Arl4AW
pFB2638 pJE050 pFBT9-Arl4A Q79L human Arl4A, from pFB2636; now Arl4AW
pFB3154 pJE215 pFBT9-Arl4A T31N human Arl4A GDP-locked
pFB3072 pJE178 pFBT9-Arl4B human Arl4B; from pFB3022
pFB2651 pJE062 pFBT9-Arl4C human Arl4C, from pFB2647
pFB2696 pJE078 pFBT9-Arl4C Q72L human Arl7, GTP-locked, from pFB2649
pFB3356 pJE237 pFBT9-Arl4C T27N human Arl4C GDP-locked; from pFB3131
pFB4714 pJE279 pFBT9-Arl4D human Arl4D (ARF4L); derived from pFB4681
pFB2642 pJE053 pFBT9-Arl5A human Arl5A, from pFB2641
pFB2838 pJE132 pFBT9-Arl5A Q70L human Arl5A Q70L; GTP-locked; from pFB2706
pFB2658 pJE069 pFBT9-Arl5B human Arl5B, from pFB2657
pFB2841 pJE135 pFBT9-Arl5B Q70L human Arl5B Q70L GTP-locked; from pFB2708
pFB2645 pJE056 pFBT9-Arl6 human Arl6, from pFB2644
pFB2840 pJE134 pFBT9-Arl6Q73L human Arl6 Q73L GTP-locked; from pFB2707
pFB3073 pJE179 pFBT9-Arl8A human Arl8A; from pFB3023
pFB3152 pJE213 pFBT9-Arl8B human Arl8B from pFB3024
pFB2661 pJE072 pFBT9-Arl11 human Arl11, from pFB2660
pFB4811 pJE409 pFBT9-Arl14 human Arl14; derived from pFB4689
pFB4697 pJE362 pFBT9-Arl15 human Arl15; derived from pFB4691
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pFB4812 pJE410 pFBT9-Arl16 human Arl16; derived from pFB4693
pFB4815 pJE413 pFBT9-ARD1 human ARD1; Arl-Related-Domain; derived from
pFB4786
pFB4813 pJE411 pFBT9-ARD2 human ARD2; Arl13B; derived from pFB4695
pFB4814 pJE412 pFBT9-ARD3 human ARD3; Arl13A; derived from pFB4696
pFB2665 pJE076 pFBT9-AFRP1 human AFRP1, from pFB2663
pFB2843 pJE137 pFBT9-AFRP1Q79L human AFRP1, GTP-locked; from pFB2703
pFB2625 pJE037 pFAT2-Arl1 human Arl1, from pFB2623
pFB2697 pJE079 pFAT2-Arl1Q71L human Arl1, GTP-locked, from pFB2626
pFB3360 pJE241 pFAT2-Arl1ΔN14 human Arl1 deleted aa 1-14; derived from
pFB3293
pFB3445 pJE256 pFAT2-Arl1Q71LΔN14 human Arl1 deleted aa 1-14; GTP-locked; from
pFB3442
pFB4818 pJE416 pFAT2-Arl1T31N human Arl1; GDP-locked; derived from pFB4675
pFB4819 pJE417 pFAT2-Arl1(d1-14)T31N human Arl1; GDP-locked; deletion aa 1-14; de-
rived from pFB4676
pFB2698 pJE080 pFAT2-Arl4A human Arl4A; from pFB2634
pFB2699 pJE081 pFAT2-Arl4A Q79L human Arl4A; GTP-locked from pFB2636
pFB4466 pJE328 pFAT2-Arl4A ΔN14 human Arl4A aa 1-14 deleted; from pFB4463
pFB2652 pJE063 pFAT2-Arl4C human Arl4C, from pFB2647
pFB2700 pJE082 pFAT2-Arl4C Q72L human Arl4C; GTP-locked from pFB2649
pFB4467 pJE329 pFAT2-Arl4C ΔN14 human Arl4C aa 1-14 deleted; from pFB4464
pFB3884 pJE284 pEGFPN3-Arl1Q71L human Arl1; GTP-locked; from pFB3617
pFB4790 pJE388 pEGFPN3-Arl1 human Arl1; derived from pFB2623
pFB4700 pEJ365 pEGFPN3-Arl2 human Arl2 derived from pFB4677
FB4701 pJE366 pEGFPN3-Arl2QL human Arl2; GTP-locked; derived from pFB4678
pFB4702 pJE367 pEGFPN3-Arl3 human Arl3; derived from pFB4679
pFB4703 pJE368 pEGFPN3-Arl3QL human Arl3; GTP-locked; derived from pFB4680
pFB2639 pJE051 pEGFPN3-Arl4A human Arl4A, from pFB2635
pFB2709 pJE091 pEGFPN3-Arl4A Q79L human Arl4A, GTP-locked; from pFB2702
pFB3143 pJE204 pEGFPN3-Arl4A T34N human Arl4A GDP-locked from pFB3133
pFB3078 pJE184 pEGFPN3-Arl4B human Arl4B from pFB3032
pFB2653 pJE064 pEGFPN3-Arl4C human Arl4C, from pFB2647; now Arl4C
pFB2656 pJE067 pEGFPN3-Arl4C Q72L human Arl4C, GTP-locked, from pFB2650; now
Arl4C
pFB3144 pJE205 pEGFPN3-Arl4C T27N human Arl4C GDP-locked; from pFB3131
pFB4704 pJE369 pEGFPN3-Arl4D human Arl4D (ARF4L); derived from pFB4682
pF4705 pJE370 pEGFPN3-Arl5A human Arl5A; derived from pFB4683
pFB4706 pJE371 pEGFPN3-Arl5A QL human Arl5A; GTP-locked; derived from
pFB4684
pFB4709 pJE374 pEGFPN3-Arl5B human Arl5B; derived from pFB4687
pFB4710 pJE375 pEGFPN3-Arl5B QL human Arl5B; GTP-locked; derived from
pFB4688
pFB4707 pJE372 pEGFPN3-Arl6 human Arl6; derived from pFB4685
pFB4708 pJE373 pEGFPN3-Arl6 QL human Arl6; GTP-locked; derived from pFB4686
pFB3080 pJE186 pEGFPN3-Arl8A human Arl8A; from pFB3033; now Arl8A
pFB3076 pJE182 pEGFPN3-Arl8B human Arl8B from pFB3034
pFB4711 pJE376 pEGFPN3-Arl11 human Arl11; derived from pFB4694
pFB4712 pJE377 pEGFPN3-Arl14 human Arl14; derived from pFB4690
pFB4713 pJE378 pEGFPN3-Arl15 human Arl15; derived from pFB4692
pFB4793 pJE391 pEGFPN3-Arl16 human Arl16; derived from pFB4789
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pFB4791 pJE389 pEGFPN3-ARD1 human ARD1; derived from pFB4785
pFB4792 pJE390 pEGFPN3-ARD3 human ARD3; Arl13A; derived from pFB4785
pFB2666 pJE077 pEGFPN3-AFRP1 human AFRP1, from pFB2664
Additional Constructs
pFB2723 pJE105 pCRIITOPO-NLPdC702 human NLP aa 1-702, BamHI XhoI
pFB679 VSV-G-SP-EGFP Gift from Kai Simons. VSV-G GFP fusion ts045
folding mutant for transport studies
pFB523 pBS84 pACT2-GM130fl pACT2 Full length rat GM130
Rab GTPases
pFB4770 pAH843 pFBT9-Rab1a.QA.Y40A Human Rab1a QA GTP locked mutant, Y40A
mutation to remove aromatic from GTP binding
cleft
pFB4772 pAH845 pFBT9-Rab6a.QA.Y42A Human Rab6a QA GTP locked mutant, Y42A
mutation to remove aromatic from GTP binding
cleft
pFB1842 pEF49 pFBT9-Rab2 Q65L human Rab2a Q65L GTP mutant, BamHI-SalI,
derived from pFB1830, + Stop codon
pFB1842 pEF49 pFBT9-Rab2 Q65L human Rab2a Q65L GTP mutant, BamHI-SalI,
derived from pFB1830, + Stop codon
pFB1842-3 pEF49-3 pFBT9-Rab2 Q65L human Rab2a Q65L GTP mutant, BamHI-SalI,
derived from pFB1830, + Stop codon
pFB2100 pEF132 pFBT9-Rab7Q67L human Rab7, GTP, derived from pFB2091,
BamHI, XhoI
pFB2102 pEF134 pFBT9-Rab8Q67L human Rab8, GTP, derived from pFB2087,
BamHI, XhoI
pFB2104 pEF136 pFBT9-Rab10Q68L human Rab10, GTP, derived from pFB2089,
BamHI, XhoI
pFB2104 pFBT9-Rab10Q68L human Rab10, GTP, derived from pFB2089,
BamHI, XhoI
pFB2294 pAH42 pFBT9-Rab11aQ69L Human Rab 11a, GTP Mutant, BamHI SalI, de-
rived from pFB2270
pFB2424 pEF205 pFBT9-Rab1 Q70L mouse Rab1 GTP restricted, derived from
pBS574
pFB2424 pFBT9-Rab1 Q70L mouse Rab1 GTP restricted, derived from
pBS574
pFB2425 pEF206 pFBT9-Rab6 Q72L human Rab6 GTP restricted, derived from
pBS146 NO STOP!!!
pFB2425 pFBT9-Rab6 Q72L human Rab6 GTP restricted, derived from
pBS146 NO STOP!!!
pFB2600 pRK pFBT9-Rab1bQ67L Human Rab1bQ67L, GTP mutant, derived from
pFB2366
pFB2601 pRK pFBT9-Rab2bQ65L Human Rab2bQ65L, GTP mutant, derived from
pFB2368
pFB2602 pRK pFBT9-Rab3bQ81L Human Rab3bQ81L, GTP mutant, derived from
pFB2369
pFB2603 pRK pFBT9-Rab4aQ72L Human Rab4aQ72L, GTP mutant, derived from
pFB2582
pFB2603 pRK pFBT9-Rab4aQ72L Human Rab4aQ72L, GTP mutant, derived from
pFB2582
pFB2604 pRK pFBT9-Rab5bQ79L Human Rab5bQ79L, GTP mutant, derived from
pFB2370
pFB2605 pRK pFBT9-Rab6aQ72L Human Rab6aQ72L, GTP mutant, derived from
pFB2371
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pFB2605 pRK pFBT9-Rab6aQ72L Human Rab6aQ72L, GTP mutant, derived from
pFB2371
pFB2606 pRK pFBT9-Rab8aQ67L Human Rab8aQ67L, GTP mutant, derived from
pFB2372
pFB2607 pRK pFBT9-Rab9aQ66L Human Rab9aQ66L, GTP mutant, derived from
pFB2373
pFB2607 pRK pFBT9-Rab9aQ66L Human Rab9aQ66L, GTP mutant, derived from
pFB2373
pFB2608 pRK pFBT9-Rab9bQ66L Human Rab9bQ66L, GTP mutant, derived from
pFB2374
pFB2608 pRK pFBT9-Rab9bQ66L Human Rab9bQ66L, GTP mutant, derived from
pFB2374
pFB2609 pRK pFBT9-Rab10Q68L Human Rab10Q68L, GTP mutant, derived from
pFB2375
pFB2609 pRK pFBT9-Rab10Q68L Human Rab10Q68L, GTP mutant, derived from
pFB2375
pFB2610 pRK pFBT9-Rab11aQ70L Human Rab11aQ70L, GTP mutant, derived from
pFB2376
pFB2611 pRK pFBT9-Rab13Q67L Human Rab13Q67L, GTP mutant, derived from
pFB2377
pFB2611 pRK pFBT9-Rab13Q67L Human Rab13Q67L, GTP mutant, derived from
pFB2377
pFB2612 pRK pFBT9-Rab14Q70L Human Rab14Q70L, GTP mutant, derived from
pFB2378
pFB2613 pRK pFBT9-Rab18Q67L Human Rab18Q67L, GTP mutant, derived from
pFB2591
pFB2613 pRK pFBT9-Rab18Q67L Human Rab18Q67L, GTP mutant, derived from
pFB2591
pFB2614 pRK pFBT9-Rab23Q68L Human Rab23Q68L, GTP mutant, derived from
pFB2380
pFB2614 pRK pFBT9-Rab23Q68L Human Rab23Q68L, GTP mutant, derived from
pFB2380
pFB2615 pRK pFBT9-Rab27aQ78L Human Rab27aQ78L, GTP mutant, derived from
pFB2383
pFB2616 pRK pFBT9-Rab27bQ78L Human Rab27bQ78L, GTP mutant, derived from
pFB2384
pFB2616 pRK pFBT9-Rab27bQ78L Human Rab27bQ78L, GTP mutant, derived from
pFB2384
pFB2617 pRK pFBT9-Rab30Q68L Human Rab30Q68L, GTP mutant, derived from
pFB2595
pFB2617 pRK pFBT9-Rab30Q68L Human Rab30Q68L, GTP mutant, derived from
pFB2595
pFB2618 pRK pFBT9-Rab31Q65L Human Rab31Q65L, GTP mutant, derived from
pFB2386
pFB2619 pRK pFBT9-Rab35Q67L Human Rab35Q67L, GTP mutant, derived from
pFB2388
pFB2620 pRK pFBT9-Rab40cQ73L Human Rab40cQ73L, GTP mutant, derived from
pFB2599
pFB2620 pRK pFBT9-Rab40cQ73L Human Rab40cQ73L, GTP mutant, derived from
pFB2599
pFB2861 pFBT9-Rab9aQ66L Human Rab9aQ66L, GTP-locked, derived from
pFB2585, replaces previous pFB2607
pFB2861 pFBT9-Rab9aQ66L Human Rab9aQ66L, GTP-locked, derived from
pFB2585, replaces previous pFB2607
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pFB3009 pRK pFBT9-hsRab20Q61L Human Rab20 GTP mutant, derived from
pFB2928 do not use, frameshift!
pFB3009 pRK pFBT9-hsRab20Q61L Human Rab20 GTP mutant, derived from
pFB2928 do not use, frameshift!
pFB3011 pRK pFBT9-hsRab24S67L Human Rab24 potential GTP mutant S67L, de-
rived from pFB2929
pFB3011 pRK pFBT9-hsRab24S67L Human Rab24 potential GTP mutant S67L, de-
rived from pFB2929
pFB3116 pAH269 pFBT9-Rab5A.QL Human Rab5A derived from pFB3112, GTP-lock
pFB3116 pAH269 pFBT9-Rab5A.QL Human Rab5A derived from pFB3112, GTP-lock
pFB3123 pAH276 pFBT9-Rab32.QL Human Rab32 derived from pFB2936, GTP-lock
pFB3204 pAh297 pFBT9-Rab22a.QL Human Rab22a GTP Lock, derived from
pFB2935
pFB3246 pAH339 pFBT9-Rab5C.QL Human Rab5C, from U2Os cDNA, Q80L GTP-
Lock
pFB3346 pRK pFBT9-hsRab19bQ79L Human Rab19b Q79L, GTP mutant, derived from
pFB3343
pFB3346 pRK pFBT9-hsRab19bQ79L Human Rab19b Q79L, GTP mutant, derived from
pFB3343
pFB3867 pRK pFBT9-hsRab19b.Q79A Human Rab19b Q79A, GTP mutant, derived
from pFB3346
pFB3867 pRK pFBT9-hsRab19b.Q79A Human Rab19b Q79A, GTP mutant, derived
from pFB3346
pFB3880 pRK pFBT9-hsRab7Q67A Human Rab7 Q67A, GTP mutant, derived from
pFB3615
pFB4764 pAH837 pFBT9-Rab4b.Q102A Human Rab4b Q102A GTP locked mutant, de-
rived from pFB4763.
pFB4764 pAH837 pFBT9-Rab4b.Q102A Human Rab4b Q102A GTP locked mutant, de-
rived from pFB4763.
pFB4773 pAH846 pFBT9-Rab6a.QA.Y42Q Human Rab6a QA GTP locked mutant, Y42Q
mutation to remove aromatic from GTP binding
cleft
pFB4774 pAH847 pFBT9-Rab27a.QA.F38A Human Rab27a QA GTP locked mutant, F38A
mutation to remove aromatic from GTP binding
cleft
pFB4775 pAH848 pFBT9-Rab27a.QA.F38Q Human Rab27a QA GTP locked mutant, F38Q
mutation to remove aromatic from GTP binding
cleft
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